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ABSTRACT 
 
Tumour vasculature is structurally different to that of surrounding tissue, and tumour 
endothelial cells (TEC) display an angiogenic phenotype. Targeting tumour 
endothelium provides a means to deliver chemotherapeutic drugs. Tumour 
microvascular endothelium also regulates CD8+ T-lymphocyte trafficking into the 
tumour stroma and is important because increased CD8+ infiltration is associated with 
improved patient survival. Thus, understanding the unique phenotype of tumour 
endothelium and how CD8+ T-cell recruitment is regulated may identify targets for 
anti-cancer therapeutics.					
Despite multiple possible treatment strategies, colorectal cancer remains the 
3rd most common cause of cancer related deaths in the world. Therefore, the aims of 
this thesis were to develop a method to isolate and culture human colorectal tumour 
endothelium, to characterize the TEC phenotype, and investigate how 
microenvironmental signals within the tumour may influence this phenotype, and to 
investigate the molecular regulation of CD8+ T-cell recruitment by TEC. 
In this thesis, I have used tissue from patients with colorectal cancer and paired 
non-involved control tissue to isolate primary endothelial cells. Endothelial cell 
phenotype was explored in CRC and normal colon (NC) using immunohistochemistry 
and TEC phenotype was validated using flow cytometry, ELISA and QPCR. I also used 
both flow-based and static adhesion assays to quantify CD8+ lymphocyte adhesion in 
the presence or absence of blocking reagents. 
I have successfully devised a method to isolate TEC, which expressed 
characteristic endothelial markers (CD31, VWF, CD105, VEGFR’s, and VE-Cadherin), as 
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well as tumour specific markers TEM8, and CD13. Interestingly CD13 expression was 
not specific to TEC. Increased CD8+ T-cell adhesion was observed in TEC compared to 
benign controls (NEC) in which adhesion was augmented after conditioning with CRC 
derived tumour associated fibroblast (TAFB) supernatant. Increased concentrations of 
IL-6 and CCL2/MCP-1 were produced by TEC and TAFB and inhibition of IL-6 and 
CCL2 reduced CD8+ T-cells adhesion to TEC. Endothelin-1 (ET1) was produced by 
TAFB supernatant. And increased levels of the corresponding Endothelin Receptor B 
(ETB) were found on CRC endothelium, inhibition of which resulted in a significant 
increase in ICAM-1 expression and CD8+ T-cell adhesion to TEC.  
 Thus, the data from my validated in vitro TEC model for CRC has confirmed 
that tumour specific endothelium has a unique phenotype as a result of 
microenvironmental signals from within the tumour. My functional studies using these 
cells suggest that ETB inhibition could augment ICAM-1 expression and facilitate 
increased recruitment of CD8+ T-lymphocytes into the tumour stroma. This 
commands further investigation with the aim of developing an anti-cancer therapy in 
CRC.  
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CHAPTER 1 
________________________________________________________________ 
General introduction 
 
Colorectal cancer is newly diagnosed in approximately 40,000 people in the UK each 
year (1). Despite multiple possible treatment strategies, colorectal cancer remains the 
3rd most common cause of cancer related deaths in the world. Interesting data 
regarding the number of tumour infiltrating lymphocytes (TIL), in particular, CD8+ T 
lymphocytes, within the tumour stroma of CRC can provide more accurate prognostic 
information than current, standard histopathological staging.  Improved patient 
survival was seen in patients who had tumours containing high numbers of TILs (2). 
One way in which lymphocytes ultimately end up in the tumour stroma is to be 
actively recruited by the tumour microvascular endothelium. To this end, much 
evidence confirms that tumour endothelium is different phenotypically and 
functionally from non-involved endothelium (3, 4). This means that tumour 
endothelium is already the target of anti-tumour treatments via inhibition of 
angiogenesis (5, 6). In this thesis, I hypothesize that the tumour endothelium may 
regulate the quantity of CD8+ T-lymphocytes that are recruited into the tumour.  I also 
propose that other tumour stromal cells such as tumour associated fibroblasts (TAFB) 
influence endothelial lymphocyte recruitment. In this thesis, I aimed to characterize 
tumour endothelial cells (TEC) from human CRC, produce an in vitro model to 
investigate the adhesive properties of TEC and explore how the stromal TAFB regulate 
the adhesion of CD8+ T-lymphocytes to TEC. Therefore, my introduction begins with 
	 2	
an overview of the anatomy and blood supply of the human colon and the blood 
supply of before moving on to discuss the changes which occur during carcinogenesis. 
I will then turn to the significance of tumour endothelium and how these cells, and 
their interplay with the host immune system present a good target for therapeutic 
intervention. Finally, I will highlight the experimental aims that were addressed in my 
investigations. This general introduction serves to set the context for the thesis work 
and more detailed information pertinent to the specific chapters follows in each 
subsequent result section. 
 
1.1 The colon and rectum 
Gross anatomy of the colon and the rectum 
The caecum, colon and the rectum are the latter parts of the digestive tract and form 
the large intestine. This luminal tract receives partially digested contents from the 
small intestine. The main roles of the colorectum are digestion, absorption, and 
transport of water and electrolytes. Digestion and absorption of remaining complex 
carbohydrates are facilitated by fermentation by obligate anaerobes that reside in the 
gut microflora.  
The colon begins with the caecum at the terminal ileum within the left iliac 
fossa, and proceeds as the ascending colon in the right paracolic gutter towards the 
liver inferior. Here it bends sharply, as the hepatic flexure, and traverses left, as the 
transverse colon, towards the spleen, inferior to which it bends sharply again, as the 
splenic flexure, and descends the left paracolic gutter as the descending colon (Figure 
1.1). The colon continues towards the rectum as the sigmoid colon finally joining the 
rectum at the rectosigmoid junction. The rectum terminates at the anorectal junction 
denoted by the dentate line. The rectum is approximately 12cm in length and has an 
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approximate capacity of 500mls. It is divided into 3 parts depending upon its 
relationship with the peritoneal reflection.  
 
 
 
	
	
Figure	 1.1.	 The	 gross	 anatomy	 of	 the	 colon,	 and	 rectum	with	 main	 arterial	 supply	 and	 venous	 drainage. 
Illustration	is	authors	own. 
 
 
 
The arterial supply to the colon comes from the superior mesenteric artery 
(SMA) and inferior mesenteric artery (IMA) which travel through, and branch into the 
ileo, right and middle colic arteries, and the left and sigmoid arteries respectively, 
through the mesentery. The SMA supplies the caecum up to the proximal two thirds of 
transverse colon and the IMA supplies the distal third of transverse colon to the 
Sigmoid	 colon
Anal	canal
Rectum
Taenia coli
Haustra
Descending	colon
Inferior	mesenteric	artery
Caecum
Appendix
Ileocaecal valve
Transverse	colon
Ascending	colon
Splecic flexureHepatic	Flexure
Superior	mesenteric	artery
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rectum. The IMA and SMA communicate via the marginal artery, which ensures blood 
supply at the SMA/IMA division. The superior rectal artery and middle and inferior 
rectal arteries supply the rectum. Arterial supply is mirrored by venous drainage 
resulting in inferior mesenteric vein draining into the splenic vein and the superior 
mesenteric vein joining the splenic vein to for the hepatic portal vein. Lymphatic 
drainage also mirrors the arterial supply.  
 
Histology of the normal colon  
The colon is divided into four layers; mucosal, sub-mucosal, muscularis propria and a 
serosal layer (Figure 1.2). The mucosal layer is the most luminal layer and usually 
smooth. The mucosal layer, surfaced by low columnar to cuboidal epithelial cells 
interspersed by Goblet cells that secrete a lubricating mucous and endocrine cells of 
Paneth in right side of the colon, form deep, straight folds called the Crypts of 
Leiberkün. Deep within the epithelial layer is the lamina propria, which contains 
microvasculature and lymphatics in addition to infiltrating immune cells. The 
muscularis mucosa is a thin, uniform muscle layer separating the mucosal and 
submucosal layer. Histologically, the muscularis mucosa represents an important 
structure, as it is a landmark used to identify stage of colorectal cancer.  
	 5	
The submucosal layer, below the muscularis mucosa contains loose connective 
tissue, microvasculature, lymphatics, inflammatory cells and the submucosal plexus of 
Meissner, containing only parasympathetic nerve fibers supplying secretormotor 
innervation to the glandular cells of the mucosal layer. The muscularis propria consists 
of an inner circular and outer longitudinal muscle layer and also contains the plexus of 
Auerbach, which consists of para-sympathetic and sympathetic nerve fibers.  
	
	
Figure	1.2.	The	structure	of	normal	colon	mucosa.	Representative	image	showing	a	section	of	normal	colon	
stained	 with	 Haematoxylin	 &	 Eosin.	 Original	 magnification	 x10.	 Labels	 indicate	 characteristic	 anatomical	
features	 and	 histological	 constituents.	 The	mucosa	 and	 submucosa	 are	 separated	 by	muscularis	mucosae.	
Within	the	mucosa	resides	the	surface	epithelium	arranged	into	crypts.	Surrounding	each	epithelial	crypt	 is	
lamina	propria	comprising	of	stroma,	fibroblasts	blood	vessels,	plasma	cells	and	lymphocytes.	These	stromal	
constituents	are	also	seen	 in	 the	stromal	compartment	of	 the	submucosa.	Deep	 to	 the	submucosa	are	 the	
muscularis	propria	and	serosal	layers	(not	shown).	Image	is	authors	own.	
	
	
1.2 Colorectal cancer 
Histopathology of colorectal cancer   
Colorectal adenocarcinoma occurs within the epithelial cells of the colorectal mucosa 
as a result of inherited or acquired genetic and epigenetic mutations. One of the most 
Mucosal crypts
Fibroblasts
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common sequences has been termed the adeno-carcinoma sequence and is outlined in 
Figure 1.3. This process is initiated by adeno polyposis coli (APC) gene abnormalities 
and subsequent disruption to the Wnt signaling pathway, which results in epithelial 
hyperplasia and early adenoma formation (7).  
 
	
	
	
	
Figure	1.3.	The	adenocarcinoma	sequence.	The	schematic	illustrates	the	series	of	mutations	occurring	during	
the	adeno-carcinoma	sequence.	 Initially,	mutation	 in	the	APC	gene	causes	uncontrolled	proliferation	via	Wnt	
signalling	pathway	and	early	adenoma	formation.	Further	mutations	lead	to	alterations	in	MAPK	signalling	and	
downstream	 dysplasia.	 Further	 mutation	 and	 loss	 of	 tumour	 suppressor	 gene,	 P53,	 results	 in	 carcinoma	
formation.	Image	is	authors	own	amended	from	(8).	
	
		
 
Further to APC gene inactivation, pro-oncogene Kirsten Rat Sarcoma viral oncogene 
homolog (KRAS) mutations (9) and hyper/hypomethylation further develop 
adenomatous polyp formation. In particular, mutations in KRAS, which are part of the 
MAPK signalling pathway, responsible for regulating cell proliferation, differentiation, 
migration and apotosis (10), lead to uncontrolled changes in regulation of these key 
cellular processes and ultimately result in malignancy.  
  Approximately 10-20% of CRC undergo an alternative pathway, known as the 
serrated pathway, which arises in serrated adenomas and leads to microsatellite 
APC$muta)on$abnormali)es!inac)va)on$
Wnt$signalling$pathway$
$
KRAS$muta)on$
MAPK$signalling$pathway$
Adenoma$Normal$mucosa$ Early$adenoma$ Adenocarcinoma$
Loss$of$p53$
Muscularis$
mucosae$ Malignant$cells$ Epithelial$cells$
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instability(11).  In these, there is a distinctively different genetic profile; methylation of 
CpG rich areas or islands occurs often resulting in tumour suppressor gene silencing, 
an occurrence termed CpG island methylator phenotype (CIMP). Tumours with CIMP 
are associated in mutations of the pro-oncogene B-Raf proto-oncogene, 
serine/threonine kinase (BRAF) which, like KRAS, is a component of the MAPK 
signalling pathway (12).  This pathway does not start with mutation of the APC gene. 
Beyond the pathogenesis of CRC, proliferation and invasion of malignant epithelial 
cells are supported by stromal cells (plasma cells, fibroblasts, infiltrating leukocytes 
and cells from the vasculature) and invade the mucosal layer as the cancer becomes 
more invasive (13) penetrating the muscularis mucosae followed by the sub-mucosal 
layer (Figure 1.4).  
 
 
 
Figure	1.4:		Histology	of	colorectal	adenocarcinoma.					
The	tissue	section	shows	the	invasive	margin	of	colorectal	adenocarcinoma	and	adjacent	dysplastic	tissue	and	
normal	 colon.	 Section	 is	 stained	 with	 Haematoxylin	 &	 Eosin.	 Original	 magnification	 x	 10.	 Labels	 indicate	
characteristic	features	and	anatomical	landmarks.	Image	is	authors	own.	
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Presentation and diagnosis 
Common symptoms in patients with colorectal cancers may include constitutional 
malaise, weight loss, fatigue and loss of appetite. Left sided cancers often cause 
patients to present with fresh rectal bleeding, change in bowel habit, and abdominal 
pain or palpable mass. In large obstructing cancers, complete constipation and signs of 
bowel obstruction may also occur. Right-sided bowel cancers may present with subtler 
features such as iron deficient anaemia, abdominal mass or pain, and general malaise. 
Advanced colorectal cancer and metastatic cancer may present with extra-colonic 
manifestations, such as capsular pain in liver colorectal metastasis.  
  In the U.K., there are broadly two pathways that patients follow to be 
investigated for colorectal cancer. Patients who have attended clinic with symptoms of 
colorectal cancer and those who have been identified in the national screening 
program as having occult blood in their faecal sample. Both groups will undergo 
endoscopic and/or radiological investigation. Where a lesion is identified, biopsy 
samples are taken for histological diagnosis. In the case of a malignant biopsy result, 
the patient undergoes further radiological imaging to identify if there are metastatic 
lesions and, in the case of some large invasive rectal cancer, to identify if the patient 
requires pre-operative radiotherapy to enable curative clearance with surgical excision. 
In this project I have utilized samples from patients who have all had surgical excisions 
of colon and rectal tumours prior to pre-operative neo adjuvant therapy.  
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Staging 
Colorectal cancer was first classified based upon invasiveness using the Dukes staging 
system, which was devised by the English pathologist Cuthbert Dukes. The system 
grades tumours depending upon their depth of invasion regarding histological 
landmarks, and presence of lymph node and metastatic involvement. Dukes stage A 
corresponds with an invasive tumour that does not extend through the muscularis 
propria. Dukes B describes a tumour that invades through the bowel wall but does not 
involve lymph nodes. A Dukes C tumour extends through bowel wall and involves 
lymph nodes and Dukes D describes a tumour with metastatic spread of disease. 
Although the Dukes staging system is often still documented, for diagnostic purposes 
in the U.K. colorectal cancer is staged by the tumour, node, metastasis (TNM) staging 
system. This is recognised by the Union for International Cancer Control (UICC) and 
American Joint Committee on Cancer (AJCC) and provides more information about 
the extent of tumour invasion. This system characterizes the depth of invasion 
according to histological landmarks, apical lymph node involvement and classifies the 
tumour accordingly. Figure 1.5 is an outline of the TNM classification in colorectal 
cancer. TNM subdivides the level of invasion through the wall of the bowel more 
comprehensively than Dukes staging and facilitates more accurate prognostic 
information. For example, Dukes B can involve T3 and T4 tumours. Another method of 
staging, often used in America is where T1/T2, tumours are described as stage 1. T3/T4 
tumours are stage 2. N1 tumours are stage 3 and any tumour with metastatic spread is 
described as stage 4. In this thesis, because tumours that had received previous pre-
operative radiotherapy were not used, TX and T0 tumours are not represented. Most 
often tumours were T1-3 and nodal involvement varied. 
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Figure	1.5.	An	overview	of	the	tumour,	node,	metastasis	(TNM)	classification	of	colorectal	cancer.	Provided	in	
the	dataset	for	colorectal	cancer	histopathology	reports	(3rd	edition)	by	the	Royal	college	of	pathologists	(14).	
	
	
	
	
	
	
 
 
 
Primary tumour 
TX Unable to assess the tumour 
T0             No evidence of tumour 
Tumour 
insitu (Tis) 
Tumour limited to the epithelium or lamina propria 
T1 Tumour involves the submucosal layer 
T2 Tumour involves the muscularis propria 
T3   Tumour invades through muscularis propria into sub-  
  serosa or into non-peritonealised pericolic or perirectal 
  tissues 
  T4a Tumour penetrates to the surface of the visceral 
peritoneum 
T4b  Tumour directly invades or is adherent to other structures 
or organs 
Lymph node involvement 
NX Nodal involvement cannot be assessed 
N0 No lymph node metastasis 
N1 1-3 regional lymph node involvement 
N1a Nodal involvement in 1 regional lymph nodes 
N1b Nodal involvement in 2-3 regional lymph nodes 
N1c Tumour deposit in the subserosa, mesentery or non-
peritoneal perirectal tissues without regional node 
metastasis. 
N2 Metastasis in 4 or more lymph nodes 
N2a Metastasis in 4-6 regional lymph nodes 
N2b Metastasis in 7 or more regional lymph nodes 
Distant metastasis 
M0 No distant metastasis 
M1 Distant metastasis 
M1a Metastasis confined to 1 organ or site 
M1b Metastasis to more than one organ 
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Treatment of colorectal cancer 
The mainstay of colorectal cancer treatment falls into 3 categories and depends upon 
the location and stage of the cancer. Most colorectal cancers will undergo surgical 
excision as primary curative treatment. The principals for surgical resection include  
resection of the tumour, along with the supplying vessels, mesentery, and 
accompanying lymph nodes. 
For right-sided cancers this usually requires a right hemi-colectomy procedure, whilst 
left sided cancers require either a left hemi-colectomy or an anterior resection. Rectal 
cancers can often be excised using an anterior resection however, if they are close to 
the anal verge, an abdominal perineal resection should be performed where the anus is 
excised and an end colostomy is created. Cancers deemed not amenable to resection 
will be considered for pre-operative radiotherapy, palliative stent insertion or other 
palliative procedures. Patients with colorectal cancers that are high risk stage  (T2 or 
cT3b or greater), have lymph node involvement, show signs of extramural vascular 
invasion or metastatic invasion will be offered adjuvant chemotherapy consisting of 
capecitabine or oxaliplatin in combination with 5-fluorouracil and folinic acid (15).  
Despite the current treatment options, median overall survival is about 22-24 months 
(16) and therefore investigation into further treatment options for all stages of CRC is 
warranted. Several preparations have been investigated in vitro and in animal models, 
and human phase III trials in advanced and metastatic colorectal cancer (mCRC) that 
target the vascular endothelium of tumour blood vessels. Blood vessels of solid 
tumours and their endothelium are reported to be structurally, functionally and 
phenotypically different from non–involved blood vessels (3, 18). Before discussing 
these agents and how the tumour endothelium can be modulated and exploited by 
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therapeutic targets, we must first understand how the tumour endothelium differs 
from nearby non-involved endothelium. 
 
 
 
1.3 Vascular endothelium in colorectal cancer  
Vascular endothelium 
Generally, the endothelium consists of a single layer of endothelial cells (ECs) on the 
luminal surface of blood vessels that exists upon a supportive basement membrane.  
The ECs throughout the body are heterogeneous in structure allowing for differences 
in organ-specific function (17). For example, EC may be continuous or discontinuous 
and may be fenestrated or non-fenestrated. Structural, functional and phenotypic 
heterogeneity of endothelium is dependent upon the cellular role. In health and 
disease, generally ECs serve the following functions: haemostatic balance, 
permeability, regulation of vasomotor tone, proliferation, blood cell trafficking, 
survival and innate and adaptive immunity (2).  
Macrovascular endothelial cells from arteries and veins are continuous and 
bound by tight junctions, which are required to maintain a patent lumen, and 
withstand the high intra-luminal pressures inside larger vessel blood flow.  
Macrovascular endothelial cells grow as a single layer of impermeable endothelium, 
tightly adhered to the basement membrane providing a non-thrombogenic surface, 
which prevents adhesion of platelets and other cells. Examples include cerebrovascular 
endothelium where ECs are continuous and non-fenestrated allowing tight control of 
transportation across the blood brain barrier (19). In contrast, hepatic sinusoidal 
endothelium is dis-continuous and fenestrated allowing cellular trafficking and 
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movement of nutrients to and from blood vessels to hepatocytes (20). The 
environmental conditions that develop within tumours stimulate a different 
endothelial cell phenotype in vessels that supply benign tissue to that of malignant 
tissue. 
The microvasulature of colorectal cancer 
In the healthy colon and rectum, the arteries meet the mesenteric border and are 
distributed round towards the anti-mesenteric border and transversely along the 
luminal layers. Corrosion casts have illustrated that these arteries divide in the sub-
mucosa into arterioles and then sub-epithelial capillaries forming a regular hexagonal 
plexus around mucosal glands. This produces a regular honeycomb appearance 
(21)(see Figure 1.6). In human colorectal adenocarcinoma, the regular, honeycomb 
structure, described in normal colon, is lost (See Figure 1.6) (21). These studies show 
that tumour vessels have lost normal hierarchy, heterogeneous density within the 
tumour, and blind-ending vessels. Other features of tumour microvasculature include 
anastomosing capillaries and frequently extravasation of resin suggestive of leaky 
vessels. Skinner et al. have illustrated that capillaries within human colon tumour 
microvasculature exhibit increased density of microvasculature between tumour cells, 
a larger mean diameter and increased vascular volume compared to normal colon 
capillaries (22).  
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Figure	1.6:	The	normal	microvascular	structure	is	lost	in	colorectal	tumours.		
Micrographs	of	casts	from	normal	colon	(top	two	images)	and	colorectal	cancer	(bottom	two	images)	show	a	
distinct	loss	of	organization	in	the	tumour.	The	figure	is	adapted	from	Konerding	et	al	(21).	
 
 
Furthermore, differential changes in microvasculature structure occur with the 
spectrum of disease. Konerding et al., found that in casts produced from larger, more 
invasive disease, the core of the tumour suggested external compression on the 
microvasculature resulting in a reduced number of vessels and a necrotic center (21). 
At the other end of the spectrum of disease, casts from adenomas exhibit a variety of 
structural characteristics ranging from minimal changes with elongation and an 
increased vein, venule and capillary diameter (22) up to an appearance 
indistinguishable from cancer microvasculature by blinded observers (21). Alterations 
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in tumour vessel architecture are also reproduced in animal models of disease. For 
example data from a murine tumour implantation model (23) shows an overall 
increase in tumour microvascular density and volume compared to uninvolved tissue. 
However, other structural characteristics diminish the flow of blood within these 
vessels. In this instance tumour microvasculature flow has been found to be chaotic, 
unpredictable, absent, and even bi-directional via vascular shunts (24). As a 
consequence, in terms of supplying tissue with oxygenated blood and removing 
products of tissue metabolism, tumour microvasculature is inefficient. Thus tumours 
in rodents (25) and humans (26) contain blood which is measurably hypoxic. 
 
Endothelium in colorectal cancer 
It is understood that for tumours to progress, grow and become more invasive, 
formation of new blood vessels is required (27). New vessel formation can either occur 
via vasculogenesis during embryological vessel formation or angiogenesis, which is the 
formation of new blood vessels from pre-existing vessels. This requires the “angiogenic 
switch” which was first described by Folkman (27). This refers to a point in the tumour 
development where for the tumour to grow beyond 0.4mm, the tumour must develop 
its own blood supply and it does this by producing angiogenic factors. There are two 
established methods of vessel formation; sprouting and intersusseptive or splitting 
angiogenesis (28). Intersusseptive angiogenesis occurs in vasculogenesis of 
embryological development and is therefore not described in this report. Sprouting 
angiogenesis, however, occurs in healing tissue and tumourigenesis and involves 
shoots growing from endothelial stalk cells towards a stimulatory signal such as VEGF-
A (Vascular endothelial growth factor A). This is accompanied by degradation of 
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basement membrane by proteolytic enzymes, endothelial cell proliferation, and direct 
migration of endothelial cells, tubulogenesis, vessel fusion, and pericyte stabilization 
to yield a mature and appropriately supported branching vessel. 
Conditions where angiogenesis is required in adults include wound healing, 
ischaemia and tumour progression and in all cases ECs are required to proliferate. The 
ischaemic conditions found in tumours initiate the surrounding parenchyma to 
express Hypoxia inducible factor 1 (HIF-1), which stimulates transcription of VEGF-A, 
FGF and TGF genes. Similarly, infiltrating macrophages that are recruited to wound 
healing or inflamed tissue can also produce these factors. VEGF-A is recognised by 
respective receptors (VEGFR-1&2) which are located on the filopodia or ‘tip’ 
endothelial cells (28, 29). Binding initiates a number of events including secretion of 
proteolytic enzymes from filopodia on tip cells which break down the extra cellular 
matrix, resulting in filopodia migration towards the VEGF-A. This leads to contraction 
of actin filaments, which pulls the tip cells behind. In addition, VEGF-A activates 
production of a cell surface ligand, Delta like 4 (DLL4), which binds to its Notch 
receptors, and initiates stalk cells to proliferate (29).  
The mechanisms which promote tumour angiogenesis are not fully understood, 
however the tumour endothelial cells (TEC), which develop as a result of tumour 
related angiogenesis are structurally, functionally and phenotypically different than 
those found in the surrounding uninvolved tissue (30, 31). This is very significant as it 
provides a means to selectively target tumour resident cells, whilst avoiding non-
malignant cells, as a means to treat cancer. As mentioned earlier, the angiogenic 
process of tumour endothelial cells in CRC has been targeted as a mechanism for 
anticancer therapeutics. Hence, growth factors such as VEGF, EGF, PDGF and EGF 
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have all been targeted to inhibit tumour angiogenesis. Furthermore, anti-angiogenic 
agents are often used in combination therapy where their “normalization” of tumour 
blood vessels allows concomitant delivery of other chemotherapeutic agents (32, 33).  
Bevucizumab is a humanized monoclonal antibody that binds to VEGF and 
prevents receptor binding and subsequent down-stream angiogenesis.  Bevucizumab 
has been approved by the FDA and is recognised as a treatment for mCRC based on 
some improvement in progression free survival and overall survival. When trialed as 
part of a combination therapy (irinotecan plus fluorouracil and leucovorin (IFL) plus 
Bevacizumab at 5 mg per kilogram of body weight every two weeks) against a placebo 
in combination with IFL, Bevacizumab improved median and progression free survival, 
and rates of response were significantly improved (5). However, a higher incidence of 
side effects in the Bevacizumab arm, including diarrhea, leukopenia, bleeding, 
hypertension, and colonic perforation was reported. In particular, a significantly 
increased incidence of all grade 3 and grade 4 (described by Common Toxicity Criteria 
of the National Cancer Institute where grade 3 is “serious” and grade 4 is  “life 
threatening”) side effects and grade 3 hypertension was observed in patients from the 
Bevacizumab arm (5).  
In vitro studies have suggested that VEGF inhibition delays wound healing (34). 
Receptor tyrosine kinase inhibitors have also shown improved patient survival in renal 
cell carcinoma in phase III clinical human trials, however Sorafenib has been 
associated with a significant increase in serious adverse events leading to 
hospitalization or death compared to a placebo arm and bleeding was more frequent.	
A suggested mechanism for haemorrhagic adverse events is inhibition of post-
traumatic endothelial cell proliferation, exposing and depleting the sub-endothelial 
	 18	
basement membrane. This results in both thrombotic events and reducing vessel 
integrity (35). 
Seemingly, adverse side effects of anti-angiogenic medications are 
mechanistically a direct consequence of the anti-angiogenic mode of action and, as 
such are intricately linked with dosing. Thus, side effects are unavoidable to be 
therapeutically optimal. Furthermore, inhibiting VEGF and VEGFR binding doesn’t 
only affect endothelial cells of tumour blood vessels but also to vessels that supply 
normal healing tissue found at the site of surgical wounds (36). These effects of anti-
angiogenic treatments have manifested in wound infection and complications (37) and 
bowel anastomotic leaks (38, 39, 40). These complications reveal that although anti-
angiogenic therapies have anti-tumour potential, they are not tumour specific and are 
associated with serious side effects. This highlights that therapeutics have not targeted 
genuinely tumour-specific phenotypic characteristics and cellular pathways; if the 
tumour vasculature is to be exploited, it is essential that the tumour specificity of 
endothelium is targeted. 
 
Identification of tumour-specific endothelial cell markers 
One of the challenges that has stalled development of genuinely tumour-specific 
vascular targeting, relates to the difficulty in isolating and culturing human colorectal 
TEC for use in in-vitro investigations. The methods of isolating pure populations of 
endothelial cells commonly depend upon molecules that are expressed by endothelial 
cells such as CD31 (41) and CD146 (42), which allows methods such as 
immunomagnetic selection and flow assisted cell sorting. Limitations of using surface 
expressed molecules are due to cross expression of endothelial cell surface molecules 
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by other cells for example, macrophages and pericytes. St Croix et al., (42) used laser 
capture methods for TEC isolation. This method does not permit in vitro expansion of 
cells and may suffer from inclusion of contaminating pericytes, but has been useful in 
analysis of TEC gene expression. Nevertheless, this work has produced important 
insights into the field of tumour specific endothelial markers. Some of these key 
markers are discussed in the sections below. 
 
Tumour endothelial markers (TEM) 1-8 
In addition to utilizing laser capture microdissection St Croix et al., performed serial 
analysis of gene expression of isolated tumour endothelial cells to identify tumour-
specific endothelial markers (42). This led to the identification of 8 new potential 
markers (TEM 1-8). One of these, Tumour endothelial marker 8 (TEM-8) was shown to 
be absent in uninvolved but present in angiogenic tissue from tumour. Furthermore, in 
murine studies, TEM-8-/- mice showed normal development and growth but tumour 
growth was arrested when compared to TEM-8 +/+ mice (43). TEM-8 has not only 
been identified as tumour specific but reports suggest that in colorectal cancer, mRNA 
expression increased with stage of disease (44). Furthermore, studies have revealed 
that DNA-vaccination with a vector targeting TEM-8 can reduce angiogenesis in 
tumours and generate potential T-cell mediated anti-tumour responses using murine 
models (45). Other TEMs of interest included TEM1 and 5, both of which were found 
on angiogenic tissue 
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CD13 
Other studies have also identified molecules enriched in tumour endothelium such as 
CD13. CD13 (Aminopeptidase N) is a cell surface proteolytic enzyme, which is 
expressed on cells including endothelium, some leukocyte populations and 
mesenchymal cells. Diverse functions have been described including metabolism of 
regulatory peptides (46), cholesterol trafficking (47), modulation of cell motility and 
migration (48) and immunoregulation (49). The cellular pathways activated, however 
depend upon cellular context. The importance of CD13 function in cancer has been 
highlighted by studies documenting differential isoform expression within angiogenic 
tumour vasculature(50, 51) and correlations between intensity of expression and 
disease staging (52). Studies examining the potential of CD13 for tumour vasculature 
targeting by coupling chemotherapeutics such as doxorubicin to NGR peptide (53) a 
ligand for CD13, and an oral inhibitor, Bestatin, show  improved  survival after 
resection in patients with lung tumours in human trials (54).  The diverse functions of 
CD13 have limited its inhibition clinically, as subsequent unwanted side effects 
manifest from the range of downstream affects. 
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ROBO4 and other newly identified markers 
Increased tumour endothelial expression of the gene for Roundabout homolog 4 
(ROBO4), a member of the receptors for slit proteins, was discovered by data mining 
techniques performed on many tumour types (breast, brain and colon) (55). ROBO4 
showed promise as a tumour endothelial target after data suggested expression was 
absent in non-angiogenic tissue (56) although expression is also found in placenta (57) 
and non-malignant angiogenic tissue (55).  Other proteins described as tumour 
endothelial markers include C-lectin type CLEC-14a (58). A functional study suggests 
that mechanistically CLEC-14a regulates tube formation in angiogenesis and so 
expression may not be limited to tumour vessel formation and thus inhibition may be 
susceptible to the same complications as other anti-angiogenic therapies (59). 
The mechanisms underlying regulation of TEC-specific marker expression by 
tumour ECs and the function of these receptors remain unclear. Schellerer et al., have 
described the isolation and culture of cells from colon and their pilot data highlight 
phenotypic differences that suggest normal and colorectal primary tumour endothelial 
cells maintain phenotypic stability in culture (60). However, comprehensive tumour-
specific phenotyping data is lacking as colonic cells have not been reliably maintained 
in long-term culture. In addition, the potential uses of these cells as an in vitro model 
for investigating cancer biology have not been explored. An in vitro model of TEC 
would also permit study of the role of tumour endothelial cells in the tumour 
microenvironment and interplay with other cells within the stroma, such as immune 
populations and tumour associated fibroblasts. These areas will be explored in my 
investigations. 
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1.4 The microenvironment in CRC  
Endothelial cells within the tumour are influenced by the microenvironment in 
which they reside and this, in turn, will alter their ability to recruit key anti-tumour 
and regulatory populations of immune cells. Lymphocytes that are actively recruited 
across the endothelium also contribute to the intra-tumoural immune context.  
 
The Adhesion cascade 
In health and disease, lymphocytes are recruited from the blood into the tissue 
through the endothelium lining vessels. This occurs, classically in 4 steps: capture, 
rolling, firm adhesion and transmigration (61) although recent insights provide a better 
understanding of the dynamics involved at each step. For the adhesion cascade to be 
successful, EC must express selectins for rolling and integrin adhesion molecules for 
firm adhesion. Furthermore, integrins that bind specifically with adhesion molecules 
must be expressed of receptive T-cells to allow adhesion. 
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Figure	1.7:	The	adhesion	cascade.		
This	schematic	outlines	the	key	events	that	occur	one	after	another	as	a	cascade	and	result	in	recruitment	of	
leukocytes	across	the	endothelial	layer	and	basement	membrane.	The	initial	step	of	capture	occurs	as	a	result	
of	reduced	vessel	diameter	and	unavoidable	leukocyte-endothelial	contact.	It	is	at	this	point	of	contact	where	
the	 leukocyte	 is	 able	 to	 detect	 the	 chemokine	 profile	 of	 the	 endothelial	 cell	 layer.	 Chemokine-chemokine	
receptor	binding	leads	to	integrin	activation	and	rolling.	Once	leukocyte	integrins	are	activated,	they	are	able	to	
bind	to	endothelial	expressed	adhesion	molecules	with	valence	and	avidity	and	results	in	leukocyte	arrest.	The	
leukocyte	 is	 able	 to	 engage	 it’s	 cyto-skeleton	 and	 reach	 an	 endothelial	 cell-endothelial	 cell	 junction	 via	
locomotion	to	migrate	along	the	paracellular	route	or	they	migrate	directly	across	an	endothelial	cell.	Image	is	
authors	own	adapted	from	(62).		
 
 
Capture 
Capture is a term used to describe the active attraction of immune cells from the 
circulation towards the endothelial surface of the blood vessel. This is achieved 
principally by changes in haemodynamics. As vessels reduce in luminal diameter and 
form networks of post capillary venules, the velocity of flow slows and leukocytes are 
in much closer contact with the endothelial surface.  
As leucocytes flow through vessels they bind to E-selectin, expressed on EC 
luminal membrane by glycosylated ligands such as P-selectin glycoprotein ligand 1 
(PSGL1) (63). This initiates slow rolling where lymphocytes travel at a slower velocity; 
approximately 5-10μm/s.  Selectins are type 1 cell surface glycoproteins that bind to 
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complex carbohydrate molecules. There are 3 selectins; L, P and E-selectin. L and P-
selectin are expressed by leukocytes and platelets respectively, whereas E-selectin is 
expressed by endothelial cells (64). The structure of E-selectin consists of one N-
terminal, one C-type lectin, one EGF-like, six sushi repeat unit, one transmembrane, 
and one intracellular domain. During rolling, Selectins and ligands that have sialyl 
LewisX complex carbohydrate bind with limited affinity and “bind and release”, which 
with shear forces from blood flow allows continued, low velocity movement (65).  The 
purpose of rolling is to facilitate the activation of integrins by chemokines allowing 
integrin-adhesion molecule binding (66). This results in firm adhesion and arrest. 
There is evidence to support binding of vascular cell adhesion molecule 1 (VCAM-1), 
which is expressed on the endothelial surface, to its integrin ligand α4β1, also known as 
very late antigen 4 (VLA-4), which is expressed on lymphocyte populations, 
contributes to slow rolling and tethering (67) (Figure 1.7). 
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Figure	1.8:	ICAM-1	and	LFA-1	binding.		
The	image	represents	ICAM-1	with	5	domains	present	on	the	endothelial	cell	surface.	The	β2	integrin	LFA-1,	is	
reported	to	bind	to	domain	1	of	ICAM-1	by	the	I	domain	(68).	Initially,	LFA-1	is	inactive	and	folded.	To	achieve	
binding,	the	integrin	must	first	be	activated	by	chemokines	on	the	endothelial	surface.	Image	in	authors	own,	
adapted	from	(69).	
 
 
Arrest  
Firm arrest arises because of lymphocyte integrin activation achieved by chemokines 
on the endothelial surface. Chemokines are cytokines with chemotactic properties. 
They are approximately 10 kilodaltons in size and are secreted by several cell types. In 
the adhesion cascade they are secreted by various cells at the site of inflammation.  
 
They bind to specific chemokine receptors found on target cells and activate 
cytoplasmic G-proteins producing downstream intracellular signaling pathways. 
Chemokines are classified into CXC, CC, CX3C and XC groups according to minor 
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differences in structure (70). Chemokines that lead to integrin β1 and 2  activation 
include CCL3, CCL4, CCL19, CCL20, Regulated on Activation, Normal T Expressed and 
Secreted (RANTES)/CCL5, CXCL9, CXCL10, CXCL12, CCL17 (68, 69, 70, 71,  72, 73). 
Chemokine-dependent activation, termed inside-out signaling, results in unfolding of 
integrins and increases the affinity of binding with the receptor. Furthermore, 
chemokine activation allows integrin clustering, which promotes multivalent binding 
and thus increased valency (74). Integrin ligands expressed on endothelial cells within 
a vessel lumen are Intercellular adhesion molecule 1 (ICAM-1) which binds with αLβ2 
(CD11a/CD18) and αMβ2 (CD11b/CD18), VCAM-1, which binds with α4β1/VLA-4 and 
Mucosal addressin cellular adhesion molecule (MAdCAM-1), which binds with α4β7 
(78). Downstream signaling as a result of integrin binding, termed outside-in signaling, 
is thought to result in adhesion(62). 
 
Adhesion strengthening and spreading 
Integrin binding results in anchoring the leukocyte cytoskeleton via proteins Talin and 
Vinculin (79, 80) and can lead to increased integrin clustering and activation (81, 82). 
The resultant integrin binding leads to arrested movement of the lymphocyte on the 
endothelial cell surface. 
 
Intra-vascular crawling and trans-endothelial migration 
Inflammatory cells use their integrins to crawl along the endothelial layer, termed 
locomotion, until they reach a point which is suitable to migrate across the endothelial 
layer (83). Migration of leukocytes across the endothelial layer has been described to 
occur by both paracellular and transcellular routes (84). Paracellular migration occurs 
at endothelial cell-cell junctions. CD31, Junctional adhesion molecules (JAMs), 
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Endothelin selective adhesion molecule (ESAM), ICAM-1 and VCAM-1 are 
preferentially expressed at these sites and actively facilitate transmigration(85, 86, 87). 
In addition, cell-cell junctions consist of adherens junctions comprised of VE-Cadherin 
complexes necessary for endothelial cell-cell adhesion (88). Increased endothelial 
cytoplasmic calcium, caused by ICAM-1 cross linking, allows cell-cell junctions to 
disassemble and thus provides a passage for leukocytes to migrate across (89). 
Ultimately, dynamics and velocity of blood flow, expression of adhesion 
molecules on endothelial cells (ECs) and lymphocytes, and products of EC and 
leukocyte activation such as chemokines are key regulatory factors in lymphocyte 
adhesion (90). Expression of key regulators of this process is site and context specific 
and thus adhesion molecules and chemokines present opportunities for therapeutic 
intervention. In particular, Mucosal Addressin Cellular Adhesion Molecule (MAdCAM-
1) has been found to be specifically expressed by venules within the lamina propria of 
human gut mucosa (91) and relies upon CCL25 present on the endothelial surface 
which binds to immune populations that express CCR9 (92). This activates integrin 
α4β7 and facilitates adhesion to MAdCAM-1 expressed on the endothelial surface (93).  
Interestingly MAdCAM-1 expression is tissue specific and has increased expression in 
venular endothelium within foci of inflammatory tissue found in Ulcerative Colitis 
(UC) and Crohns’ disease (94). This highlights possibilities to target the chemokine 
and receptor interactions to modify trafficking of immune populations across the 
endothelium.  
Similarly, expression of endothelial adhesion molecules may also be a source to 
regulate immune cell trafficking. Reports exist suggesting reduced expression of ICAM-
1 in renal tumour vasculature (95) and VCAM-1 in tumour-infiltrating vessels in human 
lung (96) which result in reduced TIL numbers. Similarly work in ovarian tumours has 
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implicated Endothelin B receptor in inhibiting recruitment of tumour infiltrating 
lymphocytes (TIL) (97), and up regulation of the chemokine CXCL16 by tumours 
following therapeutic interventions has been shown to be important for the 
recruitment of tumour-specific CD8+ lymphocytes (98).  
 
Key Immune cell and stromal sub-populations within colonic tumours 
In colorectal cancer the type, location and environment of tumour-resident immune 
cells alters the effects these cells have upon tumour and disease progression (2). The 
protective role that immune surveillance provides against tumour formation, and how 
this can be used therapeutically, has been explored recently.  
 
CD8+ T lymphocytes 
Cytotoxic T cells (CTL) that arise when CD8+ T cells are activated are known to 
destroy tumour cells (99) through lysis. Tumours have cell surface antigens that are 
tumour-specific making the process of tumour cell recognition by CTLs possible. The 
processes of CD8+ T cell activation and tumour cell recognition requires an antigen-
presenting cell, usually a dendritic cell (100), that presents major histocompatibility 
complex-1 (MHC-1) molecules to CD8+ cells (101).  
Intratumoural CD8+ and activated memory T cells have prognostic relevance. 
The characteristics and location of immune populations in tumours have been shown 
to impact disease progress and patient survival (2). Galon et al., characterized the 
immune cells found in colorectal cancer samples by microarray and 
immunohistochemical techniques. They found a significant correlation between 
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density of overall CD3+, CD8+ T cells and activated T memory cells within the tumour 
and disease-free and overall patient survival. Furthermore, these densities were more 
accurate predictors of disease-free and overall patient survival than the conventional 
TNM histological classification. A strong positive correlation with T memory and CTL 
markers and reduced tumour recurrence was observed (102). Higher intratumoural 
CD8+levels, relative to CD4+, have also been shown to correlate significantly with an 
improved 5 year survival (103). These findings suggest prognosis is dependent upon the 
adaptive immune response and, as such, augment the potential to manipulate the 
immune response for a therapeutic gain. Mechanisms that prevent intratumoural 
immune down-regulation by inhibiting Cytotoxic T-Lymphocyte Associated protein-4 
(CTLA-4) or Programmed Death-1 (PD-1) molecules have been explored. Human trials 
using Ipilimumab have shown that CTLA-4 checkpoint blockade can improve survival 
in patients with metastatic melanoma (104). Other studies show some tumour 
objective response in melanoma, non-small cell lung, and renal cancers using PD-1 
antibodies (105), however no response was found in colorectal cancer.  
 
Th17 lymphocytes 
Not all immune populations provide an anti-tumour response. While naïve CD4+ T 
cells can be differentiated into T helper 1 (Th1) when stimulated by interleukin 12 (IL-
12) (106), T helper 17 (Th17) form when CD4+ T cells are stimulated by IL-6 and TGF-b 
(107). The presence of Th17 cells correlates with a poor prognosis (102). This may be 
through IL-17 production which has been reported to promote tumour growth and 
angiogenesis (108). 
 
 
	 30	
Regulatory T lymphocytes 
Foxp3+CD25+CD4+ Regulatory T- cells (T-regs) are produced de-novo by the thymus 
as a mature subset of T cells and they can also be derived from naïve T-cells in 
response to TGF-b (109). Their immuno-suppressive characteristics are well 
understood with regards to preventing autoimmune disorders (110). In the context of 
tumours, T-regs are described to maintain their immunosuppressive qualities by 
eliminating T-cell responses to self tumour antigen (111). T-regs occupy approximately 
10% of the CD4+ intra-tumoural population (112) which is driven by CCL22 (112). T-reg 
accumulation is associated with a worsened prognosis in ovarian cancer models (113) 
and low densities within the stroma of colorectal cancer is associated with a response 
to neoadjuvant therapy (114). 
 
Tumour associated macrophages 
Macrophages originate from bone marrow in the form of monocytic precursors (115). 
Monocytes are recruited by tumour cells secreting VEGF, PDGF-1 and chemokines 
CCL2, CCL3, CCL4 and CCL5 from the circulation into tumour tissue (116)(117). They 
differentiate into M1 or M2 Tumour Associated Macrophages (TAMs) according to 
environmental stimuli (118). Differentiation towards an M1 profile occurs as a result of 
IFN-g, LPS and toll-like receptor agonists (TLR)(119). M1 TAMs express pro-
inflammatory cytokines, TNFa, IL-12, IL-23 (119). The M2 polarized macrophages are 
further subdivided into a, b, c, and d. The Th2 cytokines IL-4 and IL-13 facilitate M2a 
differentiation. LPS, TLRs, and interleukin 1 receptor agonist (IL-1ra) facilitate M2b 
differentiation. IL-10 and TGFb are able to induce M2c type macrophages (120). In 
tumours, macrophages follow a M2 differentiation which is driven by tumour derived 
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factors (121) and they produce factors which support the growth of the tumour by 
promoting tumour angiogenesis, immunosuppression and metastases. 
 
Tumour associated fibroblasts 
With regards to T-lymphocyte sub populations, it is unclear whether the dominant 
immune populations within tumours are entirely due to regulation of intra-tumoural 
proliferation, differentiation or endothelial recruitment. This is likely to be governed 
by tumour cells directly or by tumour associated fibroblasts. The chemokines and 
growth factors that define the differentiation pathway in tumours are produced and 
secreted by stromal cells such as tumour cells and tumour associated fibroblasts. 
Fibroblasts are predominantly responsible for producing the collagen matrix 
supporting the structure of tissues. In colorectal cancer, the number of fibroblast-like 
cells is greater than found in the adjacent normal colorectal tissue (122). Furthermore, 
tumour associated fibroblasts exhibit different phenotypes than those from the 
surrounding host tissue. Often fibroblasts in tumours display an “activated” phenotype 
typical of myofibroblasts by expressing smooth muscle actin (α-SMA), in addition to 
standard fibroblast markers. This may be initiated by growth factors such as TGF-b 
and PDGF released by cancer cells (123). It is likely that, once activated, they may not 
only contribute to cancer progression directly, through formation of the extracellular 
matrix, but also through releasing cytokines, such as IL-6, that can influence the 
pathway of TIL differentiation as shown in murine models (124). It is unclear whether 
the expression of phenotypic markers and adhesion molecules displayed by tumour 
endothelial cells (TEC) is entirely self-determined or requires stimulation by factors 
	 32	
either presented or secreted by tumour cells (125) or tumour-associated fibroblasts 
within the stroma. 
 
Summary 
This chapter provides an introduction into how tumour endothelium provides an 
attractive target for anti tumour therapies. Furthermore, it highlights how the 
endothelium may be exploited and regulated to increase CD8+ T-cell adhesion in 
tumours and overcome evasion of the host immunological anti-tumour response. 
Investigation of these theories depends upon developing in vitro models of human 
primary colorectal tumour endothelial cells. Thus, the hypotheses underlying my 
research project are as follows and the specific experimental aims are detailed below. 
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1.5 Hypotheses 
• Tumour endothelial cells (TEC) in human colorectal cancer express a different 
phenotype than non-malignant endothelium in normal colorectal tissue 
• By exploiting the tumour specific phenotype, primary human colorectal cancer 
tumour endothelial cells can be cultured in vitro  
• The cell surface adhesion molecule profile of colorectal tumour endothelial cell 
differs to normal endothelial cells (NEC) and moreover, the levels of adhesion 
molecule expression will vary across CRC samples reflecting the variance in 
density of tumour infiltrating lymphocytes. Some tumours will strongly express 
adhesion molecules and some will not express high levels of adhesion 
molecules. 
• The stromal, tumour associated fibroblasts in CRC regulate the adhesion profile 
and function of primary human colorectal tumour endothelial cells.  
 
1.6 Aims and objectives 
1. To develop a method to effectively isolate pure populations of tumour 
endothelial cells. These will be used to characterize cell phenotype and to 
develop and validate a method for long-term culture of primary human 
colorectal tumour endothelial cells. 
2. To use primary human colorectal NEC and TEC in in vitro models to quantify 
and investigate adhesion of CD8+ T-lymphocytes under static and flow 
conditions. 
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3. To evaluate the effect of tumour associated fibroblasts on the adhesion 
molecule profile and function of NEC and TEC, and to characterize the soluble 
factors produced by TAFB. 
4. To investigate the effect of inhibiting individual soluble factors produced by 
TAFB on the adhesion molecule profile and function of NEC and TEC. 
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CHAPTER 2 
________________________________________________________________ 
Methods and materials 
 
2.1 Human tissue and blood collection and storage 
All human colorectal tissue was obtained from the Queen Elizabeth Hospital (QEH 
Birmingham, UK) from patients who were undergoing resection of colon or rectal 
tumours of all stages, not requiring preoperative neo adjuvant chemo-radiotherapy. 
Liver tissue was also collected from patients undergoing liver resection or explanted 
livers collected during liver transplantation at the QEH. Matched specimens were sent 
for routine histopathology. Those with malignancy were staged using the TNM 
classification and for colorectal cancer, Dukes staging was also performed. Colorectal 
tissue was transported from surgical theatre to the Department of Pathology where 
consultant histopathologists provided a sample for processing in vitro. These were 
transported to the Liver Laboratories in Dubecco’s modified eagle’s medium (DMEM, 
Gibco, CA, USA), supplemented with 4% foetal bovine serum, 1%L-Glutamine and 50 
units/mL penicillin/streptomycin (Gibco, CA, USA). Samples were either stored or 
used immediately. Liver tissue samples were also collected from surgical specimens 
and stored in DMEM at 4ºC for up to 36 hours before use for cell isolation. Samples for 
histological analysis were snap frozen or formalin-fixed immediately upon receipt in 
the lab. 
 Fresh tissue samples were either in the form of approximately 1-2cm3 chunks 
used for cell culture and/or isolation, or biopsies of colorectal tumour and neighboring 
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normal tissue, that were approximately 5mm3 in size. In general, biopsies were placed 
in bijou containers, labeled and frozen at -80ºC for later use. For cryopreservation, cell 
pellets were resuspended in 1ml of FCS with 5% Dimethyl sulphoxide (DMSO), 
purchased from Sigma, UK, and then immediately transferred to a pre-labeled sterile 
cryovial, placed in a freezing container (Mr FrostyÔ) and frozen at -80°C for 24 hours, 
after which, for long-term storage, they were then transferred to liquid nitrogen.  
Blood was collected into Ethylenediaminetetraacetic acid solution (EDTA, 
molar concentration, Sigma, UK) from either healthy volunteers, patients with 
haemachromatosis (being therapeutically venesected: HFE blood) or patients 
undergoing resection of primary or metastatic colorectal tumours (CRC blood). All 
tissue samples and blood were collected and used with local research ethics approval 
and informed written patient consent. 
 
2.2 Tissue culture reagents and supplies 
Cell culture was performed under sterile conditions using class II laminar hoods, 
cleaned with industrial methylated spirits (IMS; Adams Healthcare, Leeds, UK) and 
plastic gloves (Premier Nitric). Sterile pastettes, pipettes (5,10 and 20ml), plastic tubes 
(15 and 50mls), culture flasks (25 and 75 cm2) and cryovials were purchased from 
Corning Costar Incorporated, Bucks, UK. 1.5% Gelatin, or 1% rat-tail collagen (RTC, 
both purchased from Sigma, UK) were used for flask coating. Phosphate buffered 
saline (PBS) was prepared by dissolving PBS tablets purchased from Oxoid, UK with 
de-ionized water according to manufacturer’s guidelines. Dubeccos Modified Eagles 
Media (DMEM), 1%L-Glutamine and 50 units/mL penicillin/streptomycin (PSG), heat 
inactivated foetal calf serum and human serum were purchased from Gibco, 
Invitrogen, UK. Roswell Park Memorial Institute 1640 media (RPMI 1640) was 
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purchased from Sigma-Aldrich, UK. Complete Endothelial Basal growth Media (EBM) 
was purchased from Gibco, Invitrogen, UK. Hepatic sinusoidal endothelial cell (HSEC) 
media was made up with EBM supplemented with 1% PSG and 10% human serum, 
10ng/ml of vascular endothelial growth factor (VEGF) and 10ng/ml of hepatocyte 
growth factor (HGF, both available from Peprotech, UK). 
 
Cell separation buffer (CSB) was prepared using PBS with 1% PSG 4% and 0.5mmol 
of EDTA. Fibroblast media was made with DMEM supplemented with 1% PSG and 4% 
FCS. Media used for Peripheral Blood Monocyte Cell (PBMC) isolation was made with 
RPMI 1640 supplemented with 10% FCS. Specific microvascular media “endothelial 
growth media -2- bullet kit” (EGM-2 bulletkit) purchased from Lonza, UK (cat. No. 
CC3202,), comprising basal endothelial media (cat. no. CC3156) which was 
supplemented by a pre-packaged chemokine/growth factor kit  (cat no. CC4147) 
including human Epidermal Growth Factor (hEGF), hydrocortisone, gentamicin with 
Amphotericin-B (GA-1000), 25mls of foetal bovine serum (FBS), vascular endothelial 
growth factor (VEGF), human fibroblast growth factor B (hFGF-B), R3 insulin like 
growth facor-1 (R3 -IGF-1) and ascorbic acid. Accutase, purchased from PAA 
Laboratories Ltd., and Tryp-LE, purchased from Gibco Invitrogen, UK, were used for 
detachment of cells in culture. 					
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Size of 
flask 
Number 
of cells 
(per well) 
Volume of 
media 
Volume of PBS 
per well or 
flask 
Volume of 
Accutase/Trypsin
per well or flask 
96 well 3 x 104 100-200µls 100-200µls 100-200µls 
24 well 0.2 x 106 500µls 500µls 500µls 
12 well 0.4 x 106 1ml 500µls 500µls 
6well 1.2 x 106 2.5mls 1ml 500µls 
25cm3 2.8 x 106 5mls 5mls 3mls 
75cm3 8.4 x 106 10mls 10mls 6mls 
	
Table	2.1.	Volumes	of	solutions	used	for	cell	culture	in	different	flask	and	plate	sizes. 
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2.3 General cell culture and passage 
Details of individual cell culture requirements are outlined below (Section 2.4). Cells 
were maintained at 37°C in a humidified 5% CO2 incubator and checked for growth, 
contamination and viability with an inverted phase contrast microscope (Olympus 
IX50). Media was changed according to adherent cell proliferation assessed 
subjectively. Where necessary, cell viability was quantified using trypan-blue and a 
Haemocytometer (CAM LAB, Cambridge, UK) according to standard protocols.  
 Solutions appropriate for cell type were used to detach adherent cells for 
passage. Accutase was used for colorectal endothelial cells, and Tryp-LE for all other 
cells types. Initially, media was removed and cells were washed with PBS and then a 
sufficient volume of proteolytic enzymes using Accutase or Tryp-LE (see Table 2.1) was 
added to cover the monolayer and left for approximately 5 minutes with intermittent 
agitation or until cells were detached at which point cells were collected with 1ml of 
FCS and up to 5mls of PBS and centrifuged at 550g for 5 minutes at room temperature. 
The supernatant was discarded and the cell pellet was used as required. Cells in 
suspension (non-adherent) were collected and centrifuged at 550g for 5 minutes at 
room temperature. The cell pellet was re-suspended in CSB buffer and used 
accordingly. 
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2.4 Final protocols for culture of specific cell populations 
The protocols described below detail the optimized protocols used for specific human 
cell isolation and culture. Whilst the HSEC protocol reflects that used currently in the 
Centre for Liver Research, all tumour and colon protocols were developed by me and 
optimized during the current investigation.  
 
2.4.1 Human Hepatic sinusoid endothelial cells (HSEC) 
Liver specimens (approximately 50g of tissue) were diced in a sterile beaker with 20mL 
of sterile PBS and 5mls of type-1A collagenase (0.4µg/mL, Sigma-Aldrich, UK) followed 
by an incubation period of 30-40 minutes at 37°C. The tissue was then strained 
through fine mesh. Once strained and washed several times in PBS with centrifugation 
at 550g for 5 mins, the cells were suspended over a 33/77% (wt/vol) Percoll gradient 
(Amersham Biosciences, UK) and subsequently centrifuged at 550g for 25 mins with no 
brake. The cells collecting at the interface of the Percoll gradient were collected and 
washed several times to remove debris and mucous. Immunomagnetic depletion of 
epithelial cells was performed with mouse anti-HEA-125 (Progen Biotechnic, Germany; 
50μg/ml) and then EC were positively selected using mouse anti-human CD31 
dynalbeads (Dynal A.S.,Norway). Cell counts and viability assessment were then 
performed using Trypan blue and cells were then placed into rat tail-collagen coated 
culture flasks.  
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2.4.2 Total cell isolation from human tumour and non-involved colorectal 
tissue  
All tumour samples were processed before any associated normal tissue. 6 X 15ml 
falcon tubes were prepared with 3mls of warmed endothelial basal medium (EBM, 
Lonza, Cat. no. CC3201) and then weighed. Meanwhile, the tissue biopsies were 
washed vigorously in 4x 40ml of cold PBS supplemented with antibiotics outlined 
above. Biopsies were transferred to a sterile petri dish and cut into 1mm3 pieces with a 
scalpel using a rocking motion. The diced samples were then distributed between the 
3x 15ml tubes, which were then re-weighed, and the difference was calculated resulting 
in the weight of the tissue. Collagenase II (Biochrom AG, Cat. no. C2-22) was added 
(50µl of collagenase per 0.1g of tissue) and the total volume was made up to 2ml with 
EBM.  The samples were then placed in a rotating shaker at 37°C for one hour.  This 
was performed for both normal and tumour tissue. After one hour, the tissue was 
filtered through a cell-strainer (100µm nylon, BD, cat.no. 352360). The single cell 
suspension was centrifuged at 500xg for 5 mins at 20°C, the supernatant was discarded 
and the pellet was re-suspended in EBM-2-MV and transferred to a T-25 flask pre-
coated gelatin (1.5%, Sigma, U.K.) and incubated over-night. After 24 hours the, 
supernatant was removed, the flask was washed gently sterile PBS and 5mls of fresh 
(pre-warmed) EBM-2-MV was replaced. Cell attachment to the flask was observed and 
media was changed daily until total cells reached 50-70% confluence at which point 
they underwent immunomagnetic bead-based selection to purify endothelial cell 
populations. 
Total colonic cell populations in culture, were detached from flasks to produce a single 
cell suspension that was suitable for subsequent endothelial cell isolation.  
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2.5 Endothelial cell purification from tumour and normal colorectal cell 
cultures. 
Several immunomagnetic bead techniques were trialed to isolate endothelial cells from 
the colorectal cultures described above. The protocols for the use of anti-human CD31 
Dynabeads, MACs microbeads and MACs anti-flurochrome microbeads are outlined 
below. However, for some QPCR methods, endothelial cells were isolated using flow 
assisted cell sorting. 
 
2.5.1 Use of Dynabeads 
After digestion of tissue as described above, the single cell suspension, in a 15ml falcon 
tube, was centrifuged at 500g for 5 mins, after which the supernatant was removed and 
discarded. The remaining pellet was resuspended in 500µl of CSB to which 7 µl of anti-
human CD31 dynabeads (11155D, Lifesciences, Invitrogen, U.K) were added and mixed 
well by pipetting. This solution was then incubated for 20mins at 4ºC with agitation. 
After incubation, 5mls of CSB was added to this suspension and the tube was inserted 
into a magnet (Invitrogen, cat. no. 12301D). Once the magnetic beads were identified to 
have separated from the solution, all the supernatant was aspirated from the tube and 
kept for fibroblast isolation. The tube with the positively selected cells was removed 
from the magnet. A further 5mls of CBS was used to gently wash the bead-bound cells 
and the magnetic process was repeated, however at subsequent washes the 
supernatant was discarded. The washed cells were resuspended in 5mls of pre-warmed 
EBM-2-MV (Lonza, UK) media and placed into a T-25 flask which had been pre-coated 
with 1% RTC. Cells were observed for growth and morphology, and the media was 
changed on every 24 hours until 50-60% confluence, at which point the cells either 
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underwent passage to a T-75 flask for expansion, or underwent a further anti-CD31 
bead selection process and were replaced into a T-25 flask.  
 
2.5.2. MACS micro bead method to isolate human TEC and NEC 
Cells isolated as described above were pelleted by centrifugation at 300g for 3 mins. 
The supernatant was removed completely by aspiration. The cells were re-suspended 
in CSB buffer to a maximum concentration of 1x107 per 60µl. To this, 20µl of FCR 
blocking agent was added, and cells were mixed briefly before 20µl of anti-human 
CD31 microbeads (both 130-091-935, CD31 microbead kit, Miltenyi Biotec) were added. 
The mixture was incubated for 15mins at 4°C, after which 1ml of CSB buffer was added 
before centrifugation at 300xg for 3mins. The supernatant was removed and the cells 
were re-suspended in 1ml CSB buffer ready to undergo magnetic separation. LS 
columns (130-041-306, Miltenyi biotec) were placed in the magnetic field of a 
midiMACS separator (Miltenyi biotec). The columns were prepared by rinsing through 
with 3mls of CSB buffer. The cell suspension was then applied to the column. Here, 
unlabeled cells within the solution flowed through the column and the magnetically 
labeled cells were retained within the column reservoir. Subsequent washing steps 
with 3x3mls of CSB buffer ensured that minimal contaminating cells were collected. 
Once the column reservoir was empty, the labeled cells were collected by removing the 
column from the magnet onto a collecting tube (15mls falcon), pipetting in 5mls of pre-
warmed EBM-2-MV media and then pushing the plunger through the column. The 
eluted cells were then placed into a T-25 flask, pre-coated with rat-tailed collagen 
(RTC, 1%, Sigma, UK). Of note, for initial plating gelatin was used as a flask coating (as 
mentioned above) and for subsequent passages when endothelial cells were pure, RTC 
was used.  
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2.5.3. Flow assisted cell sorting  
This process utilized a single cell suspension from freshly processed CRC and normal 
colorectal tissue. The pellet was re-suspended in 100µL CSB and 20% of the cells were 
taken as a “cells only” control sample. The remaining 80% of the cells were incubated 
with FITC-conjugated to anti human CD31 primary antibodies (Appendix 2) at 4°C in 
the dark on a rocking chamber. After incubation, the cells were washed in CSB with a 
live/dead cell marker at a concentration of 1µl/ml (eFlour780, ebioscience, U.K.) as per 
manufacturers guidelines and transferred to the cell sorter. Cell sorting was performed 
by Mr S. Suresh using the Mo-Flo High performance cell sorter (Beckman & Coulter, 
UK) and Summit 5.2 software. The cells only tube was used to correct for FITC auto-
florescence. Gating strategies entailed gating upon 100% of the live CD31 + populations 
within the FITC channel.  The remaining cells were discarded. All CD31 positive cells 
were collected in CSB and re-washed. The cell pellet was resuspended in 600µl of RLT 
buffer containing 6µl of b-Mecaptoethanol and stored at -80°C for later use. 
	
2.6  Use of normal and tumour-associated colorectal fibroblasts (NFB &TAFB) 
2.6.1 Purification	of	Fibroblasts	from	cell	populations	in	culture	
Fibroblasts were isolated from primary colorectal tumour and matched normal 
colorectal tissue as a byproduct from the endothelial cell isolation protocol. As such, 
the initial steps of tissue digestion, filtration and culture of total cell population were 
as described in 2.4.2.  After isolation of the endothelial cells with positive selection 
using CD31 immunomagnetic beads at passage 1, the cell suspension containing the 
remaining CD31- cell populations were centrifuged at 550g for 5 minutes and the pellet 
was resuspended in 10mls of fibroblast media and placed in a T-75 flask to culture at 
37°C. 
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2.6.2 Conditioning of NEC with supernatant from tumour fibroblasts 
Supernatant from cultured primary colorectal TAFB and NFB was collected and 
fibroblasts were detached and counted. Supernatants were diluted based on the 
number of cells from which it derived. The standardised supernatant concentration 
was 2.5mls from 1x106 fibroblasts. Any necessary dilutions were by using standard EBM-
2-MV media. Confluent monolayers of NEC received 5mls in total of either NFB or 
TAFB supernatant solution or received standard EBM-2-MV media as a control. After 
24 hours endothelial cells were detached and the resultant cell pellets were used as 
required. 
 
 
2.7 Purification of CD8+ T lymphocytes from peripheral blood mononuclear 
cells 
20mls of HFE blood or whole blood obtained from CRC patients (details outlined in 
2.1.1) was diluted with 20mls of MACS buffer (PBS, 2mmol EDTA, 2% FCS). 15mls of 
Lympholyte (Cedarlane Technologies, US) was placed in 2x 50mls Falcon tubes, 20mls 
of diluted blood was layered on top and samples were centrifuged for 25mins at 500g 
with no brake. Cells were collected from the interface, washed further with CSB buffer 
and centrifuged at 550g for 5 mins. The supernatant was discarded and the pellet of 
cells was resuspended in RPMI supplemented with 10% FCS. This cell suspension was 
plated in an uncoated T-25 flask and incubated at 37°C for 24 hours. After 24 hours, 
monocytes were observed to have attached to the flask, and remaining non-adherent 
lymphocytes in suspension were collected and counted. At 24 hours, the total live 
count of cells (using Trypan blue) was typically 23x106. These cells were washed with 
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CSB buffer and centrifuged at 550g for 5 mins. The supernatant was discarded and the 
pellet was then resuspended in 200µl of CSB buffer. To this a further 40µl of heat 
inactivated FCS was added and 40µl of antibody mix from the ‘Dynabeads Untouched 
Human CD8+ T cells kit’ (Invitrogen, cat. no. 11348D) was added. The mixture was 
incubated for 20 mins at 2-8°C. After this, the cells were washed in 1ml of CSB buffer 
and centrifuged at 350xg for 8 mins at 2-8°C. The supernatant was discarded and the 
pellet was resuspended in CSB buffer. 200µl of pre-washed Dynabeads was added to 
the cell suspension which was then incubated for 15mins at 18-25°C with gentle 
rotation. After incubation, 1ml of CSB buffer was added and the cells were pipetted 
thoroughly without foaming. The tubes were placed on a magnet (Invitrogen, cat. no. 
12301D) for 2 mins. The supernatant (containing all untouched CD8+ T cells) was 
transferred to a new tube. 1ml of CSB buffer was added to the tube containing 
Dynabeads to resuspend the beaded cells (unwanted cells) and magnetic selection was 
repeated to permit elution of any remaining unbound CD8+ cells  											
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2.8. Flow cytometry 
Antibodies used for flow cytometrical analysis are listed in Appendix 2. 
2.8.1. Single and multi-colour flow cytometry 
Endothelial cells isolated using CD31 selection, either from fresh tissue or from 
cultured populations, were investigated using cytometry to characterize their cell 
surface expression profiles. Cell pellets were re-suspended in 100µL MACS buffer (PBS, 
2mmol EDTA, 4%FCS) and transferred to the appropriate number of FACS tubes 
allowing for Isotype matching controls (IMCs) for each antibody. The ECs were then 
incubated with optimal concentrations of primary antibody (Appendix 2) at 4°C in the 
dark on a rocking chamber. Cells were analysed using the Becton Dickenson FACS 
caliber flow cytometer which has 488nm, 405nm and 642nm lasers. This allowed the 
measurement of FITC, PE, PE-Cy5, PE-Cy7, V460 Pacific orange, APC and APC-Cy7 
florochromes. A “cells only” control tube was always analysed first. Cell debris and 
detached beads were excluded by gating on populations within an endothelial gate 
based on size and side scatter. Voltages were adjusted so that isotype control peaks 
were positioned between 0-101 on the intensity axis (See Figure 2.1). Experiment tubes 
were subsequently analysed against their respective IMCs (Appendix 3).   
Where multi-colour flow cytometry was performed, single colour tubes of 
normal colorectal endothelial cells stained with a single fluorochrome- conjugated 
antibody per tube were used for compensation.  To compensate for fluorochrome 
spillover, median fluorescence intensity (MFI) of the positive and negative populations 
were aligned against the relevant channels and then cells were analysed. Both 
percentage positivity and median channel value (MCV) were collected.  
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Figure	2.1:	Representative	Flow	cytometry	univariate	histograms. 
Flow	cytometry	was	performed	to	assess	the	percentage	and	MCV	expression	for	cell	surface	markers	on	both	NEC	and	TEC	
using	Summit	v4.3	software.	These	plots	are	representative	of	data	obtained.	Event	counts	are	plotted	on	the	x	axis	and	is	
set	between	100	and	10	1.	A.	contains	data	for	TEC	only	with	matching	IMCs	in	the	adjacent	histogram.	B.	contains	data	for	
matching	NEC	and	TEC	with	matching	IMCs	superimposed	in	one	histogram. 
 
 
Co
un
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2.9.    Polymerase Chain Reaction (PCR) 
2.9.1. mRNA extraction from whole tissue and human cells 
Whole tissue, stored either at -80°C or in RNA later (Sigma, UK), or cultured cells were 
used for mRNA extraction. For extraction of total RNA, the RNeasy kit (QIAGEN, UK) 
was used according to manufacturer’s instructions. Where whole tissue was used, no 
more than 30mg was homogenised in 600µl of RLT buffer containing 6µl of b-
Mecaptoethanol. The resultant solution was then passed through a blunt 20-gauge 
needle fitted to an RNAse free syringe, 5 times. When tissues were homogenised, it was 
centrifuged at full speed for 3 mins. The lysate was carefully transferred to a new 1.5 ml 
collection tube. To homogenise cells after culture, immediately after detachment they 
were placed into a 1.5ml collection tube in 600µl of RLT buffer containing 6µl of b-
Mecaptoethanol and cells were lysed using a blunt 20-gauge needle fitted to an RNAse 
free syringe, 5 times. Homogenised tissue or cells were either used immediately or 
stored at -80°C for future use. For mRNA extraction, all preparations were treated 
using the manufacturers standard protocol (Qiagen, UK) and the resultant mRNA was 
eluted using RNase free water. Purity and yield of mRNA were calculated using a 
nanodrop spectrophotometer (Implen, UK). 
 
2.9.2. cDNA synthesis from mRNA extracts 
cDNA was made from mRNA extracted as described above using an iScript Ô Select 
cDNA synthesis kit (BioRad laboratories, U.K.) according to the manufacturers 
guidelines. The components were added (4µl of 5X iSript select reaction mix, 2µl of 
random primers, 1µl reverse transcriptase, 1µl mRNA sample, Nuclease free H20 to 
make up to 20µl) to a 0.2ml PCR tube and samples were incubated through 25°C for 
5mins, then 42°C for 30mins, then at 85°C for 5 mins using the G-Storm Thermocycler 
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(Labcare, UK), then stored at -20°C. Of note, the same amount of mRNA was used in 
samples being compared. The volume used was calculated from the concentration of 
mRNA provided by the nanodrop measurement.  
 
2.9.3. Standard PCR and semi-quantitative analysis 
PCR was performed using BioMix Red (Bioline,UK) with self-designed primers of 
approximately 200 base pairs (Sigma, UK, see Appendix 4). The components were 
added (1µl Primer mix, 1µl cDNA, 3µl ddH2O, 5µl BioMix Red) to a 0.2ml PCR tube and 
then incubated using G-Storm Thermocycler (Labcare, UK). The thermal profiling 
details are outlined in Appendix 5. Proteins were separated through a 2% agarose gel 
incorporating 1.5µl ethidium bromide in 1L of 1%TBE for 90 minutes at 133volts. Semi-
quantitive information of gene expression was visualized using GeneGenius Bio 
Imaging System (Syngene, UK) and Genesnap software (Syngene, UK). 
	
2.9.4. Quantitative PCR and analysis 
All mRNA isolation and cDNA synthesis was performed as outlined in sections 2.9.1 
and 2.9.2. Where ECs were isolated from fresh tissue, flow assisted cell sorting with 
collection of ECs directly into 600µl RLT buffer (QIAGEN minikit) with 6µl β-MTE was 
performed. Due to low concentrations of mRNA extracted from some samples, 45ng of 
mRNA was used to synthesize cDNA for subsequent RT-QPCR. 
 
A) QPCR using TaqMan® (Lifetime technologies) primer and probes (Appendix 6). 
Using 96 well, skirted plates (Applied Biosystems, UK), primers for our genes of 
interest or housekeeping genes (b-actin and GAPDH) were placed into triplicate wells 
ensuring that wells on the edge of the plate were avoided. GAPDH and b-actin were 
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chosen as best housekeeping genes for comparing colorectal cancer tissue and 
matched normal colon tissue based on current literature (126). To each well, the 
following was added; 1 µl cDNA, 5µl of 2xTaqMan MasterMix (Applied Biosystems, 
UK), 0.25µl of primer of interest (above), 3.75µl of RNAse free water (QIAGEN, UK). 
This made up 10µl of solution in which we were careful not to create air bubbles. An 
optical adhesive cover (Applied Biosystems, UK) was applied and a seal was achieved. 
The plate was then centrifuged for 3 mins at 55og.  
 
B) RT2- profiler PCR array (QIAGEN, 96-well format, human endothelial cell biology 
kit, cat no 330231 PAHS-015ZA). Before starting, the 2xRT2 SYBR green mastermix 
(QIAGEN, U.K.) was centrifuged for 10-15 seconds to bring the contents to the bottom 
of the tube. For each 96well plate, 1350µl of mastermix, 102 µl of cDNA (at 45ng of 
mRNA/µl), 1248 µl of DNAse free water (QIAGEN, U.K.) was mixed in a 5ml bijoux 
before being transferred to a RNAse free loading reservoir. Each RT2 profiler PCR array 
plate was removed from its foil wrapping. Using an 8-channel pipette and DNAse free 
filtered tips, 25µl of the mix was added to each of the 96 wells. The tips were replaced 
for each well to reduce the risk of primer contamination between wells. 12 thin wall 8-
cap plastic strips, provided with the 96 well plates, were used to tightly seal the plate, 
which was then centrifuged at 1000g for 1 minute at room temperature to remove all 
air bubbles. 
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2.9.5. QPCR Analysis 
For both methods detailed above, a Stratagene® (model Mx3000P) QPCR machine was 
used to run a standard QPCR protocol for 2hours 31 mins. During set up of the cycler, 
the 96-well plate was kept on ice and when inserted into the machine, a compression 
pad was applied as recommended by the cycler manufacturer. This protocol involves 1 
cycle at 95°C for 10 minutes to activate the DNA Taq polymerase and is then followed 
by 40 cycles at 95°C each lasting 15 seconds followed by a single 1 minute cycle at 60°C 
to collect fluorescence data.  Data was then collected in the form of CT values and 
amplification curves. To work out the differential expression of the gene of interest the 
DDCT formula was used (Figure 2.2). 			
	
Fig	2.2.	Calculation	used	for	relative	quantification	of	gene	expression.	Adapted	from	Pfaffl	et	al	(127).	 
 
 
 
 
 
 
DCTTEC	=	(CTTEC	gene	of	interest)	–	(CTTEC	housekeeping	gene)	
DDCT=	DCTTEC	-	DCTNEC	
Fold	change	=	2-	DD	CT		
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2.10. Immunohistochemistry  
 Immunohistochemistry was performed using 5-7µm tissue sections from human 
colorectal tumour, uninvolved colorectal tissue, colorectal liver metastasis and 
uninvolved liver tissue.  Frozen sections were cut at 7μm and mounted onto coated 
slides (Leica Biosystems, UK) before being acetone-fixed, and stored in foil at -20°C. 
Frozen tissue sections were removed from storage but kept in foil and warmed to room 
temperature for 30 minutes prior to staining.  Endogenous peroxidases were blocked 
using 0.3% hydrogen peroxide solution in methanol (both Sigma UK) for up to 40 
minutes. Slides were then washed. 10% Casein was used for 30 minutes to block non-
specific staining. The slides were then incubated at room temperature on a rocking 
moisture chamber with optimal concentration of primary antibody or IMC control for 1 
hour (see Appendix 7). After further washing, the slides were then incubated with 
vector Immpress Anti mouse MP7402 secondary reagent (Vector labs, UK) for 30 
minutes. Impact DAB (Vector labs, UK) was then used as a substrate and left for 2 
minutes, and filtered Mayers haematoxylin was used as a counterstain. The slides were 
dehydrated using ascending sequence of alcohol and clearene and then mounted with 
cover slips using DPX mountant. Slides were viewed with bright field microscopy using 
a Zeiss Aviovert microscope and images were collected using Axiovision software. 
Images were captured at 10x magnification unless otherwise stated on the results. Semi 
quantification of the images was performed by 2 or more observers and both 
proportion of cells/vessels stained and intensity of staining were observed. Positive 
staining was marked as following; 0 = absent or no positive staining, 1 = partial or weak 
staining, 2 = most or strong staining and 3 = all or intense staining observed. 
Quantification of IHC staining was performed using Image J software which is 
described in section 2.13.	
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2.11. Enzyme Linked Immunosorbant assay (ELISA) 
2.11.1. Indirect ELISA technique for cultured cells 
Endothelial cells were grown to confluence on RTC-coated 96 well plates (Microtest 
tissue culture plate, BD sciences, U.K.) and underwent stimulation with recombinant 
human Interleukin-1β (IL-1β, Peprotech, U.K) or recombinant Tissue Necrosis Factor 
(TNFα, Peprotech,U.K.). Concentrations of 10ng/ml of IL-1β and TNFα and 100µg/ml of 
Bestatin hydrochloride (Sigma, U.K.) were made up using 50% EBM-2-MV media and 
50% of un-supplemented EBM. Where endothelial cells were treated with fibroblast 
supernatant, the solution contained 50% harvested supernatant and 50% EBM-2-MV 
media. After treatment, each well was washed twice with 100µl of PBS and then fixed 
with 100µl 100% methanol. After incubation, the methanol was removed and then 
100µl of PBS was added and cells were either used immediately or stored at 4°C for 
future use.  
To develop the ELISA, PBS was aspirated and the cells were washed once with 
PBS, and then incubated with 1% goat serum and 1% horse serum (Sigma,UK) for 20 
minutes to block non-specific binding. This was then removed and cells were washed 
twice in PBS, before 50µl of primary antibody or isotype control antibody, was added 
(Appendix 8) and incubated for 3 hours. After incubation with the primary antibody, 
the cells were washed 3 times in 100µl PBS with 0.1% tween (Sigma, UK). 50µl of 
secondary antibody (goat anti-mouse horseradish peroxidase-conjugated antibody 
1:1000, Sigma, UK) was then added and wells were incubated at 4°C, in the dark, for 60 
minutes. Following incubation, the secondary antibody was aspirated and the cells 
washed 5 times with 1% PBS with 0.1% tween. 50µl of TMB buffer substrate (Sigma, 
U.K.) was added and left for 5 mins, immediately after which, 50µl of stop reagent (1M 
Sulphuric acid, Sigma, U.K.) was added. Absorbance of each well was determined at 
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450nm. All antibodies and treatments were tested in triplicate and absorbance values 
were calculated as a mean triplicate absorbance, which was either pooled or tabulated 
as a ratio with non-treated values, once the isotype matched control value had been 
deducted.  
 
2.11.2. Sandwich ELISA to quantify soluble mediators 
To quantify soluble IL-6 produced by TAFB and NFB, a commercially available human 
IL-6 sandwich ELISA duo kit (R&D, U.K. cat DY206) was used according to 
manufacturer’s guidelines. Similarly, CCL2 in supernatants of NEC and TEC, was 
quantified using a commercially available human CCL2 (MCP-1) sandwich ELISA 
(ready-set-go88-7399 eBioscience, Affymetrix, U.K).  Briefly, the capture antibody was 
used to coat the 96-well plate, which was then incubated with a blocking agent 
followed by either a recombinant protein to create a standard curve or cell 
supernatants in triplicate. Streptavidin HRP conjugated secondary antibodies were 
used followed by a stop solution and plates were read immediately at 450nm. Each kit 
contained a positive control recombinant cytokine which was used to generate a 
calibration curve for protein concentration. 
 
2.11.3. Proteome profiling arrays 
Supernatants taken from several endothelial and fibroblast cell cultures were 
centrifuged at 500g for 5 mins to remove any solid debris, and samples were stored at -
20°C until use. These were assayed using the human chemokine array kit or 
angiogenesis kit (Proteome Profiler Array, cat numbers ARY005 and ARY007 
respectively, R&D, UK). The chemokine array was used to identify differences present 
in supernatants produced by primary human colorectal tumour and normal colonic 
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endothelial cells in culture. In addition, the array was used to investigate the 
differences between supernatants produced by primary human colorectal tumour 
associated fibroblasts and normal fibroblasts in culture. The angiogenesis array was 
used for TAFB and NFB supernatants only. The arrays were performed following the 
manufacturers guidelines.  The array kit contained an antibody cocktail and a 
nitrocellulose membrane with capture proteins bound to the membrane at defined 
“spot” locations in duplicate. The supernatants were mixed with the biotinylated 
antibody cocktail whilst the membrane was incubated with a blocking agent. The 
membrane and the supernatant-antibody mix were then incubated together overnight. 
Proteins present in the supernatant, having formed antibody complexes could be 
captured on the membrane. A Streptavidin-Horseradish Peroxidase reagent and 
chemiluminescent detection reagents are added to allow imaging of the duplicate 
protein “spots”. The intensity and size of the signal produced at the “spot” locations is 
proportionate to the amount of chemokine bound to the membrane. Signals were 
imaged by developing chemiluminescence detection film (Amersham, Biosciences) for 
10mins with a Kodac X-omat 1000 processor (Birmingham, U.K.). The signal intensity 
was quantified using an Image-J macro courtesy of Dr S.T.Ward (see Appendix 9). To 
allow comparisons between samples, quantification was normalized against the 
median of the positive reference spots.  
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2.12.  Functional adhesion assays 
2.12.1. Stamper Woodruff (static adhesion assay) 
Frozen tissue sections of CRC and matched NC cut at a thickness of 10 microns, either 
fixed with acetone or not fixed, were collected for use. The sections were prepared on 
the same day as CD8 + T cell isolation (see Section 2.7.4). The sections were defrosted 
at room temperature for 30 mins, then underwent rehydration with PBS for a further 
30 mins. For specific blocking of adhesion molecules of interest, a reservoir was drawn 
around the section with a wax pen and then function-blocking monoclonal antibodies 
were applied at optimal concentrations (based on immunohistochemical staining see 
Appendix 10) for 1 hour at room temperature in a moisture chamber on a rocker. The 
antibody was then gently washed off with PBS and tween (0.1%) before applying 100µl 
total untreated CD8+T-cells at a concentration of 5 x 105 cells per ml. The slides were 
left static at room temperature for 30 minutes. After this the slides were washed gently 
with PBS 3 times, before being fixed for 2 mins in acetone and then undergoing 
haematoxylin and eosin staining. The slides were mounted with coverslips using 
Immunomount. Once dry, 3 representative fields illustrating cell adhesion were 
captured with a bright field microscope (Zeiss axioscope, Axiovision software) and the 
numbers of cells in the superior plane to the tissue were counted by two blinded 
reviewers, to account for inter-observer variability, using Image J software (cell counter 
tool).  
 
2.12.2. Static adhesion assay using endothelial cell monolayers 
Endothelial cells from tumour and normal colorectal tissue were grown to confluence 
in RTC-coated 24-well plates. Once confluent, cells were treated with agents of interest 
or left untreated. Agents used for treatment are outlined in Appendix 9. Whilst the 
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endothelium was stimulated on day 1, PBMCs were simultaneously prepared for CD8+ 
T cells isolation (see Section 2.7.4). CD8+T-cells were either left untreated or 
underwent prior incubation with blocking antibodies (see Appendix 11). Where 
receptor-blocking antibodies were used, incubation periods and washes were followed 
in according to manufacturer’s guidelines. CD8+T-cells were then labeled with CSFE 
cell tracker according to manufacturer’s guidelines (C34554 Invitrogen, UK) and then 
resuspended in EBM-2 (LONZA, UK) with 1% BSA at a concentration of 25x104 CD8+T-
cells/ml. NEC and TEC were incubated in the dark at 37°C for 30 minutes with 500μl of 
labeled CD8+T-cells. Adherent CD8+T-cells and TEC were fixed with methanol as 
previously described, and triplicate images captured at x20 magnification using Ultra 
violet microscopy (Nikon eclipse TE2000-5). Labeled cells bound to the endothelial 
monolayer, were counted using Image J software (cell counting tool). To compare data, 
the mean and SEM of the three images taken for triplicate wells was obtained.  
 
2.12.3. Chemotaxis assays 
To assess how CCL2 in colorectal TEC supernatant may affect the homing of CD8+ T 
cells TEC chemotaxis assays were performed across inserts with 5μm pores. (See Figure 
2.3.) Anti-human CCL2 blocking antibody (R&D systems, U.K.) was used to treat 
triplicate wells of confluent primary human colorectal TEC (passage 4) in a 24 well 
plate. The wells were incubated with the blocking antibody for 1 hour. Simultaneously, 
CD8+ T-cells were isolated using CD8+T-cell untouched isolation bead kit (Invitrogen, 
UK) from HFE PBMCs. Lymphocytes were labeled with CSFE cell tracker and CD8+ T-
cells were resuspended in EBM-2 (LONZA, UK) with 1% BSA at a concentration of 
25x104 CD8+T-cells/ml. Both antibody-treated and control TEC were incubated in the 
dark at 37°C for 12 hours with 500μl of labeled CD8+T-cells separated by Transwell 
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inserts (5μm sized pores, Corning Inc. USA, purchased from VWR U.K. cat no. 29442-
118) after which inserts were removed, cell supernatant was aspirated and CD8+T-cells 
were counted using trypan blue and a haemocytometer. Adherent CD8+T-cells and 
TEC were fixed with methanol as previously described, and triplicate images captured 
at x20 magnification (Nikon eclipse TE2000-5). Data for captured cells were presented 
as absolute figures. Labeled cells adhered to the endothelial monolayer, were counted 
using Image J software (cell counting tool). To compare data, the mean and SEM of the 
three images taken for triplicate wells was obtained. 
 
 
 
 
Figure	2.3.	A	diagrammatic	representation	of	chemotaxis	assay	set	up.	
To	 understand	 if	 CCL2	 produced	 by	 tumour	 endothelial	 cells	 may	 contribute	 to	 chemotaxis	 of	 CD8+	
lymphocytes,	 Transwell	 inserts	 that	 would	 cause	 a	 partial	 barrier	 were	 employed.	 Quantification	 of	 cells	
attracted	 towards	 the	 TEC	monolayer	 was	 performed	microscopically	 in	 the	 presence	 and	 absence	 of	 CCL2	
inhibitor.	
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2.12.4 Flow-based adhesion assays 
Endothelial cells from tumour and normal colorectal tissue were grown to confluence 
in Ibidi  µ-slide sVI0.4 (IB-80606, Thistle Scientific, U.K.) according to manufacturer’s 
guidelines (see Figure 2.4). This facilitates the study of lymphocyte rolling and 
adhesion in conditions similar to those in vivo (see photo insert of Ibidi slide in Figure 
2.4). Once confluent, the cells in each lane either underwent specific treatments as 
required or were left untreated. Agents used for treatment are listed in Appendix 9. 
Simultaneously CD8+T-cells were isolated from HFE PBMCs. For flow assays CD8+ T-
cells were used untreated. The flow-based assay was set up so that cultured Ibidi slides 
were adhered to the stage micrometer with masking tape and flushed with wash buffer 
(EBM-2 with 1% BSA) to ensure air bubbles are avoided. The equipment was set up as 
shown in the representative diagram (Figure 2.4); the syringe pump was set to a flow 
rate of 0.28ml/minute; the field area was 10x magnification; one syringe contained cells 
at a concentration of 1x106/ml; the TV and recorder were set up ready for use. After 1 
minute of washout the washout, a 5 minute cell perfusion period occurred during 
which rolling was recorded for the middle 3 minutes. The endothelial layer was then 
washed again with buffer for 4 minutes and the latter 3 minutes were recorded for 
adhesion. Recording, for both rolling and adhesion, was performed in 12 fields lasting 
at least 5 second, from the “out end” to avoid recording duplicate cells. This was 
repeated from each lane of the Ibidi slide. Rolling and adherent cells were then 
analyzed and counted off line. Rolling cells were described as those moving slower 
(typically 10-20um/sec) than the non-adherent cells in free flow of liquid (typically 
100’s of um/sec) but not static. Adherent cells were all those considered static, 
transmigrated, or adherent and shape changed/activated. Rolling was presented as a 
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percentage of adherent cells. Adherent cells were calculated using the equation in 
Figure 2.5. 
 
 
Figure.	2.4.	A	diagramatic	representation	of	the	flow	assay	set	up.	
Here,	the	ibidi	slide,	with	a	confluent	endothelial	cell	monolayer,	is	placed	on	a	stage	of	a	microscope	which	is	
attached	to	a	TV	and	DVD	recorder.	Lymphocytes	and	wash	buffer	are	perfused	over	the	endothelial	monolayer	
and	into	the	waste	syringe.	Real	time	video	recordings	are	analysed	off	line	to	permit	quantification	of	CD8+	T	
cell	interactions	with	the	monolayer.	
 
 
Figure.	2.5.	The	equation	used	to	calculate	CD8+T-cell	adhesion	to	the	primary	human	colorectal	tumour	and	
normal	endothelial	monolayer	after	flow-based	assay.		Courtesy	of	Dr	P.	F.Lalor.	
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2.13. Image J analyses and Statistical Analysis 
Image J is a Java image and processing and analysis program. The cell counter tool was 
used by downloading and opening available plug ins for “cell counter”. 
Simultaneously, the image captured required for counting is opened. After initializing 
the image, counting can begin by selecting each identifiable cell with a coloured 
number corresponding to the cell type. After each click the counter is updated. Other 
Image J tools used included quantification of immunohistochemical staining. This was 
performed by converting the required image to greyscale, isolating positive DAB 
staining setting the threshold at 33% and then measuring the threshold areas as 
percentages of the image area.  
Where data were continuous, results were presented in graphs as a mean and standard 
error. Within the results data was also presented as mean and standard deviation and 
this is annotated. Between multiple comparisons, statistical significance was calculated 
using ANOVA and significance between single comparisons were calculated using two-
tailed Student’s t-test. Both using SPSS software (IL,USA). Spearman’s rank correlation 
coefficient by PRISM software (Graphpad, USA) was used to analyse the significance of 
correlation on two occasions; between CD31 expression of vessels in tumour and the 
corresponding number CD8+ tumour infiltrating lymphocytes and between aSMA 
expression in tumours and corresponding number CD8+ tumour infiltrating 
lymphocytes. Data was considered significance where P <0.05. Data annotated with the 
following asterisks refers to significance accordingly; * denotes P<0.05 but >0.005, ** 
denotes P<0.005 but > 0.0005 and *** denotes P<0.0005. 
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CHAPTER 3 
________________________________________________________________ 
Long term culture and phenotype of endothelial cells derived from human 
primary colorectal tissue and colorectal cancer. 
________________________________________________________________ 
 
3.1 Introduction 
Pre-clinical studies aimed at targeting TEC-specific markers have often used cell lines 
to explore the regulatory mechanisms of “molecules of interest” (128). Murine models 
are then used to test synthetic analogues or antibodies that inhibit the “molecule of 
interest”, where tumours are implanted subcutaneously into nude mice, before being 
trialed in cancer patients (129, 130). Whilst these approaches generate valuable 
information, cell lines and murine models are not truly representative of what occurs 
in vivo. Differences between microvascular and HUVEC or large vessel endothelium 
are well documented and include variation in E-selectin, ICAM-1 and VCAM-1 
expression in response to cytokine stimulus between small bowel (131) and dermal 
microvascular EC (132). For example, Haraldeson et al report increased expression of 
total cellular E-selectin in response to Il-1β stimulation in human intestinal 
microvascular endothelial cells (HIMEC) up to 72 hours, in contrast to a rapid biphasic 
response in HUVEC and a dose dependent up-regulation of VCAM-1 by IL-4 treated 
HUVEC, peaking after 8 hours compared to minimal effect on HIMEC. Similarly, 
dermal microvascular endothelial cells (HDMEC) show no significant VCAM-1 
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expression in response to IL-1β whereas this cytokine causes significant VCAM-1 up-
regulation by HUVEC.  
These findings provide our rationale for using tissue- and disease- specific 
endothelial cell culture models for functional studies and so, to understand the 
functional role or potential for targeting of TEC in CRC we must investigate the 
phenotype and conduct functional assays using primary endothelial cells derived 
specifically from human colorectal tumours. To date, only 2 laboratories have 
successfully isolated and cultured primary human TEC and matched host NEC. This is 
largely due to the convenience of cell lines and the perceived difficulties of culturing 
primary cells. Phenotyping data from these 2 studies collectively reveal in vitro 
colorectal NEC and TEC isolated by positive CD31 selection, express endothelial 
markers CD105 and VE-Cadherin. In vitro stimulated NEC and TEC are reported as 
expressing adhesion molecules E-selectin, ICAM-1 and VCAM-1 (133,  134). TEC are also 
documented to express higher levels of VEGFR-2 (134) than their matched host NEC. 
Despite these findings, to date, there is no available data to confirm whether TEC 
maintain tumour specific phenotype in vitro. Further to this there are no data 
describing use of cultured human colorectal NEC and or TEC in in vitro functional 
assays.  
Therefore, this chapter outlines our data reporting the in vivo and ex vivo phenotype of 
NEC and TEC. I also describe how the optimal culture conditions were ascertained for 
NEC and TEC.  
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The key aims of this chapter are listed below. 
1. To investigate the in vivo phenotype of microvascular endothelium derived from 
colorectal tumour and matched normal colon.  
2. To explore whether the in vitro and in vivo phenotypes of NEC and TEC 
correlate. 
3. To identify the optimal culture conditions for long term culture of these cell 
types. 
4. To explore if there is a tumour specific phenotype of endothelial cells derived 
from CRC.  
 
 
 
 
 
3.2. Results 
 3.2.1. CD31 is expressed by human colonic tumour microvascular endothelium  
To assess the potential for isolation of endothelial cells from human colonic tumours, 
we sought to identify the most consistently expressed vascular-endothelium specific 
surface marker. We began by using immunohistochemical staining to assess the 
density of vessels in colorectal cancer and normal colon tissue sections. Examination of 
tissue sections stained with CD31 (see representative images in Fig 3.1) revealed 
positive cytoplasmic and membrane staining of the vascular endothelium through all 
tissue layers from mucosa to the deeper muscle layers in normal colon and through 
invasive mucosal and tumour stromal layers in colorectal cancer sections.   
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The intensity, consistency and microvascular-endothelial specific localisation of 
positive staining was reviewed and graded with a consultant histopathologist. Normal 
colon and colorectal cancer sections both displayed membrane and cytoplasmic CD31 
staining on microvascular endothelial cells throughout the mucosal, submucosal and 
deeper muscle layers of NC and invasive and stromal tumour tissue from CRC.  In 
addition, CD31 positive staining was also present in lymphocyte populations within 
both normal colon and colorectal cancer tissue. 
Normal colon and colorectal cancer both displayed CD146 staining of the 
vascular endothelial cells. Importantly, CD146 expression was not present on the 
microvasculature of the lamina propria of the normal colon mucosal layer but 
predominantly on larger vessels. CD146 was also expressed by the smooth muscle and 
pericytes surrounding the larger vessels (Figure 3.1). Semi-quantitative analysis was 
performed to compare the intensity and proportion of positive staining by all cell types 
within both NC and CRC (Table E, Figure 3.1). Positive CD31 and CD146 staining was 
scored from 0-3 (where 0 is no positive staining and 3 is intense staining and staining 
of all cell types) for 9 pairs of matched NC and CRC. The mean proportion of 
microvascular endothelial cells stained positive with CD31, 2.6± 0.58, was significantly 
more than CD146, 1.3±0.58 (p=0.047). However, there was no statistical difference 
between the intensity of staining. There were significantly more immune cells stained 
by CD31, (mean 1.3±0.58 compared to 0, p=0.016), and more smooth muscle pericytes 
stained by CD146 (mean 0 compared to 1.6±0.58, p=0.007). There were no differences 
between NC and CRC in staining of CD31 or CD146 by cell type. 
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A B
C D
Figure 3.1 CD31 expression in whole tissue NC and CRC. All images represent immunohistochemical staining with microwave
antigen retrieval technique of either anti-CD31 (A&B) or anti-CD146 (C&D) antibody with indirect DAB staining and
haematoxylin counterstaining in paraffin wax embedded sections of normal colon (NC, images A and C) and Dukes C primary
colorectal cancer (CRC, images B and D). Sections were imaged with Zeiss Axiovert microscope and images were captured
with Axiovision software. Images were then assessed for positive endothelial cell membrane and cytoplasm staining within
the microvasculature of both NC and CRC at x20 magnification by CD31 and CD146. A semi-quantitative and descriptive
analysis of immunohistochemical staining using anti-CD31 and anti-CD146 antibodies to stain normal and tumour colorectal
tissue is presented in table E. This was performed for 3 matched samples NC and CRC. Both the intensity of staining and the
proportion of vessels stained by each protein was scored by one reviewer, and given a value between 0-3 where 0 is no
positive staining/ none cells of interest present stained and 3 is very intense positive endothelial staining/ all cells of interest
present in the field view positively stained. Data is presented as mean and standard deviation and, where appropriate
(range). A quantitative analysis of positive CD31 and CD146 staining throughout normal and tumour colorectal tissue is
presented in table F. The percentage area of most intense positive staining was obtained on 3 matched samples of NC and
CRC that had undergone immunohistochemistry for anti-CD31 and anti-CD146 antibody. Stained section images were
captured by Axiovision software which were then analysed with image J software (see section 2.13). Data shown is as a mean
% of positive staining per field view area. Significance of data for CD31 compared to CD146 were assessed using paired
Student’s t- test.
Cell	type
Antibody
Endothelial	
cells
Immune	cell
infiltrates
Epithelial	
cells
Fibroblasts Smooth	muscle
NC CRC NC CRC NC CRC NC CRC NC CRC
CD31
Proportion
of		staining 2.6	(2-3) 2.6	(2-3)
1.3 (1-
2) 1.6	(1-2) 0 0 0 0 0 0
Intensity	
of staining 3 2.6	(2.3) 1.3	(1-2) 1.3	(1.2) 0 0 0 0 0 0
CD146
Proportion
of		staining 1.3 (1-2)
1.3 (1-2) 0 0 0 0 0 0 1.6 (1-2) 1.6 (1-2)
Intensity	
of staining 2.6	(2-3)
2.6	(2-3) 0 0 0 0 0 0 1.6	(1-2) 1.6	(1-2)
Tissue	type
Antigen
Normal	colon
%	Area	of	most	intense	positive	staining	
(number	of	samples)
Colorectal	cancer
%	Area	of	most	intense	positive	staining	
(number	of	samples)
CD31 16.16±4.17	(5) 9.34±5.84	(6)
CD146 0.67±0.67	(3)*** 0.56± 0.89	(3)*
E
F
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Next a quantitative analysis was performed of the percentage positive staining 
across a section using Image J software.  Using field areas that were comparable in 
terms of amount of stroma and numbers of vessels, CD31 expression, mean 16.2±4.17%, 
was found to be higher than CD146, mean 0.67±0.67% in NC (p=0.008). CD31 
expression was also higher in CRC samples (Table F, Figure 3.1) where the mean CD31 
expression was 9.34±5.84% compared to 0.56±0.89% found in CD146 staining (p=0.04). 
As a result of these findings, CD31 was subsequently used as the membrane bound 
endothelial marker of choice for endothelial isolation procedures. 
 
3.2.2. Development of a protocol for isolation and culture of primary 
endothelial cells from colorectal tumour and matched normal colon tissue 
The final protocol I used for isolation of colonic endothelium is detailed in the main 
Material and Methods chapter (sections 2.4.2 and 2.5). However, this chapter details 
the development of this final protocol and so additional methodological detail is 
supplied here. The following sections outline the changes made to existing protocols, 
and their success. The success of either a protocol or the changes made was judged on 
the following criteria in order. 
 
1. The yield of total cell population before culture 
2. The absence of infection 
3. The typical endothelial cell morphology and lack of contaminating cells 
4. The viability of endothelial cells in long-term culture 
5. The yield of endothelial cells at each passage 
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Below are the evolutionary steps and progress made from September 2011 to May 2012 
and refers only to work done during that time frame followed by the learning points 
and subsequent changes made as a result my visit to Dr Naschberger at the Division of 
Molecular and Experimental Surgery, at the University Medical Center Erlangen.  
 
The Birmingham Experience  
In total from 15th October 2011 to 1st May 2012, 32-paired fresh tissue specimens were 
used for pilot isolation and culture of endothelial cells from colorectal tumour and 
matched normal colon (TEC and NEC) in order to develop an optimized protocol. To 
achieve this, systematic adaptations were made to published protocols for isolation 
(20) and culture of endothelial cells from non-malignant samples and tissue other than 
colon or rectum (20, 135, 136). 
Methods of digestion were based on in-house human primary hepatic endothelial 
isolation protocols (HSEC isolation) and used a slicing technique with 2 sterile scalpels 
followed by a 30-minute incubation period with collagenase 1b (SIGMA, C9891 
>125units/mg). In addition, a mechanical method of digestion was adopted by using 
the Miltenyi Biotech GentleMACS™ digestor, and human tumour dissociation program 
1. This increased the total cell population yield from normal colon (NC). A mean of 5.5 
x 106 cells were extracted using GentleMACS™ compared to a yield of  0.41 x 106 cells 
per gram of tissue from 5 independent experiments for each method of digestion. 
However, despite an improved yield in single-cell suspension with the Gentlemacs, 
only 1 out of 5 preparations expanded in culture after use with the mechanical 
digestion compared to 4 out of 5 from the enzymatic digestion alone. I also noted 
excess mucous in the preparation of normal colon and mucinous tumour types, which 
was most noticeable at filtration immediately after digestion and interfered with cell 
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isolation. To address this, an increased volume of PBS was used to dilute the cell 
suspension and this lead to an increased mean yield of total cells from NC to 6.89 x 106 
cells per gram of tissue. After this initial digestion, I used a cell selection step with 
CD31 or Ulex lectin immunomagnetic beads according to the HSEC protocol or the 
Bicknell tumour endothelium isolation protocol (Appendix 1) respectively. Irrespective 
of the target protein used to isolate the ECs, excess mucous inhibited the yield from 
the bead separation step. The bead-bound cells would persistently be trapped within 
the mucous and thus did not attach to the magnet effectively. Increased dilution steps 
at this point also increased total cell yields from approximately 6 x 104 to 2 x 106 cells 
per gram of tissue.  
Use of biotinylated immunomagnetic beads attached to Ulex lectin has been 
reported to isolate microvascular endothelium (137). In our experience, where Ulex 
Lectin was used to isolate endothelium (Appendix 1), the resultant cultures did not 
exhibit typical endothelial morphology but instead, appeared spikey and characteristic 
of overgrowing fibroblasts (not shown). In contrast when CD31 Dynabeads (section 
2.5.1) were used, most cultures exhibited typical cobblestone endothelial morphology 
(see representative images in Figure 3.2). On occasion we still saw contaminating non-
endothelial populations using this strategy (Figure 3.2) but results were preferable to 
using Ulex Lectin, and therefore, CD31 Dynabeads was used to isolate the endothelium 
for the remainder of isolation protocols.  
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Figure 3.2: Primary colorectal tumour endothelial cells isolated with CD31 dynal beads display a
cobblestone appearance in culture. Image represents two photos taken of the resultant cells from 2
different isolation techniques (2011-May 2012). Image A. represents the resultant cells at passage 2 after
using CD31 coated immunomagnetic beads to isolate the endothelial cells. The black arrow represents
the anti-CD31 immunomagnetic Dynabeads used in the isolation process. Image B. shows isolated
endothelial cells on the le ft abutting contaminating fibroblasts on the right. Images taken at original x10
magnification with a phase contrast microscope.
Figure	3.3:	Primary	Human	TEC	derived	from	colorectal	cancer	2	hours	post	Flow	assisted	cell	
sorting.	Image	represents	TEC	in	vitro	adherent	to	culture	plate	of	a	t-25	flask	with	10	minutes	of	
isolation	by	Flow	assisted	cell	sorting	using	anti-CD31	antibody	conjugated	to	FITC.	Image	is	
captured	at	x20	magnification	with	a	light	phase	contrast	microscope.	
A B
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Of note, although this selection strategy was generally reliable, problems were 
identified with some loss of endothelial morphology after first passage and occasional 
bacterial or yeast infections during culture. During the pilot phase, 8 infections 
occurred. On 3 occasions, both NC and CRC were affected (2 x bacterial, 1x yeast) and 
the remaining 5 related to either NC or CRC (3 and 2 infections respectively) with 
either yeast or bacterial contamination. All infections occurred from October 2011 to 
May 2012. The problems and our successful refinements to avoid them are summarized 
in Table 3.2. At this point email contact was made with Dr Naschberger at the division 
of molecular and experimental surgery, Erlangen to obtain some advice about their 
published protocol (60) and how they maintained endothelial cell morphology and 
eliminated infections.  
In addition, I tested the potential of cell isolation by flow assisted cell sorting 
using fluorescence conjugated anti-human CD31 antibodies. The method is outlined in 
Chapter 2. On 2 occasions the resultant cells were plated in culture under our standard 
growth conditions. Both NEC and TEC were observed to adhere to the culture plate 
after FACS (Figure 3.3) however over the course of the subsequent 48 hours cell 
detachment was noted and expansion was not possible.  
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Table 3.1. A summary table of the main problems encountered when using both the HSEC CD31
endothelial culture and isolation protocol, and the Bicknell tumour isolation Ulex Lectin pr otocol to
isolate and culture tumour and normal endothelial cells from colorectal tissue. This table charts the
problems from October 2011-May2012 and the steps taken to address the problems.
Stage	and	initial	method
Problem	with	protocols,	
October	 2011	-May	2012 Protocol	 amendment
Bicknell	 tumour	endothelial	
isolation	 protocol Fibroblastic	contamination Switch	to	CD31	as	a	selection	strategy	
Tissue	 dissociation	with	both	
Bicknell	 tumour	Ulex	Lectin	
isolation	 and	HSEC	CD31	
methods
Excess	mucous	leading	to	lower	yields	
and	reduced	isolate	specificity
Mechanical	digestion	in	larger	
samples
Excess	mucous	reducing	isolate	
specificity
Multiple	washes	at	post	collagenase	
stage	 and	magnet	stage
Bicknell	 tumour	Ulex	Lectin	
isolation	 and	HSEC	CD31	
methods
Persistent	loss	of	endothelial	cell	
morphology	after	cell	detachment	at	
passage
Contact	made	with	Erlangen
-Use	 Accutase	instead	of	Trypsin	
based	cell	detachment
Bicknell	 tumour	Ulex	Lectin	
isolation	 and	HSEC	CD31	
methods
Either	 bacterial	or	yeast	 infections	in	
culture	of	about	40%	of	both	normal	
colon	and	CRC	isolates
Contact	made	with	Erlangen
-Increase	 washes	and	use	antibiotic
supplemented	PBS
Objectives	of	trip Protocol	 changes	resulting	 from	trip
Reduce	risk	of	infection
Wash	both	normal	 colon	and	CRC	tissue	
vigorously	at	least	3	times	in	a	minimum	
of	40mls	buffer	solution	 (supplemented	
with	antibiotics)	 prior	 to	digestion	step.	
Improve	yield	of	cell	 count	 in	
single	cell	 population
Use	collagenase	II	from	Biochrom,	 which	
has	a	high	unit	of	activity
Avoid	shearing	forces	when	cutting	 the	
tissue	with	scalpels
Reduce	contamination	 cells	and	
improve	Endothelial	 cell	 purity
Place	ECs	in	culture	 before	bead	isolation	
step
Table 3.2. Table outlining the remaining problems with the endothelial cell isolation protocol changes
adopted based on di scussion with Erlangen. Protocol changes that resulted from the trip to Erlangen, to
resolve outstanding protocol issues are outlined
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The Erlangen Experience 
Our early data demonstrated that cultures of cells, which displayed endothelial cell 
morphology, lost this after passage. Flow cytometry also showed passaged cells to be 
CD31 negative and CD90 positive (not shown). Thus our method for passage and cell 
detachment was re-assessed. Schellerer and Naschberger et al (60) are the only group 
who have published data from cultured NEC and TEC from colorectal tissue. Their 
methods state that 1 x 0.5 g/l trypsin and 0.2 g/l ethylenediaminetetraacetic acid 
(EDTA) was used to dissociate their cells, which is similar to the HSEC protocol. 
However, on contact with Dr Naschberger, from the group, she noted, there had been 
issues with the trypsin cleaving cell surface CD31 and that subsequently, further CD31 
isolation at passage 1 was ineffective. Interestingly, using Trysin and Tryp-LE on HSEC 
does not have the same effect on the CD31 epitope. However, Accutase, a gentler form 
of enzymatic cell detachment was recommended to preserve expression. This had a 
dramatic effect and at one-week post detachment further purification steps with CD31 
beads were possible for both NEC and TEC. CD31 positivity maintained by NEC and 
TEC, was confirmed by our flow cytometrical, indirect ELISA and 
immunocytochemical analysis (Figure 3.4, detailed later). This would not have been 
possible without this change in protocol and has meant that phenotyping of NEC and 
TEC post culture and future functional studies can be performed. Other learning 
points from the trip included increased number of preparation washings with buffer 
and increased use in Gentamycin and amphoteracin and Penicillin, streptomycin and 
glutamine. In addition, the use of collagenase differed to collagenase II from Biochrom. 
This produced yields between 5-6x106 cells/gram of tissue for both NC and CRC 
without mechanical digestion; which was preferable. Furthermore, as a result of the 
visit, culture of total cell populations was performed and isolation with anti-human 
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CD31 immunomagnetic beads occurred after expansion in culture, which allowed 
expansion to passage 4 more frequently that isolates prior to initial culture expansion 
(data not shown).  
 
3.2.3 Validation of in vitro model of colorectal tumour Endothelium 
To confirm that both NEC and TEC maintain typical vascular endothelial cell 
characteristics in vitro, immunocytochemistry (ICC), flow cytometry and in-direct 
enzyme-linked immunosorbent assay (ELISA) were performed. CD31 was expressed by 
both NEC and TEC at the plasma membrane throughout most the monolayer and 
occasionally cytoplasmic CD31 expression was within the cytoplasm by ICC. 
Cytoplasmic VWF was identified in NEC but was reduced in TEC. Flow cytometry of 
TEC confirmed at least 93% CD31 positivity (Figure 3.4). CD31, VWF and ICAM-1 
expression was found on un-stimulated and stimulated NEC. ELISA confirmed that 
CD31 was expressed more than VWF or ICAM-1 by un-stimulated NEC, and was 
slightly up regulated by IL-1β stimulation but not TNFα. In contrast ICAM-1 expression 
was most increased after stimulation with TNFα. The effects of TNF stimulation were 
more marked for TEC with the percentage of cells that expressed VCAM-1 increasing 
over 4 fold (un-stimulated 2.5% to TNFα 12.6%) and the median channel value 
increasing (un-stimulated 19.4 to TNFα 26.8) after 8 hours of TNFα treatment (Figure 
3.4). 
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Expression of endothelial phenotypic markers in normal human colonic 
endothelium and tumour microvascular endothelium. 
In addition to identifying reliable endothelial markers for subsequent isolation 
methods, we sought to characterize expression of von Willebrand Factor (VWF), VE-
Cadherin, Vascular endothelial growth factor receptor 2 (VEGFR-2) and CD105 in both 
colorectal tumour endothelium (TEC) and non-diseased colorectal endothelium (NEC) 
to understand the differences between un-involved and malignant tissue. 
Immunohistochemical techniques were used to identify the localisation and quantity 
of positive staining of the molecules of interest through NC and CRC tissue sections 
(see representative images in Figure 3.5). 
Positive cytoplasmic VWF staining of the endothelium was seen throughout 
both NC and CRC tissue and within the microvasculature of mucosal, submucosal and 
deeper muscle layers of NC and invasive mucosa and stroma of CRC, with expression  
more abundant in NC.  However, a semi-quantitative analysis performed on 3 paired 
NC and CRC sections, revealed the same mean score reflecting intense positive 
endothelial staining of 3 for both NC and CRC (Figure 3.5). However, the proportion of 
vessels stained was higher in NC than CRC (3 v’s 2.6 respectively). 
 There was very little positive endothelial staining for VE-Cadherin in either NC 
or CRC compared to the isotype-matched control. In NC sections and to a lesser extent 
in CRC, cytoplasmic staining was found in a few microvasculature endothelial cells of 
the submucosal layer and stromal layer, but not all endothelial cells of the same vessel 
showed positive expression. Where staining occurred, the intensity appeared less in 
CRC sections.  Semi-quantitative analysis of VE-Cadherin expression produced a mean 
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score of 0.3 (2 sections scored 0, and one scored 1) for proportion of vessels stained and 
for intensity; NC scored 1, whereas CRC scored a mean of 0.6.  
Membrane and cytoplasmic VEGFR-2 expression by the microvascular 
endothelium in the lamina propria of NC and through the stroma of CRC was observed 
(Fig 3.5 panels E and F). Small amounts of artifact staining were seen at the mucosal 
edge of NC but no non-specific staining was seen in NC or CRC compared to isotype-
matched control. Where endothelial positive staining was seen, not all endothelial 
cells from a vessel expressed VEGFR-2 in both NC and CRC. Semi-quantitative analysis 
suggested a similar proportion of vessels were stained in NC section compared to CRC 
(mean score of 1.3 v’s 1.3) whereas the intensity score suggested CRC displayed slightly 
more intense positive staining (mean score of 1 v’s 1.3).  
 Cytoplasmic and membranous CD105 expression (Fig 3.5 panels G and H) was 
noted on all endothelial cells of micro vessels of the submucosal layer of NC, 
particularly near areas of high lymphocytic infiltration and extensively throughout the 
stroma of CRC sections. Findings from the subjective analysis were supported by semi-
quantitative assessment, which suggested CD105 expression was relatively high in both 
NC and CRC compared to other proteins. CD105 was found on a higher proportion of 
vessels and was more intense in CRC compared to NC (mean scores of 2.3 v’s 2.6 and 
1.6 v’s 2.3 respectively). 
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Mean semi-quantification score	(n=3)
NC CRC
VWF
Proportion of	endothelial	
staining
3 2.6±0.58	(2-3)
Intensity	of staining 3 3
VE-
Cadherin
Proportion of	endothelial	
staining
0.3±0.58	(0-1) 0.3±0.58	(0-1)
Intensity	of staining 1 0.6±0.58	(0-1)
VEGFR-2
Proportion of	endothelial	
staining
1.3±0.58	(1-2) 1.3±0.58 (1-2)
Intensity	of staining 1 1.3±0.58	(1-2)
CD105
Proportion of	endothelial	
staining
2.3±0.58	(2-3) 2.6±0.58 (2-3)
Intensity	of staining 1.6±0.58	(1-2) 2.3±0.58	(2-3)
Figure 3.5: Expression of endothelial markers by normal colorectal tissue and colorectal cancer.
Immunohistochemistry was performed using unfi xed frozen whole tissue sections of NC and CRC (7μm thickness)
by an indirect DAB staining method. Mouse anti-human antibodies against Von Willebrand factor (VWF), VE-
Cadherin, Vascular Endothelial growth factor 2 (VEGFR-2) and CD105 were used in addition to isotype matched
controls. Representative images were taken at 20x magnification and retrieved usingAxiovision software. Images
A,C,E,G represent NC and B,D,F,H represent CRC. A&B show VWF, C&D show VE-Cadherin, E&F show VEGFR-2,
G&H show CD105 staining. A semi-quantitative score was performed for 3 matched samples for both the
intensity of staining and the proportion of vessels stained by each protein between 0-3 where 0 is no positive
staining/ none of the endothelial cells present stained and 3 is very intense positive endothelial staining/ all
endothelia present in the field view positively stained. The mean (range) is shown as a table in image I.
Significance was tested using student T test. Data between NC and CRC were not significant.
I
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Quantitative flow cytometry (Figure 3.6) was used to explore the expression of VE-
Cadherin, CD105, and VEGFR-2 by isolated endothelial cells derived from CRC and NC 
(TEC and NEC). There were no significant differences between the mean percentage 
membranous expression of VE-cadherin in NEC, over 6 paired and non-paired 
samples, compared to CRC (28.66% vs 17.75%, Figure 3.6). The data describing 
percentage expression suggests VE-cadherin is expressed by fewer cells compared to 
CD105 but not VEGFR-2 for both TEC and NEC although using ANOVA, there is no 
statistical difference. Furthermore, the data indicates that a higher percentage of NEC 
express CD105 and VEGFR-2 compared to TEC. However, analysis of the median 
channel value expression for these molecules suggests that VE-Cadherin is expressed 
significantly less intensely compared to VEGFR-2 and CD105 in NEC (p=0.023 and 
p=0.01). VE-cadherin expression is also significantly less intense compared to VEGFR-2 
in TEC (p=0.027, Figure 3.6).  
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3.2.4 Analysis of key functional genes expressed by normal human colonic and 
tumour microvascular endothelium. 
Gene expression data were obtained by performing a commercially available profiling 
array containing 85 genes of interest and additional controls (Figure 3.7). The genes are 
divided into functional groups such as those contributing to angiogenesis, 
inflammatory response and cellular adhesion. Data retrieved from 3 Flow assisted cell 
sorted (FACS) TEC with matched NEC, were organized into those genes down and up-
regulated in TEC using NEC as a comparative baseline after comparison to GAPDH 
and b-Actin as housekeeping genes. This revealed little consistency in gene expression 
across the samples. Very few genes were consistently either up or down regulated by 
all 3 samples. Within the angiogenesis gene grouping, the gene that transcribes VEGF-
A, a ligand for VEGF-2 was upregulated by all TEC samples relative to matching NEC 
and resulted in a mean up-regulation in TEC of 7.2. Although the mean gene 
expression for EDN1, EDNRA and eNOS were also increased (mean fold increase in 
TEC relative to NEC of 7.04, 23.5 and 4.06 respectively), there was significant 
heterogeneity between expression of these genes between individual samples to 
provide significant data (Figure 3.7).  
 Within the functional group for inflammatory response, the mean expression of 
genes transcribed for inflammatory chemokines IL-6, CCL2 and CCL5 were up-
regulated (mean fold increase of 4.65, 1.42 and 1.83 in TEC relative to NEC respectively) 
however, this was not statistically significant. In addition, the mean expression of 
genes transcribing for proteins E-selectin and Vascular Cellular Adhesion Molecule -1 
(VCAM-1) were marginally upregulated at mean 6.08 and 8.42 fold increase in TEC 
relative to matched NEC, but	 significant heterogeneity of gene expression between 
individual samples mean data is not generalizable.  
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Figure	3.7:	Profiling	of	change	in	gene	expression	between	normal	and	tumour	endothelial	
cells.
Primary human colorectal endothelial cells were isolated with Flourescence assisted cell
sorting (FACS) from single cell suspensions of 3 matched NC and CRC samples using CD31 FITC
and a live/dead cell marker (Section 2.5.3). Isolated cells were collected in RLT buffer (Qiagen,
UK), homogenized and underwent mRNA extraction (Qiagen Rneasy minikit, UK) and cDNA
extraction (Iscrip, Biorad, uk). RT-QPCR was undertaken using an original concentration of 45ng
/μl of mRNA for all samples using the commercially available RT2 profiling PCR array Endothelial
cell biology (SABiosciences, QIAGEN, UK). Analysis was performed using ΔΔCT method (Section
2.9.5) using GAPDH and Beta Actin as housekeeping genes and obtaining the TEC value as
sample of interest against matched NEC. Data in each graph is presented as floating bars
showing the max, minimum and mean (shown by mid bar line) values of the 3 relative gene
expression values. Data is presented in each graph according to grouping of cell function. The
red line on each graph is drawn at 1 to represent NEC value. Data did not reach significance.
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Expression of genes transcribing other proteins of interest, were grouped under 
the cell adhesion function. These included PECAM-1 (CD31), Cadherin-5 (VE-
cadherin), VWF, ICAM-1. Our data shows the mean gene PECAM-1, Cadherin-5 and 
VWF gene expression was lower in TEC samples compared to relative expression in 
NEC (mean fold change of 0.83, 0.78, 0.92 in TEC relative to NEC respectively). The 
mean ICAM-1 gene expression was 4.3 fold higher in TEC samples relative to matched 
NEC however, this data did not reach statistical significance (Figure 3.7). 
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3.2.5 Key differences between TEC and NEC are maintained in culture 
To investigate if TEC maintain a tumour-specific phenotype in culture, protein and 
gene expression of TEC and NEC were quantified using immunocytochemistry and 
qPCR. Tumour marker endothelium 8 (TEM-8) was tested as a marker of tumour 
endothelium, by performing immunohistochemistry with anti-human anti-TEM-8 on 
CRC tissue sections (see Figure 3.8). Cytoplasmic and membranous TEM-8 staining 
was seen within the microvascular endothelial cells of CRC and not in nearby NC (see 
Figure 3.8, image B). Comparison of TEM-8 expression in NEC and TEC by flow 
cytometry revealed both MCV and percentage of cells expressing TEM-8 were higher in 
freshly isolated TEC than NEC (see Figure 3.8). Expression of TEM-8 was also analysed 
on cultured cells using flow cytometry, suggesting that both percentage expression and 
median channel value of TEM-8 expression remains higher in TEC compared to NEC 
(Figure 3.9). This was confirmed using ELISA on 3 in vitro NEC samples compared to 
one TEC sample where the absorbance values suggested TEM-8 was elevated in TEC 
(Fig 3.9).  
Fig 3.9 illustrates with standard PCR, a visible band representing TEM-8 gene 
expression in freshly isolated NEC, however the signal is less intense than that 
representing CD31 or that produced by matched freshly isolated TEC. In contrast, 
cultured NEC did not produce a visible band for TEM-8 gene expression whilst 
expression is similar in cultured TEC. Expression was quantitatively assessed using 
qPCR (Figure 3.9) which confirmed increased expression in TEC with a mean of over 
15-fold increase in expression in TEC relative to NEC.  
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Figure 3.8: Tumour endothelial marker 8 (TEM-8) is expressed by Colorectal tumour endothelium in whole
tissue and isolated primary TEC from human CRC. Immunohistochemistry was performed using unfixed frozen
whole tissue sections of Dukes D CRC (7μm thickness) by an indirect DAB staining method. Mouse anti-human
antibody against TEM-8 were used in addition to isotype matched controls. Images A-C show representative
sections of CRC with positive endothelial cell anti-human TEM-8 antibody staining taken using Axiovision
microscope at 20, 10 and 40x magnification respectively. Images were retrieved using Axiovision software. The
dashed black line in image B illustrates the margin between invasive CRC (right) and nearby NC (left). Image C is a
closer look at the staining in image A and the black arrow linking image A to C highlights positive endothelial
staining. Primary human endothelial cells were isolated from human normal colorectal and colorectal cancer
tissue samples. Cells were then stained and washed for 30 mins with mouse anti-human TEM-8 antibody with
isotype matched control (Appendix 3). The isolated normal and tumour endothelial cells then underwent flow
cytometrical analysis on a standardised protocol using Becton Dickenson Cyan flow cytometer and Summit v4.3
software. Images D illustrates flow cytometric data describing TEM-8 expression by both NEC and TEC. Both
graphs show data for unpaired samples in both percentage expression (left panel) and median channel value
(right panel) expressed as mean and SEM. Statistical analysis was performed using un-paired, two tailed T-test. %
TEM-8 expression was significantly higher in TEC.
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Figure 3.9: Tumour endothelial marker 8 (TEM-8) expression by in vitro primary isolated TEC from human CRC.
Primary human endothelial cells that had undergone positive CD31 selection from human normal colorectal and
malignant tissue samples were cultured to confluence (passage 4). Cells were stained and washed for 30 mins with
mouse anti-human TEM-8 antibody with isotype matched control (see appendix 3). NEC and TEC then underwent flow
cytometrical analysis on a standardised protocol using Becton Dickenson Cyan flow cytometer and Summit v4.3
software. Images A illustrates TEM-8 expression by both NEC and TEC. Both graphs show data for paired samples in
percentage expression (left) and MCV (right) expressed as mean and SEM. In vitro NEC and TEC in flat bottom 96 well
were then stained with TEM-8 and expression was determined using indirect HRP and TMB indirect ELISA. Absorbance
was read at 450nm using an absorbance plate reader and calculated against isotype matched controls. Image C
illustrates the mean comparative absorbance of TEM-8 by 3 in vitro NEC samples and 1 in vitro TEC sample. In vitro
cells underwent mRNA extraction (Qiagen Rneasy minikit, UK) and cDNA synthesis (Iscrip, Biorad, uk). Real time qPCR
and standard PCR was undertaken using an original concentration of 45ng /μl of mRNA for all samples using Taqman
gene probes and primer (Invitrogen) or Sigma self designed primers (see appendix). For qPCR, CT values were
calculated using Stratagene Mx3000P and analysis was performed using ΔΔCT method (Section 2.9.5) using GAPDH
and Beta Actin as housekeeping genes and obtaining the TEC value relative to NEC. Images of gene expression by
standard PCR was visualized using GeneGenius Bio Imaging System (Syngene, UK) and Genesnap software (Syngene,
UK). Image D illustrates resultant qPCR data. Image E illustrates standard PCR data for TEM-8 expression against CD31
gene expression as a positive control. The bars represent; i. freshly isolated NEC, ii. freshly isolated TEC, iii. NEC in
culture at passage 4, iv. TEC in culture at passage 4. Where applicable, statistical analysis was performed using un-
paired, two tailed Student’s t-test.
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Figure 3.10: CD13 (WM15) expression by NC and CRC whole tissue and primary NEC and TEC isolated from
human NC and CRC. . Immunohistochemistry was performed using unfixed frozen whole tissue sections of
Dukes C CRC (7μm thickness) by an indirect DAB staining method. Mouse anti-human antibodies against
CD31 or CD13 (WM15) were used in addition to isotype matched controls. Images A, representing CD31
staining, and image B, representing CD13 (WM15) staining were taken using Axiovision microscope at 10x
magnification and image C, which also represents CD13 (WM15) staining and is a closer look at image B, was
taken at 40x magnification. Images were retrieved using Axiovision software. The black narrow connecting
images B&C illustrates positive endothelial staining. Primary human endothelial cells that had undergone
positive CD31 selection from human normal colorectal and colorectal cancer tissue samples were cultured
and subsequently purified up to passage 4. Cells were stained and washed for 30 mins with mouse anti-
human CD13(WM15) antibody with isotype matched control (see appendix). The isolated normal and
tumour endothelial cells then underwent flow cytometrical analysis on a standardised protocol using Becton
Dickenson Cyan flow cytometer and Summit v4.3 software. Images D illustrate data obtained describing
CD13(WM15) expression by both NEC and TEC. Both graphs show data for paired and unpaired samples in
both percentage expression (Image D) and median channel value (Image E) expressed as mean and SEM.
Data in table (F) is presented as mean, standard deviation and (number of samples). Statistical analysis was
performed using paired, two tailed T-test, and did not reach significance.
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Figure 3.11: Bestatin hydrochloride prolongs interruption in CRLMEC monolayer up to 12 hours.
Human primary endothelial cells derived from liver metastasis from colorectal primary disease were isolated
by positive selecting using antI-CD31 immunomagnetic Dynabeads and cultured up to passage 4 in 6 well
plates. Monolayers were treated with bestatin hydrochloride for 12 hours or left untreated as a control and
then the monolayer was interrupted as outlined in chapter 2. Images were obtained using phase contrast
microscope at 20x magnification and approximate measurements were made based on the images taken.
Semi-quantitative analyses were made by calculating the % remaining distance between endothelial
monolayer as a result of the scratch in comparison to the distance at time 0 hours. Image A represents CRLM
immediately after a scratch. Image B illustrates the area of the remaining scratch in CRLM endothelial cells.
Image C illustrates the area of the remaining scratch in CRLM endothelial cells that were a control and left
untreated. Graph D outlines the data collected by measuring the distance between the scratch test edges in
both Bestatin treated CRLM endothelium and the control from 0 to 72hours at 5 time points. Data represents
the mean of 3 test repeats for 1 biological repeat. Significance was not tested.
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A similar approach was applied to the quantification of CD13 expression by NEC and 
TEC. Expression of the isoform WM15 was initially explored by immunohistochemistry 
of CRC tissue sections. Expression through tumour stroma was expressed by 
membrane and cytoplasm of some endothelial cells of microvasculature but not all 
vessels revealed positive staining (see examples in Figure 3.10). Cytometric analysis 
suggested values for NEC and TEC from both paired samples and un-paired samples 
were not significantly different.  We also tested for function of CD13 between 
colorectal liver metastatic EC (CRLMEC) by using Bestatin, an inhibitor of the 
aminopeptidase activity of CD13. Bestatin-treated and untreated monolayers of 
CRLMEC were scratched and imaged at 12, 24, 48 and 72 hours to assess the distance 
between the two edges of the monolayer (Figure 3.11). The distance was measured 
semi-quantitatively and reported as a percentage of the initial scratch distance. The 
distance between edges in the scratch test assay in the Bestatin treated CRLMEC 
remained wider for longer compared to the non-treated group.  
 
 
 
 
Results	summary:	
• We	achieved	successful	development	of	long	term	in	vitro	model	of	
NEC	and	TEC	from	CRC.	
• Expression	of	basal	CD31	was	similar	between	NEC	and	TEC.	
• There	were	no	significant	differences	between	expression	of	CD105,	
VEGFR-2	and	VE-Cadherin	between	endothelial	cells	from	CRC	or	NC.			
• TEM-8	is	significantly	upregulated	by	TEC	but	not	NEC.	
• TEM-8	expression	is	maintained	in	TEC	but	not	NEC	through	long	term	
culture	
• CD13	WM15	expression	was	not	tumour	specific	
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3.3 Discussion 
3.3.1 Generation of my protocol for isolation of colonic endothelial cells 
I began by seeking a suitable endothelial marker to use for cell isolation. Staining 
experiments suggested that CD31 is a more specific endothelial cell marker than 
CD146. This was found for both NC and CRC where predominantly endothelial cells 
lining blood vessels throughout the whole tissue, and only few immune cells expressed 
CD31.  A Nature protocol (136) published similar data from pre-isolation 
immunohistochemistry where human normal colon, colorectal cancer and placenta 
tissue sections were stained with anti-CD31, CD34, CD105 and anti-CD146 antibodies to 
identify which of these four endothelial markers would be the most endothelial-
specific to use in isolation methods.  They found that CD31 would be the optimal 
marker given that CD105 positive staining was found within the stromal cells of both 
NC and CRC and that CD146 was not endothelial specific. CD31, also known as 
PECAM-1 is a cellular adhesion molecule of 130kDa. It has an extracellular domain with 
6 immunoglobulin folds (138) which can bind homo-typically to CD31 as a ligand, and 
also hetero-typically to integrins αvβ3 (139). The CD31 expression on vascular 
endothelial cells in most tissues (140) and its homophilic binding property allows 
endothelial cell-cell adhesion. Some leukocyte populations (141) also express CD31 
which can facilitate monocyte, T-cell and neutrophil transmigration (30, 31) across the 
endothelium. Interferon gamma (IFN-ϒ) and Tissue necrosis factor α (TNFα) may 
down regulate (143) or redistribute (144) the expression of CD31 as shown in HUVEC. 
Any variance in CD31 expression between ECs in different tissue samples may 
compromise standardization of its use as a tool for EC isolation methods. However, my 
semi-quantitative analysis of “proportion of vessels stained” and “intensity of staining” 
across immunohistochemistry of 9 matched samples of NC and CRC reveals that the 
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proportion of vessels stained and intensity of CD31 expression is similar between NC 
and CRC.  Thus, I was confident in my decision to proceed using this receptor for 
isolation 
There are few published protocols for NEC and TEC isolation specifically from 
colon, and therefore protocol optimization was a major aim of this chapter. Existing 
protocols from the literature include; Isolation and culture of EC derived from small 
bowel (135); Isolation and culture of human EC derived from CRC and matched NC 
(60) (134); Isolation only, using anti-ulex lectin (137), anti-CD146, anti-VE-cadherin, or 
anti-CD105 immunomagnetic beads; Isolation of EC derived from human CRC using 
anti-CD31 and flow assisted cell sorting (FACS) (136) and FACS isolation and culture 
expansion of murine EC (136). The key aspects of the protocols highlighted by these 
papers collectively are outlined below.  
Isolating endothelium from larger vessels such as the umbilical vein for HUVEC 
involves direct cannulation of the vessel. This is not possible with colorectal 
microvasculature and tissue must be homogenised whole and the endothelial cells 
must be isolated from this cell mixture. For each method, a single cell suspension is 
obtained. This is achieved by enzymatic digestion. The use of collagenase (60) and 
dipase is common and is used together (134) with DNAse in some protocols (135, 136). 
Time of incubation with enzymes ranges from 30 mins to 18 hours, and alterations in 
cell phenotype after incubation with enzymes for just 1 hour has been reported for 
some cells (145).  This has been explored most thoroughly in immune cells (146, 147) 
for which loss of cell surface proteins occur readily with collagenase and protease but 
not with mechanical digestion.  Data is scarce regarding potential consequences for 
EC, however variations in the enzymes and incubation times used makes it difficult to 
determine the consequences of differing protocols. Homogenization by hand also 
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poses the problem of standardization between preparations, risk through exposure to 
aerosolized material and shear-induced tissue damage.  
New commercially available mechanical dissociation kits and systems such as 
the Gentlemacs allow performance of standardized and optimized protocols for 
specific tissues. In addition such mechanical methods are reported to preserve the 
phenotypic profile of immune cells (147).  However, I found that EC that had 
undergone mechanical separation did not expand in culture and so for functional in 
vitro assays, this method was not preferable. Mechanical separation methods may also 
be beneficial by potentially optimizing cell yields, which is useful where tissue samples 
are small, as is the case in tumour samples where care is taken not to compromise the 
material required for patient staging. Van Beijnum et al (136) recommend using >1 
gram tissue as a minimum, however Schellerer et al (60) report success with as little as 
0.5 grams.  I have refined my protocol over the course of this year to develop a means 
to isolating CD31+ cells from approximately 0.5-1 grams of normal or tumour tissue.  
Once a single cell suspension is obtained the mixture is filtered allowing 
passage of particles up to 100μm to remove mostly debris and mucous. Some report 
that the use of a density gradient centrifugation at this point can eliminate 
erythrocytes, granulocytes and cell debris (135, 136). This step has the advantage of 
purifying the cell mixture before endothelial isolation however it is entirely operator 
dependent and therefore more difficult to standardize. 
Endothelial isolation can occur prior to expansion or after one passage. My 
experiences are similar to those from Erlangen with improved subsequent expansion 
and growth of both NEC and TEC after allowing initial culture, with cells such as 
smooth muscle cells, fibroblasts, and monocytes and in TEC, tumour cells. All culture 
conditions are ‘artificial’ and so allowing EC to initially expand in “co-culture” 
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potentially mimics the tissue environment in vitro, by permitting production of 
regulatory factors found in tissue or tumour milieu.   Historically, various manual 
methods such as cell scraping, diathermy and even laser have been used to remove 
contaminating colonies (148) in vitro, however, these methods are time consuming, 
tedious and ineffective. Immunomagnetic selection is a better option, and Schellerer et 
al (60) have described successful culture at 93% purity in both NEC and TEC using this 
technique. They detach the cells once ECs have colonized and use CD31 magnetic 
beads to isolate the ECs, which are then re-plated. We had similar success with CD31 
beads in this study, and therefore have used CD31 over any other antibody in our final 
protocol.  
Rather than using beads to select cells from a heterogeneous population, 
fluorescence activated cell sorting has been described for isolation of microvascular 
murine EC using anti-CD31 (136) and bovine adrenal microvascular EC based upon the 
uptake of acetylated low density lipoprotein (149). FACS and subsequent expansion in 
culture of NEC and TEC from human CRC has not been described in the literature to 
date. Difficulties with FACS include the direct effect on cell viability due to the 
shearing forces applied during the sorting and the cost. However, the benefits of a pure 
sample for subsequent assays such as next generation sequencing and functional assays 
are obvious. I have been able to successfully isolate human colonic EC using this 
approach. Our data suggesting that the procedure does not cause undue harm to cells 
and our photographs of EC reattaching in culture after this isolation route are 
therefore promising. 
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3.3.2 TEC in culture maintain a distinct and appropriate phenotype 
The phenotype of isolated microvascular EC is often characterized by 
confirming expression of CD31, VWF, ICAM-1 and inducible VCAM-1 in response to 
inflammatory cytokines. Other molecules such as VEGFR-2, CD105, VE-Cadherin, 
TEM-8 and CD13 are often reported as expressed in angiogenic tumour endothelium. 
Further to developing a reproducible protocol at my institution, I analysed CD31 
expression of NEC and TEC by flow cytometry revealing that more than 93% of isolated 
NEC and TEC at passage 4 express cell surface CD31. This was a reassuring finding that 
was supported by immunochemical staining. Interestingly, the cytometric cell surface 
CD31 expression was similar between both NEC and TEC in percentage and median 
channel value, although PCR data suggested that PECAM-1, the gene coding for CD31 is 
down regulated in TEC. The differences between in vitro ICC and FC data and the PCR 
data may relate to the time point of these experiments. The PCR results came from 
freshly isolated cells immediately upon removal from tissue in contrast to cultured 
cells used for antibody-based detection.  Thus TEC may have responded to regulatory 
factors, such as IFN-ϒ and TNFα within the tumour microenvironment. This is 
supported by our ELISA data, where although experimental repeats are low, the 
expression of CD31 moderately decreased in NEC when stimulated with TNFα. 
Interestingly, CD31 production appeared to be up-regulated by IL-1β. Certainly, when 
TEC were stimulated by TNFα and analysed by FC, the percentage and MCV VCAM-1 
expression increased, which is typical of NEC and TEC (60). Basal expression of 
VCAM-1, ICAM-1 and other adhesion molecules is discussed in later chapters however 
here, they have been used to characterize vascular endothelial phenotype. 
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VWF was expressed at a protein and transcription level in CRC and NC based 
on IHC and gene expression data. However, only modest differences were found 
between NC and CRC shown by semi-quantitative IHC analysis and QPCR supporting 
current data (150). VWF is a glycoprotein produced by vascular endothelial cells in 
most tissues and is stored in the Weibel-Palade bodies. It’s main purpose is to bind to 
other proteins such as factor VIII via its D’/D3 domain and collagen which is important 
to coagulation (151), hence expression in megakaryocytes is also seen. In vitro studies 
with HUVEC suggest that VWF is up regulated by angiogenic factors such as VEGF and 
FGF-2 and hypoxia at a transcriptional level (152). Interestingly, the same study 
performed preliminary data using tissue from CRC and matched NC for semi-
quantitative rt-PCR. This revealed heterogeneity, described previously (153), in VWF 
gene expression with a similar or even lower level of gene expression in CRC tissue in 3 
of 9 patients (152). Furthermore, expression of VWF in CRC tissue by IHC, was 
reportedly not related to stage of disease (150). I found that TEC express less 
intracellular VWF than matched NEC, shown by qualitative analysis of ICC which 
supports similar findings ex vivo and in vitro (60). Interestingly Schellerer et al (150) 
found that when stimulated with cytokines,  NEC down-regulate VWF expression 
similar to matched TEC. Thus, expression of VWF by my cells confirms their vascular 
endothelial nature and in addition suggests that cytokines within the tumour 
environment may modestly downregulate expression on TEC compared to NEC. 
CD105 overexpression is reported in human tumour types and has been 
suggested to contribute to tumour angiogenesis. Levels are increased on neovessels, 
and studies have explored the use of CD105 as a prognostic marker in colorectal cancer 
(154). CD105 is a homodimeric transmembrane that binds with TGF-β (155) and is 
expressed by microvasculature of many tumour types including colorectal cancer (156). 
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My FACS data suggested that TEC have moderate expression, along with strong 
positive vascular endothelial CD105 staining by IHC on both NEC and TEC. Regulatory 
factors for CD105 include TGF-β 1 (157) and gene expression can be induced by hypoxia 
(158). Although our IHC findings did not reach statistical significance the semi-
quantitative score revealed a marginal increase in ex vivo expression in CRC compared 
to NC, which could be supported by QPCR data where Endoglin gene expression, 
which codes for CD105 protein, was up regulated in TEC. Thus, my data support the 
concept that expression of CD105 is enhanced on TEC compared to NEC. However, the 
endothelial specificity of CD105 has been questioned as expression has been identified 
in macrophages, fibroblasts and smooth muscle cells, although (159) lymphatic 
endothelial cells do not express CD105. Thus, CD105 would not be valuable as a 
confirmatory marker to positively identify endothelial cells in the absence of negative 
staining for key immune cell and pericyte markers. 
Semi-quantitative analysis showed that microvascular endothelial expression of 
VE-cadherin expression is present in both CRC and matched NC tissue, although this 
was at low levels and intermittently throughout the tissue. VE-cadherin, a member of 
the cadherin superfamily is key to endothelial cell-cell adhesion (160)(161). The 
transmembrane glycoprotein has an extracellular compartment that engages in 
homophilic binding where VE-cadherin acts as both ligand and receptor (162). The 
intracellular compartment then attaches the plasma membrane to the cytoskeleton via 
catenins (163). Interestingly, our FC findings based on 6 matched samples, suggests 
that VE-cadherin is expressed on approximately 25% of NEC and almost 20% of TEC. 
The overall percentage expression of VE-Cadherin by both NEC and TEC is lower than 
expected and may be a result of the isolation process. This may cause lysis of the 
adherin junction by enzymatic activity as encountered previously (164). Although not 
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reaching statistical significance, lower levels of expression on TEC was expected.  The 
tumour vessel “leakiness” may result from down-regulation, or internalisation of 
endothelial VE-cadherin or tyrosine-phosphorylation of VE-cadherin junctions. This 
may derive from VEGFR-2 signaling since soluble VEGF may cause “loosening” of the 
EC-EC junction thus increasing HUVEC permeability (165). Down-regulation of 
Cadherin-5, the gene that codes for VE-adherin in tumour endothelium is supported 
by our QPCR data. This shows down-regulation at a transcription level of Cadherin-5 
in TEC relative to matched NEC however the regulatory mechanisms have not been 
explored. 
 So, in total my data support the identification of cells isolated using my 
protocol as endothelial and that TEC maintain some ‘tumour-specific’ markers in vitro. 
However, some data sets had large error bars suggestive of heterogeneity within the 
sample group, which is relatively small consisting of just 6 patients. Thus, use of larger 
numbers of patients from well-characterized disease stages may be warranted. 
Despite interesting differences of pan-endothelial marker expression, the main 
objective of this data was to compare the phenotype of isolated EC with that available 
in the literature and provide a baseline phenotype to compare to that of in vitro 
cultured NEC and TEC. To that end, we investigated the expression of TEM-8 to 
confirm ‘tumour’ phenotype and, importantly, we showed that tumour endothelial 
cells demonstrate tumour phenotype through multiple passages. This finding is crucial 
as successful isolation and culture of tumour endothelium, which require 
immunomagnetic bead isolation processes through passage to achieve the high purity 
essential for subsequent functional assays.  
Tumour endothelial marker 8 was identified as a result of serial analysis of gene 
expression (SAGE) of tumour endothelium isolated by laser capture by St Croix et al 
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(2000) (42). TEM-8 is a cell surface glycoprotein and an Anthrax toxin receptor 
(ANTXR1) up-regulated by many human and mice tumour types (18), (166). 
Functionally, TEM-8 has been shown to bind to basement membrane collagens and 
promote EC migration. Although our data has not investigated the functionality of 
TEM-8, expression suggests that tumour specific functions are preserved. Although the 
gene expression for TEM-8 is down regulated in NEC, it is still present at low levels per 
our rtPCR data. It is interesting that through culture passages, gene expression is lost 
in NEC but not in TEC. This suggests that there are regulatory factors in tissue that 
regulate TEM-8 expression. It is unlikely that such regulatory factors derive from 
angiogenic pathways, as unlike other angiogenic markers in tumours, TEM-8 is absent 
from benign, physiological angiogenic tissues such as corpus luteum and ovaries (42), 
and TEM-8 -/- knockout mice have been reported to be near normal (43) albeit with 
reduced growth (167). Furthermore, TEM-8 gene expression reportedly increases with 
stage in CRC (4). This ‘tumour’, and not ‘angiogenic’ expression pattern provides an 
attractive case for use of TEM-8 both as a tumour marker, and as a vehicle to deliver 
anti-cancer therapies. Thus, studies have targeted TEM-8, also known as anthrax toxin 
receptor-1, by utilizing internalisation lethal toxin upon binding of PA (one of three 
proteins comprising the anthrax toxin) to the TEM-8 cell surface receptor (168)(169).  
CD13/Aminopeptidase-N expression, has been identified by the vascular 
endothelium of several types of inflamed tissue and tumour tissue, including colorectal 
(170). Expression is isoform specific with the WM15 isoform being more specific to 
tumour vessels than other isoforms. Our data reveal similar CD13 expression levels in 
tumour and normal endothelium, with staining of whole CRC tissue suggesting there 
was endothelial specific staining evident. A commercially available agent Bestatin, that 
binds cell surface CD13 Wm15 has been explored for its value as an anti-tumour 
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therapy. Bestatin competitively inhibits the protease effects of CD13 WM15 and its 
efficacy in prolonging survival as a post-operative adjuvant therapy after curative 
resection of stage 1 squamous cell lung cancer has been highlighted by clinical trials 
(54). Reduced angiogenesis (171) and capillary tube formation has been reported in 
HUVEC by using Bestatin to block CD13, but not in primary endothelial cells from 
colorectal liver metastasis. Our data demonstrating delayed proliferation/migration of 
EC derived from CRLM with Bestatin may indicate its use in the treatment of Dukes D 
CRC, which currently has a <5% 5 year survival. Chemokine profiling is underway to 
identify factors and chemokines that may be predominantly responsible for regulation 
of CD13. Data from monocyte populations suggests that lipopolysaccharide (LPS) and 
TGF-β, Il-10 and TNF-α regulate CD13 expression. Areas open to further exploration 
include the efficacy of modulating CD13 driven monocyte adhesion and diapedesis by 
chemokines. A CD13 positive immunosuppressive T-cell subpopulation has also been 
described in lung tumours (172), in addition to myeloid derived suppressor cell 
(MDSC) population that express CD13 (173). Thus, there is much potential for 
therapeutic intervention targeting CD13. 
In this chapter I have developed a protocol for isolation and longterm culture of 
primary human tumour endothelial cells derived from colorectal cancer. I have 
characterised the NEC and TEC as microvascular in origin and explored their 
phenotype and gene expression relative to their origin. Furthermore, for the first time I 
have revealed that colonic tumour derived endothelium persistantly express tumour 
specific markers in culture. In the next chapters, I use NEC and TEC in models to 
investigate the differences in lymphocyte recruitment between NEC and TEC and 
explore possible regulatory factors to tumour lymphocyte recruitment for therapeutic 
exploitation.  
	 103	
CHAPTER 4 
________________________________________________________________ 
Endothelial adhesion molecule expression and cytokine production in 
colorectal cancer.  
 
4.1 Introduction 
In a process called immunosurveillance, first described in the early 20th century by 
Ehrlich, the immune system can prevent tumour formation by recognizing cells that 
are undergoing malignant transformation before malignancy is identified clinically 
(174). This tumour suppressor role of the immune system was further strengthened in 
studies using athymic nude mice which were found to be only partially 
immunodeficient having functional natural killer cells and cytotoxic T- lymphocytes 
that responded to concanavalin -A (175). Further detail on the anti-cancer properties of 
the immune system was discovered largely by the discovery of tumour specific 
antigens (176) which are identified by T-cells (177) and initiate an immune reaction, 
leading to tumour cell death (178, 179). This knowledge of tumour specific antigens 
arose from increased understanding of host rejection of tissue grafts during and after 
WW2 (180), and the apparent host protection against subsequent tumours after 
induction and removal of a primary tumour, illustrating both specificity for and 
memory of the tumour antigen by the host immune system (176).  
Activated CD8+ T-cells, known as cytotoxic lymphocytes (CTLs) induce death 
of foreign cells, including tumour cells (177, 178). Thus, an increased number of CD8+ 
T-cells in colorectal cancer (2) and some other solid tumour types (e.g. ovarian, (181, 
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(182) is associated with improved prognosis. CTLs release pro-inflammatory cytokines 
and cytotoxic granules containing perforin and granzyme-A and B (183). Perforin 
perforates the tumour cell membrane to allow entry of granzymes A and B into the cell 
to degrade intracellular proteins. CTLs can also kill tumour cells using TNF-related 
apoptosis-inducing ligand (TRAIL) and Fas receptor–ligand binding which induce 
apoptosis or cell death (184, 185). These mechanisms also allow regulation of activated 
CTLs so that the body can down-regulate an immune response as desired.  
Despite the efficacy of the cell-based anti tumour responses described above, 
tumours have been found to escape the body’s immune system via immune-escape or 
editing (186, 187). These mechanisms have clear clinical relevance, with future 
therapeutics possibly exploiting and manipulating the mechanisms of immune escape 
to reinstate effective immune control. For example, methods have been identified to 
promote the lifespan of CTLs in the tumour stroma, and focus on checkpoint blockade 
and the efficacy of CTLA-4 inhibitors often in combination with programmed –death-1 
(PD-1) inhibitors to increase the effector T-cell function and promote an anti-tumour 
response (188, 189).  
There are broadly two subsets of colorectal cancer; Antigenic and Non-antigenic 
(190). Unfortunately, clinical treatment does not account for these differences to date. 
Antigenic tumours stimulate the recruitment of CD8+ T-cells but employ immune-
escape pathways (187). In contrast, Non-antigenic tumours, which in CRC have a worse 
prognosis, lack cytokine expression but exhibit very little immune effector cell 
inhibition. Thus, it is interesting to speculate whether modulation of CD8+ T cell 
recruitment into non-angiogenic tumour stroma by up-regulating EC adhesion 
molecule expression would be prognostically beneficial? To answer this question, the 
	 105	
role of adhesion molecules in tumour EC and the proinflammatory factors produced by 
fibroblasts, epithelial, endothelial and immune cells must be explored.  
C-C chemokine ligand (CCL2) is a chemotactic cytokine, also known as 
monocyte chemotactic protein 1 (MCP-1), with a monomeric polypeptide structure 
weighing 13kDa. As the name MCP-1 suggests, it has a well-described role in recruiting 
monocytes and clinically is implicated in diseases characterized by monocytic 
infiltrates. Although CCL2 is predominantly released by monocytes, macrophages and 
DC, evidence suggests CCL2 is expressed by human microvascular endothelial cells 
(191) and can be induced by low-density lipoprotein (LDL). CCL2 has been implicated 
in T cell recruitment (192) and therefore has been investigated in this chapter.  
Elevated levels of adhesion molecule expression by colorectal cancer cells and 
tumour fibroblasts have been described (193,  194, 195) and in murine models this has 
been associated with tumour pathogenesis or worsened tumour outcomes (196). 
Presence of intercellular adhesion molecule-1 (ICAM-1), Vascular cell adhesion 
molecule-1 (VCAM-1), and E-selectin has been quantified in CRC patient serum, and 
are elevated compared to healthy controls (197). However, reporting of expression of 
adhesion molecules specific to EC is often inconsistent and predominantly based on 
semi-quantified immunohistological data (193, 198, 199, 200).  
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Therefore, this chapter aims to shed light upon the mechanisms, which may govern 
CD8+ T lymphocyte recruitment into colorectal tumours by;  
 
• Characterizing colorectal cancer and matched normal colorectal endothelial cell 
expression of the adhesion molecules, ICAM-1, VCAM-1, MAdCAM-1 and E-
selectin.  
• Comparing chemokine and chemotactic soluble factor profiles produced by 
tumour endothelial cells and normal endothelial cells  
• Identifying the in vitro function of adhesion molecules and chemokines by their 
selective and strategic inhibition through a series of static adhesion assays. 
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4.2 Results  
4.2.1 Colorectal tumours are infiltrated by lymphocytes and numbers correlate 
with vessel density 
In this chapter my aim was to understand the differences in the expression of adhesion 
molecules by NEC and TEC and how this affects CD8+ T-cell recruitment. I began by 
staining tissue sections from CRC to assess the amount of infiltration by CD8+ T cells 
within the tissue stroma (Figure 4.1). This enabled quantification of CD8+ lymphocytes 
in all the samples within our cohort and correlation with disease stage. Figure 4.1 
shows representative images for CD8 positive cells in two Dukes stage C cancers, but 
with the left image representing tissue that is highly infiltrated by CD8+ lymphocytes 
(panel A) and the image on the right representing tissue with few infiltrating 
lymphocytes (panel B). When we considered our cohort we found that mean number 
of CD8+ cells ranged from 93 to 328 CD8+T-cells per field view. When the numbers of 
CD8+ T-cells were plotted against the anatomy of the primary tumour, there was a 
trend towards higher tumour infiltrating lymphocyte number in those tumours 
originating in the right hand side, which includes the caecum ascending colon, hepatic 
flexure and right of the midpoint transverse colon (Figure 4.1E). When plotted against 
Dukes stage of disease there was no significant correlation. Finally, to identify if there 
was any relationship between the number of TILs and the abundance of vessels within 
the sample, tissue sections from the same specimen underwent CD31 
immunohistochemistry. Representative images of tissues found to have low and high 
CD31+ vessel density are shown in panels 4.1 C and D respectively. The percentage of 
CD31 staining found within each tissue section was significantly and directly 
proportional to the number of TILs (Spearmans rank correlation coefficient, p=0.05).  
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4.2.2. Expression of MAdCAM-1, ICAM-1, VCAM-1 and E-Selectin in CRC and NC. 
To understand the mechanisms that might contribute to trafficking towards, and 
retention of CD8+ cytotoxic T-cells within CRC and NC, IHC was performed on whole 
tissue to identify the locality of adhesion molecules. Both NC and CRC 
microvasculature expressed positive cytoplasmic and membranous MAdCAM-1 
staining within the mucosal lamina propria and submucosal layers of NC (Figure 4.2). 
In CRC, positive MAdCAM-1 staining of the stromal vessels was also noted, however 
this was less consistent than NC and generally staining was less intense (see Figure 
4.2), confirmed by semi-quantitative analysis of 6 paired samples. This revealed a 
significantly higher proportion of positively stained vessels, but not intensity, in NC 
compared to matched CRC (Figure 4.3, 2.3 v’s 1.5, p=0.0041). 
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Figure	4.1.	Variation	in	the	density	of	tumour infiltrating	CD8+	lymphocytes	amongst	Colorectal	tumours.	
CD8	count	was	performed	using	immunohistochemistry	of	frozen	tissue	sections	with	rabbit	anti-human	
CD8+	antibody	and	DAB	substrate	with	haematoxylin	counterstain.	3	different	fields	were	captured	from	3	
different	sections	of	each	CRC	samples	at	20x	magnification	and	retrieved	using	Axiovision	software.	This	
resulted	in	9	different	field	views	per	sample,	each	of	which	was	used	to	count	the	CD8+	cells	within	the	
tissue	stroma,	using	cell-counter	from	Image	J	software.	From	this	the	mean	was	calculated.	Images	A	and	B	
represent	tissue	where	CD8+	T-cells	were	more	and	less	abundant	respectively.	Images	C and	D are	from	
representative	CRC	sections		stained	with	CD31	to	reveal	the	extent	of	the	vasculature	in	the	tissue	stroma.	
Image	C	illustrates	a	tissue	section	with	few	vessels	whereas	D	illustrates	tissue	with	more	abundant	
vasculature.	
Tumour infiltrating lymphocyte abundance was assessed for correlation with the anatomy of the primary
tumour (E, left panel) and Dukes stage of the disease (E center panel). 1 specimen only was found to be
Dukes A, 4 specimens were Dukes B, and the remaining were Dukes C. The final chart (E right panel) presents
the correlation between %CD31 staining, and CD8+ count. Data presented in E are mean and SEM.
Differences between data in E (left and center panels) were analysed for statistical significance using two
tailed student T test and significance was accepted where p<0.05. A significant correlation between variables
in E, right panel was found (Spearmans rank correlation coefficient, p=0.049).
E F G
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ICAM-1 was constitutively expressed by vessels and occasionally fibroblasts within the 
and submucosa of NC and through CRC stroma (see representative images in Figure 
4.2). In addition, ICAM-1 was expressed at the membrane of several lymphocyte 
subsets throughout both NC and CRC. Positive staining of larger blood vessels found 
nearer the deeper muscle layers was also noted. The staining in both tissue types was 
noted predominantly at the cell membrane although some cytoplasmic staining was 
seen. Semi quantitative scoring of 4 paired sections revealed a significantly higher 
proportion of positively stained vessels in CRC compared to NC (Figure 4.3, 3 v’s 2.25, 
p=0.05), but no difference in the intensity of staining. 
 Similar analyses were performed for VCAM-1, and we saw positive vascular 
endothelial staining in both NC and CRC (Figure 4.2). Positive cytoplasmic and 
membranous endothelial staining in NC was predominantly within the submucosal 
layer, and VCAM-1 was also expressed by vascular smooth muscle cells and within the 
muscularis mucosa (see representative image in Figure 4.2). In CRC the positive 
staining was more specific to the cytoplasm and membrane of vascular endothelium 
(Figure 4.2). Whilst the intensity of staining for VCAM-1 tended to be higher in NC 
samples and the proportion of vessels stained tended to be higher in CRC in 4 matched 
samples (Figure 4.3), these changes were not significant.  
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ICAM-1
VCAM-1
E-Selectin
Figure 4.2: Expression of vascular endothelial adhesion molecules by NC and CRC.
Immunohistochemistry was performed us ing unfixed frozen whole tissue sections of NC and CRC (7μm
thickness) by an indirect DAB staining method. Mouse anti-human antibodies against indicated molecules
were used in addition to isotype- matched controls. Representa tive images shown were taken at 20x
magnification and retrieved using Axiovision software.
Normal	Colon															Colorectal	Cancer
MAdCAM-1
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Mean score	(range)
P	valueNC CRC
MAdCAM-
1	
(n=6)
Proportion of	
vessels	stained 2.3	(2-3) 1.5	(1-2) 0.004**
Intensity	of
staining 1.3	(1-2) 1.3	(1-2) 1.0
ICAM-1
(n=4)
Proportion of	
vessels	stained
2.5	(2-3) 3	(3) 0.18
Intensity	of
staining
2.25	(2-3) 1.5	(1-2) 0.06
VCAM-1
(n=4)
Proportion of	
vessels	stained
2.5	(2-3) 3	(3) 0.9
Intensity	of
staining
2.25	(2-3) 1.5	(1-2) 0.21
E-selectin
(n=3)
Proportion of	
vessels	stained
2(2) 2.3	(2-3) 0.42
Intensity	of
staining
2.3	(2-3) 1.7 (1-2) 0.18
Figure 4.3: Semi-quantitative assessment of expression of vascular endothelial
adhesion molecules by NC and CRC.
Immunohistochemistry was performed using unfixed frozen whole tissue sections of NC
and CRC us ing an indirect DAB staining method. A semi-quantitative score was
performed for 3 matched samples for both the intensity of staining and the proportion of
vessels stained by each protein between 0-3 where 0 is no positive staining/ none of the
vessels present stained and 3 is very intense positive endothelial staining/ all vessel
endothelia present in the field view positively stained. Staining was compared to isotype-
matched control samples in all cases. Statistical analysis was performed using paired
student T-test. Significance was considered where p>0.05 * (**p>0.005, ***p>0.0005)
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 IHC also confirmed E-selectin expression by CRC and NC. In NC, vascular 
endothelial expression was cytoplasmic and membrane bound and mostly sub-mucosal 
although specific staining was found in smooth muscle cells and infiltrating 
lymphocyte populations (Figure 4.2). In CRC, specific staining was limited to the 
vascular endothelium within the stroma and some smooth muscle although there was 
some additional artifact staining noted (Figure 4.2). When this was assessed by semi-
quantification score, the proportion of vessels stained was higher in CRC compared to 
NC (mean score 2.3 v’s 2, respectively, Figure 4.3) however, NC scored a higher mean 
score of 2.3 for the intensity of vessels stained compared to 1.7 which was the mean 
score for the CRC sections. 
 
4.2.3 Expression of MAdCAM-1, ICAM-1, VCAM-1 and E-Selectin in endothelial 
cells derived from colorectal tumour and normal colorectal tissue. 
Primary human colorectal tumour (TEC) and normal colorectal microvascular 
endothelial cells (NEC) were analysed by flow cytometry (FC). Analysis of 
membranous MAdCAM-1 expression showed a higher percentage MAdCAM-1 
expression by NEC compared to matched TEC (mean % NEC 36.6± 35 v’s TEC 11.6±16.2, 
p=0.04, Figure 4.4 A). Whilst this agreed with our findings in tissue sections, the 
difference was not maintained when data was pooled to including non-paired samples 
and reflects the variation in the different donors. Of note the amount of MAdCAM-1 
expressed per cell (median channel value (MCV)) for paired NEC and TEC was the 
same (51.9±48.3 and 52.9±75.9) respectively, (Figure 4.4 B). 
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Expression of ICAM-1 by isolated primary TEC and NEC indicated a trend towards 
lower percentage expression of membranous ICAM-1 by TEC than NEC although this 
was not statistically significant (Figure 4.4 A). However, there was significantly higher 
MCV expression of membranous ICAM-1 in TEC indicating that where cells did express 
cell surface ICAM-1, in TEC this was more intense than in NEC (Figure 4.4 B, mean 
MCV TEC 46.52±39.3 v’s NEC 37.79±31.8, p=0.05). Similar to our data for MAdCAM-1, 
when we compared all samples that were not paired, no significant difference in 
expression between TEC and NEC was found (Figure 4.4 C, mean MCV TEC 41.9±41.7 
v’s NEC 64.4±97.4).  
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Constitutive VCAM-1 expression in paired and unpaired NEC and TEC was 
much lower than seen for MAdCAM-1 and ICAM-1 although there was little difference 
between NEC and TEC. The higher MCV for cell surface VCAM-1 found in paired NEC 
compared to TEC (Figure 4.4 B, 41.3 NEC v’s 22.5 TEC,) was not maintained in the 
larger unpaired cohort. Similarly, there was little difference between percentage 
expression and MCV for membranous E-selectin expression in NEC and TEC, (Figure 
4.4).  
 Total NEC and TEC expression of ICAM-1, MAdCAM-1 and VCAM-1 protein was 
investigated by ELISA. Higher levels of ICAM-1 were identified across 3 x NEC samples 
compared to 1x TEC sample (Figure 4.5 A), and ICAM-1 was the most abundant 
adhesion molecule found in 3 in vitro primary NEC and 1 in vitro sample of primary 
TEC. In NEC, the mean ICAM-1 expression was twice that of VCAM-1 or MAdCAM-1. 
Overall VCAM-1 and MAdCAM-1 levels were similar in the single TEC sample although 
slightly lower than the mean value for NEC. After treatment with IL-1β and TNFα for 12 
and 8 hours respectively, NEC ICAM-1 expression increased significantly compared to 
untreated NEC. However, expression of MAdCAM-1 and VCAM-1 did not change 
following treatment with either IL-1β of TNFα (Figure 4.5 B).  
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Figure 4.5: ICAM-1, VCAM-1 andMAdCAM-1 expression in human primary in vitroNEC and
TEC.
In vitro NEC and TECwere cultured at passage 5 in flat bottom 96 well plates until confluent.
Where indicated, cells were stimula ted with 10ng/ml of IL1β or TNF α for 12 hours.
Expression was determined using indica ted primary antibodies and HRP-conjugated
secondary antibody with TMB substrate. Absorbance was read at 450nm and background
values for isotype matched controls were subtracted from test data. Graphical data is
presented as mean and SEM. Graph A presents data comparing adhesion molecule
expression by untreated in-vitro NEC and TEC. Comparative data using stimulated NEC by
IL1β or TNFα after 12 hours incubation is presented in graph B. Statistical analysis was
performed using 2 tailed student T-test. Significance was considered where p<0.05.
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4.2.4. MAdCAM-1, ICAM-1, VCAM-1 and E-Selectin gene expression in colorectal 
TEC and NEC.  
Quantification of MAdCAM-1, ICAM-1, VCAM-1 and E-Selectin gene expression by 
QPCR revealed that in most cases, expression was higher in TEC than NEC, although 
there was no significant increase found in TEC compared to NEC. VCAM-1 gene 
expression was even more variable between donors. In two samples TEC expressed 
more than 20 times the VCAM-1 mRNA seen in NEC. Similarly, E-Selectin gene was 
found to at least double in 3 out of 4 cases (Figure 4.6). Thus there was clear variation 
in individual mRNA expression for key adhesion molecules between donors and no 
pattern of regulation within the same TEC sample.  
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Figure	4.6:	Adhesion	molecule	 mRNA	is	increased	in	TEC	compared	to	matched	 NEC.
Primary human endothelial cells were isolated from human normal colorectal and colorectal cancer
tissue samples by positive selection using anti-human CD31 immunomagnetic beads. Isolated NEC and
TEC homogenates underwent mRNA extraction (Qiagen Rneasy minikit, UK) and cDNA synthesis (Iscript,
Biorad, uk). Real time qPCR was undertaken using an original concentration of 45ng /μl of mRNA for all
samples using Taqman gene probes and primer (Invitrogen). CT values were calculated using Stratagene
Mx3000P and analysis was performed using ΔΔCT method using GAPDH and Beta Actin as housekeeping
genes and obtaining the TEC value as sample of interest againstmatched NEC.
This method was subsequently used to evaluate MAdCAM-1, ICAM-1, VCAM-1 and E-selectin transcripts
by QPCR. Graph presents CT values for relative gene expression of MAdCAM-1, ICAM-1, VCAM-1 and E-
selectin of TEC normalised to matched NEC. B presents actual CT values for data in A. Statistical analysis
was performed using paired student T-test. Data was not found statistically significant.
Gene	of	interest CT	values	for	TEC	 relative to	matched	NEC
MAdCAM-1 3.2 6.3 1.3 0.3 7.6 0.5
ICAM-1 3.0 1.3 11.0 2.2 0.3 0.5
VCAM-1 3.3 23.4 2.7 0.5 21.6 -
E-Selectin 5.1 2.8 2.3 0.6 6.5 -
A
B
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4.2.5 CRC tissue displays increased CD8+T-cell adhesion compared to NC 
To understand the functional properties of adhesion molecules in CRC we used frozen 
preserved whole tissue sections to perform static adhesion assays using CD8+T-cells. 
All 5-matched untreated NC behaved differently to CRC sections where higher 
numbers of CD8+ T-cells bound compared to NC (mean number of CD8+ T-cells 
counted in field of view 409 ± 318 v’s 233.4 ±148 respectively Figure 4.7). The image in 
Figure 4.7.B represents a CRC tissue section and the black arrows indicate adhered 
CD8+T-cells to the surface of tissue identified. After ICAM-1 blockade the number of 
CD8+ T cells binding to normal tissue did not change significantly (mean control NC, 
168.25±35 v’s ICAM-1 inhibited NC, 206.5±97.6 Figure 4.7.C). In contrast, there was a 
significant reduction in CD8+T-cell adhesion to CRC sections when ICAM-1 was 
inhibited (CRC control 532.14 v’s ICAM-1 inhibited CRC 377.43, paired Student’s t-test 
p=0.0069 n=7 samples, Figure 4.7.D). MAdCAM-1 blockade did reduce CD8+ T cell 
binding to normal colon samples (mean control NC, 173.00±41.6 v’s 127.00±36.1 
MAdCAM-1 inhibited NC, n=3 samples Figure 4.7.C) but the change was not 
significant. However as with ICAM-1, for CRC tissue, there was a significant reduction 
in mean CD8+T-cell adhesion when MAdCAM-1 was blocked (CRC control 587.67 v’s 
363.83 MAdCAM-1 inhibited CRC 377.43, paired Student’s t-test p=0.0069, paired 
Student’s t-test p=0.0169, Figure 4.7.D). 
 
 
	 120	
 
 
 
 
B
CR
C 
IgG
 co
nto
l
IC
AM
-1 
blo
ck
 
CR
C 
IgG
 co
nto
l
MA
dC
AM
-1 
blo
ck
0
200
400
600
800
1000
** *
M
ea
n 
C
D
8+
 T
-c
el
l s
tro
m
al
 a
dh
er
ea
nc
e 
/fi
el
d
NC
 Ig
G 
co
ntr
ol
IC
AM
-1 
blo
ck
 
NC
 Ig
G 
co
ntr
ol
MA
dC
AM
-1 
blo
ck
0
100
200
300
400
M
ea
n 
C
D
8+
 T
-c
el
l s
tro
m
al
 a
dh
er
ea
nc
e 
/fi
el
d
Figure	4.7:	CRC	tissue	supports	increased	CD8+T-cell	adhesion	compared	to	NC.	
CD8+ cells, isolated from human PBMCs, were incubated with unfixed frozen tissue sections of NC and
CRC treated with either an anti human ICAM-1or MAdCAM-1 antibody or a isotype matched control
under static conditions. Sections were stained using haematoxylin and eosin. 3 different fields were
captured from 3 different sections of each NC and CRC sample at 20x magnification and retrieved using
Axiovision software. This resulted in 9 different field views per sample, each of which was used to count
the CD8+ cells, using cell-counter from Image J software. Image A represents NC and matched CRC
sections with adhered CD8+ T lymphocytes highlighted by black arrows. Graph B illustrates the control
binding of CD8+ T cells to untreated tissue Graphs C and D compares the mean number of CD8+ T
lymphocyte count per field view for when ICAM-1 and MAdCAM-1 were blocked compared to their
isotype matched control for NC and CRC respectively. Data illustrates the mean number of adhered CD8+
T-lymphocytes of 9 field views. Each dot represents data for one biological repeat. Statistical analysis was
performed using paired Student’s t-test.
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4.2.6. Cytokines produced by colorectal-derived NEC and TEC and the influence of 
CCL2 on CD8+ lymphocyte chemotaxis and adhesion.  
By using proteome profiling arrays and culture supernatants, I compared cytokine 
production by colorectal derived NEC and TEC (Figure 4.8 A and B). The most abundant 
analytes in both NEC and TEC were CD40, CXCL1/GRO, IFN-gamma, IL-8, IL-23, MIF, 
CCL5/RANTES. IL-8 was more than 5 times more abundant, and IL-23 was twice as 
abundant in NEC supernatant than TEC supernatant (Figure 4.9.C). In contrast, CCL2 was 
5 times more abundant in supernatant of TEC compared to NEC (Figure 4.9). Thus, further 
quantification of CCL2 by ELISA was performed confirming that CCL2 protein was present 
at higher levels in 3 TEC supernatant samples, where the mean concentration was 
1102.3pg/ml, compared to one sample of NEC where the concentration was 862.3pg/ml. 
Statistical analysis was not conducted as only one NEC sample was used. 
TEC was treated with a functional inhibitor of CCL2 and then a CD8+ T-cell 
transmigration assay was performed. The number of lymphocytes that migrated across the 
membrane towards the CCL2-inhibited TEC was less than 20% that of the control TEC 
(Figure 4.10.C). The proportion of these cells that adhered to the TEC in the bottom of the 
wells was also reduced by CCL2-blockade. The mean adhesion of lymphocytes to CCL2-
inhibited TEC was reduced to 36.3±20.0 cells per field view compared to control TEC where 
a mean of 171.7±60.5 cells per field view was observed. 
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Figure 4.8: Differential expression of key cytokines in supernatants from colorectal derived NEC and TEC.
Graphs represent quantification of soluble cytokines from the culture supernatant produced by primary tumour
endothelial cells (TEC, bottom panel) isolated from human colorectal cancer and the supernatant of matched normal
endothelial cells (NEC, top panel) from matched uninvolved colorectal tissue. Cytokines were detected using a Proteome
Profiler (Human Cytokine Array Panel A, R&D, UK) as per manufacturers guidelines. The supernatants were incubated
with a pre-mixed biotinylated detection antibody cocktail mix and a nitrocellulose membrane (pre-spotted with capture
antibodies). Streptavidin-HRP and chemiluminescent reagents were used to the detect bound cytokine/detection
antibody complexes. The intensity of signal for each spot is relative to the amount of cytokine bound. Quantification of
the abundance of cytokine produced was performed by measuring pixel density with Image J software. Data are mean of
2 spots in 3 biological repeats using matched NEC and TEC.
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Figure 4.9: Quantification of key cytokines in supernatants from colorectal derived NEC and
TEC.
Graphs represent quantification of soluble cytokines from the culture supernatant produced by
primary tumour endothelial cells (TEC, white bars) isolated from human colorectal cancer and
the supernatant of matched normal endothelial cells (NEC, black bars) from matched uninvolved
colorectal tissue. Cytokines were detected using a Proteome Profiler (Human Cytokine Array
Panel A, R&D, UK) as per manufacturers guidelines. Graph A illustrates the pixel density of the
most abundant cytokine in NEC and TEC supernatants presented as abundance relative to the
mean positive control pixel density for the respective samples. B illustrates the pixel density of
CCL2 in each of the 3 supernatants illustrated as a percentage of the mean pixel density of the 3
positive reference spots for the respective sample, p=0.03. C represents the concentration of
CCL2 found in NEC and TEC supernatants (standardised by dilution to number of cells in culture)
by sandwich ELISA (Ready-set-go, Affymetrix, UK). The absorbance values were collated in
triplicate for 3 TEC supernatant samples and concentration was interpolated from mean
absorbance value (450nm) against the standard curve of known CCL2 concentration.
A
B C
n=3n=1NEC TEC
0
2
4
6
8
10
C
C
L2
 a
bu
nd
an
ce
 (%
 o
f  
re
fe
re
nc
e)
*
	 124	
 
	 125	
4.2.7. T-cell adhesion by primary in vitro NEC and TEC 
Next we determined whether changes in adhesion molecule and cytokine production 
by TEC had functional consequences for T cell binding. Figure 4.11.A shows that data 
from our larger cohort and illustrates that higher numbers of CD8+Tcells bind to 
cultured TEC than NEC in static assays (mean number of CD8+T-cell per field/view 
296.88±44.1 v’s 501.6±129.0 respectively, p=0.0004 Figure 4.11.A). To ascertain the 
importance of key adhesion molecules in CD8+T-cell adhesion, 3 different TEC 
samples were incubated with functional blocking antibodies raised against ICAM-1 or 
MAdCAM-1 (Figure 4.9.B). Reduced fluorescently labeled CD8+ T-cell adhesion was 
noted after ICAM-1 and MAdCAM-1 blockade although the decrease was significant 
(p=0.03) only after MAdCAM-1 blockade (mean number of CD8+T-cell per field/view, 
control TEC, 440±50.6 v’s ICAM-1 inhibited TEC 296.3±154.9, v’s MAdCAM-1 inhibited 
TEC 267.0±104.4, Figure 4.11.B).  
When NEC were incubated with functional blocking antibodies, an 
approximately 50% reduction in CD8+ T-cell adhesion was noted with both individual 
ICAM-1 and VCAM-1 blockade compared to the NEC control wells. Combination of 
both ICAM-1 and VCAM-1 blocking antibodies had no additional effect on binding. A 
similar pattern occurred in TEC (Figure 4.11.C) although the magnitude of the blocking 
effect was smaller for TEC than NEC. Here, when ICAM-1 was blocked, there was a 
significant reduction in CD8+ T-cell adhesion (mean number of CD8+T-cell per 
field/view, TEC control 164.7 v’s TEC after ICAM-1 inhibition 128.0, p=0.034,). A 
reduction was also seen in TEC treated with VCAM-1 inhibiting antibody, although this 
was not significant either alone, or in combination with ICAM-1 blockade.  
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Pertussis toxin treatment of which cells also reduced CD8+ T-cell adhesion to 
both NEC and TEC. The reduction was over 50% in NEC (control NEC mean 28.3 v’s 
pertussis toxin treated NEC mean 63.3) and approximately 40% in TEC (control TEC 
mean 164.6 v’s pertussis toxin treated TEC mean 102.6, p=0.0054, two tailed, unpaired 
student T-test). In addition to investigating the importance of endothelial surface 
adhesion molecules in CD8+ T-cell trafficking, we pre-treated the CD8+ T-cells with 
inhibitory antibodies against CD11a (integrin alpha L) and CD49 (integrin alpha 2). The 
results for both NEC and TEC suggest that inhibition of CD11a had no effect, whilst 
CD49-blockade increased adhesion to TEC (mean number of CD8+T-cell per 
field/view, control TEC 164.7±18.7 v’s CD49 inhibited CD8+ T-cells 301.7±23.4, p=0.004, 
two tailed unpaired student T-test, Figure 4.11.D).  
To investigate CD8+ T-cell adhesion under more physiological conditions we 
conducted flow assay experiments using NEC and TEC grown to confluence in Ibidi 
flow chambers. Again, we observed higher adhesion of CD8+ T cells to TEC than NEC. 
The mean number of adhered cells per mm2/106 from 2 samples of TEC was 215.5±20.8 v’s 
59.6± 6.7 by NEC. After inhibition of ICAM-1, VCAM-1 or MAdCAM-1, adhesion to NEC 
decreased modestly to 46.9±4.6, 55.8±6.2 and 56.5±3.8 cells per mm2/106, respectively 
(n=2, Figure 4.12.A). In contrast when TEC was treated with the functional blocking 
antibody against ICAM-1, adhesion reduced by about a third to a mean of 128.9±40.9 
adhered cells per mm2/106. VCAM-1 or MAdCAM-1 inhibition, caused a far less dramatic 
reduction in CD8+T-cell adhesion to 176.9±13.1 and 183.1±71.7 cells per mm2/106, 
respectively.  
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Figure 4.12: CD8+ T-cell adhesion to NEC and TEC under flow conditions.
Primary colorectal derived NEC and TEC were cultured in Ibidi chambers until confluent. EC were
incubated with indicated blocking antibodies for 1 hour prior to undergoing flow based adhesion
assay with isolated CD8+ T-cells from HFE blood. Images were taken with a phase contrast
microscope at x20 magnification. Images were captured using DVD recorder and assessed off-
line. Graph A represents mean and SEM adhesion of cells/mm2/106 cells perfused. Graph B
represents the % of the adherent CD8+ T-cells that were observed rolling at low velocity over
the EC surface. Data are derived from multiple replicate fields of view in 2 independent
experiments. Photographic images shown are representative. Arrows indicate adhered
lymphocytes.
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However, for TEC, combined inhibition was far more effective with combined ICAM-1 and 
VCAM-1 blockade reducing adhesion by more than 50% (89.4±6.2 cells per mm2/106) and 
combined VCAM-1 and MAdCAM-1 blockade resulting in more than 6 times less adhesion 
(32.1±16.5 cells per mm2/106). Despite differences in numbers of adhered cells, there were no 
differences in the number of CD8+ T-cells observed rolling across the endothelium. This 
remained at approximately 5% of cells rolling for both NEC and TEC regardless of 
inhibitory antibody used (Figure 4.12.B). 
 
 
 
 
 
Results	summary:	
• CRC	specimens	can	be	categorized	into	those	that	contain	high	
numbers	of	CD8+	Tumour	infiltrating	T-lymphocytes.	
• Tumours	with	high	levels	of	CD8+	TIL	had	higher	levels	of	stromal	
vascular	CD31	expression	suggesting	these	specimens	have	more	
vessels.	
• CRC	contain	more	CD8+	Tumour	infiltrating	T-lymphocytes	than	matched	
normal	tissue.	
• In	vivo	CRC	vessels		show	less	intense	ICAM-1	expression	and	fewer	vessels	
in	CRC	express	MAdCAM-1.		
• The	in	vitro	adhesion	molecule	expression	is	generally	similar	for	
endothelial	cells	in	normal	colon	and	in	CRC.	
• Despite	this,	CD8+	T	cell	were	more	adherent	to	tumour	endothelium	in	
CRC	and	in	vitro	TEC.	
• Inhibition	of	the	key	adhesion	molecules	investigated,	resulted	in	
reduced	CD8+	T	cell	adhesion	to	NC	&	CRC.	
• TEC	produced	higher	levels	of	CCL2	chemokine	than	NEC.		
• Inhibition	of	ICAM-1,	VCAM-1,	MAdCAM-1,	CCL2	and	pertussis	toxin-
sensitive	receptors	resulted	in	reduced	CD8+	T	cell	adhesion	TO	NEC	
and	TEC.	
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4.3 Discussion 
4.3.1 Colorectal cancers can be categorized according to number of tumour 
infiltrating CD8+T-lymphocytes. 
Tumour infiltrating lymphocytes are a beneficial prognostic indicator in CRC. There is 
some evidence to suggest that different pathogenetic mechanisms govern right and left 
sided colorectal cancers (201, 202, 203) based on differing environmental factors and 
genetic predispositions. Right-sided colorectal tumours are reported to have 
microsatellite instability (MSI) and a loss of mismatch repair (MMR) function (204). 
Colorectal tumours with high levels of activated CTLs are reported as more prevalent 
in tumours with MSI and loss of MMR (205). To validate the cohort according to the 
literature, I compared the number of infiltrating CD8+ cells in 12 randomly selected 
frozen tissue samples from our available bank by IHC analysis. My data confirm that 
greater numbers of CD8+ cells are found within tumours compared to matched 
uninvolved tissue and although there was no statistical significance difference, there 
was a trend supporting a higher number of CD8+ cells in right-sided colorectal 
tumours in this cohort. Sample heterogeneity is large and therefore a larger group 
would be required to reach statistical significance but my findings conform to the 
reported literature.  
We compared the CD8+ TIL count to conventional histopathological staging 
and there was no trend or significant correlation between numbers of CD8+ TIL and 
Dukes stage of disease. This finding is also not unexpected. Galon et al have 
documented that the immune cell type and their location in a tumour can be a more 
accurate predictor of overall and disease free survival in colorectal cancer (2). It is 
conceivable that, the patients with few CD8+ TIL despite being histologically Dukes 
stage A and B, may have a worse 5-year survival than predicted by Dukes or TNM 
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staging systems available. I also found there was significant inter-patient heterogeneity 
within my sample cohort. This wide variation with some colorectal tumours having 
abundant and some few CD8+ TIL may reflect antigenic and non-antigenic tumour 
types described in the literature (190). We found that there was a correlation between 
the number of CD8+ TIL and the expression of CD31 within the same tissue sections. 
This may simply be an index of tumour inflammation with CD31 positivity being 
associated with immune populations such as type 2 tumour associated macrophages 
(TAM2), neutrophils, mast cells and TIE-2 expressing monocytes, all of which can 
induce VEGF, FGF, TNFα (206, 207, 208, 209). It does, however raise the possibility 
that more vascular tumour types allow increased opportunity for CD8+ lymphocyte 
trafficking into tumours and that where tumours had high number of CD8+ TIL, this is 
due to active recruitment rather than entirely clonal expansion in situ. Certainly my 
staining shown in chapter 3 (Figure 4.3) shows that CD31 expression was 
predominantly localized to vessel structures. Moreover, endothelial CD31 expression 
has been shown to be necessary for T-cell recruitment in murine models (210). Thus, 
an increased density of CD31 –positive vessels drives increase recruitment of immune 
cells into the tumour environment. 
However, the presence of vessels is not a given for active lymphocyte 
recruitment. When Suzuki et al (211) investigated the distribution of lymphocytes in 
colorectal cancer compared to inflammatory bowel disease they also used CD31 
expression in relation to lymphocytic markers (CD3, CD4, CD68) (211). Their findings 
were similar to Galon et al (2) in that the majority of lymphocytes were located at the 
invasive margin instead of the central core. Although they investigated E-selectin and 
ICAM-1 expression by endothelium and found a direct correlation with lymphocyte 
number, they did not investigate mechanisms of recruitment or retention of 
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lymphocytes within the tumour. They further examined tumour lymphocyte subsets by 
quantifying granzyme-B and CD45RO expression as markers of CTL and CD8+ 
memory T-cells respectively. They revealed higher numbers of CTL at the invasive 
margin but higher numbers of CD45RO cells in the tumour core in all patients (2). 
Whether the difference in the CD8+ lymphocyte distribution is due to recruitment, 
retention or apoptosis has not been thoroughly investigated.  
 
4.3.2. Adhesion molecule expression of CRC and TEC reveal little differences 
between NC and NEC.   
Generally, my data suggests that there is little difference between ICAM-1 and 
MAdCAM-1 and VCAM-1 expression between colorectal tumours and NC and TEC and 
NEC. However, in tissue, fewer CRC vessels expressed MAdCAM-1 and there was a 
trend towards less intense ICAM-1 staining in CRC vessels. Significant differences in 
expression were only noted in paired data suggesting that these comparisons are 
authentic. Tumour endothelium has been reported to down regulate adhesion 
molecule expression in other studies (199, 97), more notably in higher stage disease 
(212), and so my data fits well with this picture. This may also explain why treatment of 
normal EC with cytokines resulted in a down-regulation of expression of key receptors, 
perhaps modeling the environment in a less inflamed tumour. However, this 
experiment was conducted using a single patient sample and data was collected after 12 
hours of stimulation. Schellerer et al (60) used different timeframes to stimulate their 
colonic endothelium depending on the cytokine used, and  therefore we may be 
observing a time or cytokine-dependent variation in expression and missing peak 
expression of MAdCAM-1 and VCAM-1. Further experimental analysis of the temporal 
effects of different cytokines in increased numbers of patients is therefore required.  
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Interestingly, higher levels of soluble ICAM-1 have been reported in serum from 
malignant and metastatic patients, and studies suggest that INF-γ cleaves ICAM-1 from 
the cell surface of EC (213). Thus, some increased levels of message for adhesion 
molecules in matched tumour samples and lower protein expression may indicate that 
these receptors are cleaved within the tumour environment. In studies investigating 
leukocyte adhesion in vivo in murine models of tumour angiogenic tissue, ICAM-1 
expression is reported to be down regulated by angiogenic factors such as VEGF and 
fibroblast growth factor (214, 215). These growth factors were not available on our 
proteome array so it is not clear if a similar mechanism may be operating in our 
samples. However, IFN-γ was present in our endothelial supernatants and so this may 
be one means to explain reduced ICAM-1 expression.  
 
4.3.3 CD8+T Lymphocytes preferentially adhere to TEC and CRC compared to 
NEC and NC. 
It is interesting to consider our observation of enhanced CD8 recruitment in the 
context of reduced adhesion molecule expression. Stromal cells express ICAM-1 to 
promote retention of lymphocytes (195). This is supported by IHC data in Figure 4.2 
which revealed ICAM-1 expression by fibroblasts and by static adhesion data to whole 
tissue in Figure 4.7 which shows that inhibition of tissue ICAM-1 reduces CD8+ T cell 
binding. This may reflect the role of stromal fibroblasts in retention of lymphocytes 
after initial recruitment. Inhibition of ICAM-1 (β2 dependent) significantly reduced 
adhesion in static endothelial in vitro models in addition to tissue sections, and had a 
greater impact than VCAM-1 alone (partial β1). The addition of β2 integrin inhibition 
together with partial β1 integrin adhesion augmented total CD8+ T-cell adhesion, 
compared to their inhibition in isolation, which is not previously reported. This may 
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represent a lymphocyte driven up-regulation of β7 integrin, highlighting the 
importance of MAdCAM-1 in CD8+ T-cell adhesion. 
Documented evidence suggests that memory subsets of CD8+ T-cells home 
specifically to gut mucosa by expressing α4β7 and CCR9, and that intra-tumoural 
CD8+ T–cells express α4β7 the integrin ligands for MAdCAM-1 (216). Certainly, I found 
a significant reduction in CD8+T-cell adhesion by MAdCAM-1 inhibitory antibody 
suggesting a similar mechanism operates within colorectal tumours. All CD8+ 
expressing T-cells were isolated from blood samples, including potential effector 
memory T-cells and naïve T-cells. this allowed larger numbers of lymphocytes to be 
used, but also, the addition of CD45RO memory T-cells is important as their presence 
within CRC tumour stroma directly correlates with an improved patient survival (2). 
Furthermore, analysis was not performed to explore if the HFE CD8+T-lymphocytes 
were activated or naïve. Naïve, in addition to memory and activated CD8+ T-cells are 
recruited to non-lymphoid tissue  specifically via MAdCAM-1 α4β7 binding (217) as in 
colorectal cancer, it is suggested that some CD8+ cells are activated in situ (218). This 
may skew data and limit the conclusions drawn from significant data regarding 
abrogation of adhesion caused by MAdCAM-1 inhibition under static conditions 
(Figure 4.11).  
Static assays using TEC may mimic some conditions in CRC where flow is 
erratic, slow and static in part and therefore be more physiologically representative of 
CRC than initially thought. This is unlikely to be the case for NEC static adhesion 
assays as the blood flow through NC is predictable and uni-directional. In this 
instance, the static adhesion assays may not support selectin-mediated rolling and 
then chemokine-activation of lymphocytes. However, significant abrogation of 
lymphocyte adhesion to TEC but not NEC by pertussis toxin was observed. The 
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mechanism is via inhibition of chemokine G-protein coupled receptor, and suggests 
that chemokines are key for lymphocyte binding to tumour endothelial cells in 
particular, whereas binding of lymphocytes to EC from non-malignant tissue may rely 
upon rolling mediated lymphocyte activation.  
Flow based adhesion assays using primary human tumour endothelial cells are 
not described in the literature to date. Flow assays in HUVEC cell lines and primary 
endothelium (219) suggest that we observed relatively low levels of lymphocyte rolling 
in NEC and TEC. Very little data is available using in vitro primary EC models in their 
resting state. Our phenotyping and proteome profiling data suggests stimulation with 
inflammatory cytokines would perhaps not reflect the tumour milieu and would 
counteract physiological relevance. Further study with different flow rates and 
systematic inhibition of selectins, is required to rule out significant differences in 
lymphocyte rolling. Interestingly, for TEC flow based assays data is similar to that of 
static adhesions assays implying that ICAM-1, VCAM-1 and MAdCAM-1 are key to 
CD8+ T cell adhesion to TEC, however in isolation ICAM-1 had the greatest impact. 
 
4.3.4. CCL2 is preferentially produced by TEC compared to NEC and may 
regulate CD8+ T lymphocyte adhesion to EC. 
My study represents the first incidence in which validated in vitro NEC and TEC have 
been used to explore T lymphocyte adhesion under static or flow conditions. 
Chemokines produced by NEC and TEC are of significance in the recruitment of 
lymphocytes using such models. Therefore, I explored the soluble factors present in 
supernatants from in vitro NEC and TEC. In common with our finding of reduced 
adhesion molecule expression within the tumour environment, we also saw lower 
concentrations of key inflammatory cytokines such as IL-8, IL-23, CCL5, IFN-ϒ and 
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CXCL1/GRO in TEC supernatants from one representative patient. This may suggest 
that similar mechanisms are responsible for down-regulation of both adhesion 
receptors and chemotactic factors at this site. However, most literature available 
describes the usual characteristics of the tumour microenvironment, i.e. hypoxia, 
increased VEGF levels as up-regulating these chemokine (220, 221, 222). However, 
since this data was generated from a single individual, and heterogeneity in this 
patient cohort is evident, it would be important to confirm this result in material from 
other cases and correlate with clinical details such as stage of disease.  
CCL2 was consistently found at higher concentrations in TEC compared to NEC 
by proteome profiler and ELISA techniques. This is supported by data from studies 
that have investigated the epithelial, stromal or overall CCL2 levels in tumours 
including breast, lung and liver cancers (223, 224, 225).  Studies investigating the role 
of CCL2 in tumour progression and metastasis formation found that, in mouse models, 
circulating inflammatory monocytes are preferentially recruited via CCL2/CCR2 axis to 
metastases and that inhibition of CCL2 resulted in fewer metastases suggesting that 
the CCL2/CCR2 axis drives metastatic progression of disease (226).  
Our data suggests that CCL2 contributes to CD8+ T-cell adhesion, and where 
blood flow is static may contribute to CD8+ T-cell migration towards the tumour 
endothelium, in addition to other lymphocyte subsets and macrophages. Thus 
enhanced CCL2 expression could account for elevations in CD8 recruitment that we 
see, and retention in tumour tissue in the absence of differential adhesion molecule 
expression between matched normal tissue and cancer specimens. It is possible that 
CCL2 would also have this effect on immunosuppressive regulatory T-cells and 
monocytes. 
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Evidence exists that stromal, not epithelial, CCL2 expression correlates with 
reduced recurrence free survival (223) and that blockade in hepatocellular carcinoma 
(HCC) inhibits intratumoural TAMs and slows malignant cell growth, inhibits 
metastases, and improves survival (224). In a study of lung tumours using mice 
models, blockade of CCL2/CCR2 axis inhibited growth of established tumours. 
However, surprisingly an increase in the number of lung metastases was observed 
CCL2-/- and CCR2-/- mice despite a slowing in the growth of the primary tumours. 
The authors theorize that this indicates a role for CCL2/CCR2 blockade as a 
therapeutic for established tumours but that this blockade may reduce 
immunosurveillance and open the door for new tumour formation. A human 
monoclonal antibody against CCL2 has been trialed in human patients with solid 
tumours revealing 2 out of 33 patients saw a reduction in serum tumour markers, 
however non saw an response to treatment (227). By demonstrating CCL2 as a 
promoter of adhesion of CD8+ T lymphocytes to TEC and showing that pertussis toxin 
reduced adhesion to TEC, my data suggests a possibility that CCL2 is responsible for 
triggering firm adhesion to adhesion molecules or chemotaxis. Therefore, blocking 
CCL2/CCR2 may also impede the hosts anti-tumour immune response. 
This chapter has shown that the numbers of tumour infiltrating CD8+ T 
lymphocytes in different colorectal cancer specimens varies and supports the body of 
literature that describes CRC divided into those with high numbers of TIL and those 
that have few TIL, which correlates with patient survival. Generally, there was little 
difference in the expression of key adhesion molecules between NC and CRC and in 
vitro NEC and TEC. However, the limitations of small sample sizes and heterogeneity 
of data illustrate the need for larger studies. Despite this, my data confirms that these 
adhesion molecules are essential for adhesion of CD8+ T-lymphocytes to TEC under 
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both static and flow conditions by using a novel in vitro TEC model. I have also 
identified CCL2 as a factor preferentially produced by TEC that may promote 
recruitment of lymphocytes using these receptors thus revealing potential to explore 
CCL2, and constituents of the stromal tumour microenvironment further, using the 
colorectal derived TEC model.  Interleukins and other molecules within the tumour 
microenvironment in colorectal cancers and how they may regulate adhesion molecule 
expression by NEC and TEC derived from colon and CRC is discussed in the next 
chapter. 
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CHAPTER 5 
___________________________________________________________________________ 
How the tumour microenvironment regulates CD8+ T-lymphocyte 
adhesion to tumour endothelium in CRC. 
 
5.1 Introduction 
So far, this thesis has investigated the role of in vitro cultured tumour endothelium in 
recruiting lymphocytes. In vivo, endothelial cells are likely to be influenced by 
neighbouring cells within the tumour stroma. The cellular component of stroma is 
predominantly formed by fibroblasts, which are spindle shaped cells derived from 
mesodermal tissue, that produce collagens and glycosaminoglycans to form the 
extracellular matrix acting as a scaffolding framework supporting other stromal cell 
types. In benign and non-inflammatory tissue where the stroma is not reactive, 
phenotyping shows that fibroblasts express vimentin and desmin but do not express 
the protein alpha smooth muscle actin (αSMA) (228). There is a subset of fibroblasts in 
the cancer stroma that express αSMA and therefore share a similar phenotype to 
myofibroblasts, which are considered “activated” fibroblasts. However, it is unclear 
whether these cells are structurally the same as myofibroblasts found in reactive but 
benign tissue, and so there is reluctance for these to be termed  “myofibroblasts” 
without evidence from electron microscopy (229). These cells are commonly termed 
cancer or tumour associated fibroblasts (CAF or TAFB); but in this thesis, the term 
TAFB will be used.  
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There is much interest in studying TAFB. They represent a main contributor to the 
tumour microenvironment and may contribute to tumour genesis and metastasis. 
Activation of fibroblasts in the context of cancer may occur because of growth factor 
stimulation. Key factors implicated include TGFb, EGF, PDGF, FGF-2, adhesion 
molecules, other molecules produced by tumour cells or in response to injury or 
trauma (229). The role of fibroblasts in tumour formation is not well understood but 
the main theory arises from epithelial-mesenchymal transition, where cells undergoing 
this change, carry a malignant predisposition (230). TAFB are better described to 
promote epithelial cancer cell proliferation (229, 230) by overproduction of Tenascin-
C, MMPs and growth factors (TGFb and HGF). In addition, TAFB can influence the 
tumour microenvironment by polarizing stromal immune cells towards a pro-tumour 
differentiation state (Figure 5.1). For example, TAFB can induce Th17 T-helper 
differentiation (231) by producing chemokines such as IL-6 (232, 233, 234). IL-6 can 
interact with a predominantly soluble receptor to activate the glycoprotein, gp130 
complex. Both the soluble and the membrane bound IL-6 receptor initiate the Janus 
activated (JAK) kinase-STAT3 pathway. The down-stream effects of this pathway 
include cell proliferation, survival migration and chemokine formation (233), thereby 
enhancing tumour growth. 
Furthermore, high levels of IL-6 in the serum of patients with cancer, are 
associated with a worsening prognosis (231, 232). However, despite evidence that TAFB 
production of IL-6 may be detrimental, there is also evidence that the reverse may be 
true. There remains a hypothesis that the stromal TAFB in CRC regulates lymphocyte 
recruitment and thus can contribute to either a pro or anti-tumour immune-polarity.  
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Figure	5.1:	The	role	of	TAFB	in	maintenance	of	the	tumour	microenvironment.	
This	 schematic	 outlines	 the	 roles	 of	 tumour	 fibroblasts	within	 the	 tumour	microenvironment.	 Here,	 tumour	
associated	fibroblasts,	stimulated	by	tumour	cells	(EGF,	TGFb, PDGF	and	FGF-2)	suppress	anti-tumour	immune	
populations,	 promote	 tumour	 angiogenesis,	 attract	 suppressive	 immune	 populations	 and	 overall,	 promote	
tumour	 growth.	 Tumour	 fibroblasts	 may	 produce	 factors	 that	 suppress	 the	 adhesion	 of	 anti-tumour	
lymphocytes	 to	 tumour	 endothelium	 thereby	 suppressing	 an	 anti-tumour	 immune	 response.	 Image	 authors	
own	adapted	from	(229)	
 
 
 
Furthermore, high levels of IL-6 in the serum of patients with cancer are associated 
with a worsening prognosis (231, 232). However, despite evidence that production of 
IL-6 by TAFB may be detrimental, there is also evidence that the reverse may be true. 
There remains a hypothesis that the stromal TAFB in CRC regulate microvascular 
lymphocyte recruitment and thus can contribute to either a pro or anti-tumour 
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immune-polarity. Fibroblasts from inflammatory and autoimmune conditions (for 
example, rheumatoid disease) have previously been shown to regulate lymphocyte 
trafficking into tissues by vascular endothelium (233, 234, 235). However, the 
consequences of IL-6, and other molecules produced by TAFB, on CD8+ T-cell 
adhesion by CRC TEC has not yet been described in the literature.   
 
 
 
Therefore, the aims of this chapter were as follows;  
• To study ways in which normal and colorectal tumour derived fibroblasts 
regulate CD8 T-cell adhesion by colorectal NEC and TEC and quantify changes 
in adhesion molecule expression by conditioned NEC and TEC.  
• To investigate the regulation of CD8+ T cell adhesion to NEC and TEC under 
static and flow conditions because of stimulation by individual proteins found 
in TAFB supernatants, such as IL-6 and Endothelin-1.  
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5.2 Results 
5.2.1 Colorectal tumour associated and normal fibroblasts (TAFB and NFB) 
condition colorectal tumour and normal endothelial cells. 
Initially, αSMA expression by NC and CRC was examined using immunohistochemical 
analysis of tissue sections. In NC, strong membrane and cytoplasmic αSMA expression 
was noted only in the perivascular smooth muscle in all layers from the lamina propria 
(Figure 5.2 A), across the muscularis mucosa, and into the sub-mucosal layer (Figure 
5.2 C). In CRC, moderate membrane and cytoplasmic αSMA staining was noted by 
stromal fibroblasts with less intense, patchy perivascular staining at the center and 
invasive margin of the tumour. Fibroblast positive staining was variable between CRC 
sections independent of stage, illustrated by Figure 5.2 D and E where one Dukes B 
CRC section revealed extensive fibroblast staining throughout the whole tumour 
(Figure 5.2 D) and another Dukes B CRC section where very little fibroblast positive 
αSMA staining is noted. αSMA positive staining was quantified using Image J where 
the amount of positive αSMA staining was expressed as a percentage of pixels in 
representative images. The % αSMA staining was then plotted against the number of 
TIL in the same specimen (based on CD8+ staining as discussed in Chapter 4). Figure 
5.2F shows that there was a significant correlation between % αSMA expression and 
number of CD8+ TIL (p=0.043, Figure 5.2 F). Here higher expression of αSMA was 
associated with lower numbers of CD8+ TIL in tissue. Next, supernatants from in vitro 
NFB and TAFB cultures were used to condition human primary colorectal NEC and 
TEC to see whether fibroblasts influence immune cell recruitment and expression of 
adhesion molecules by tumour endothelium.  
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Figure 5.2: αSMA expression in NC and CRC.
To asses the expression of αSMA, immunohistochemical staining was performed on frozen
sections of CRC and matched NC. Sections were imaged with Zeiss Axiovert microscope and
images were capturedwith Axiovision software. Image A illustrates positive αSMA expression
in a representative section of NC at x10 magnification. Images B&C, illustrate positive αSMA
expression in normal colon lamina propria and smooth muscle , respectively, at x20
magnification. Images D and E illustrate αSMA expression in 2 different Dukes B CRC sections
at x10 magnifica tion. Panel F shows data from immunochemical staining for αSMA in 9
different CRC sections. % αSMA expression was quantif ied using Image J software and panel
F presents the corre lation between %αSMA staining and CD8+ count. Statistical analysis was
performed and data were significant using Spearmans rank correlation co-efficient (p=0.04).
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 Pilot flow cytometry analysis (Figure 5.3) suggests that supernatant from 3 
different samples of normal colorectal fibroblasts marginally up-regulated the mean 
percentage of cell surface MAdCAM-1 to 91.67±2.08% on NEC from the control 
percentage of 84.88±11.5% (Figure 5.3 A and C), with an increase in median channel 
value (MCV) from 60±62 to 116±10.5 (Figure 5.3 B and C). In contrast supernatant from 
tumour derived fibroblasts had no significant effect upon percentage MAdCAM-1 
expression compared to control NEC. TAFB supernatant conditioning produced a 
similar elevation in MAdCAM-1 MCV expression to NFB. Treatment of NEC with 
supernatant from normal or tumour fibroblasts had no significant effect on the 
percentage positive or MCV values for ICAM-1 and E-Selectin compared to untreated 
endothelium as shown in Figure 5.3. 
Next we used indirect enzyme linked immunosorbent assays (ELISA) (Figure 
5.4A) to quantify membranous and cytoplasmic expression of MAdCAM-1, ICAM-1, and 
VCAM-1 protein by NEC and TEC monolayers after conditioning with NFB and TAFB 
supernatants. Expression was quantified for 3 NEC samples, treated with matched NFB 
and TAFB supernatants. NEC conditioned with NFB supernatant did not significantly 
alter the expression of MAdCAM-1, ICAM-1 or VCAM-1. TEC displayed different 
pattern of phenotype to NEC when conditioned with the same matched TAFB 
supernatants. There was a significant reduction in ICAM-1 expression (0.15±0.1 to 
0.1±0.008). MAdCAM-1, and VCAM-1 expression were not significantly altered from 
TEC control as shown in Figure 5.4B. 
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5.2.2 Normal and tumour fibroblast supernatants have differential effects on 
CD8+ T-cell adhesion to colorectal NEC and TEC under static conditions. 
To assess lymphocyte recruitment and adhesion to NEC and TEC in vitro, cells were 
treated with supernatant from patient-matched fibroblasts (i.e. NEC with matched 
NFB supernatant and TEC with matched TAFB supernatant). Isolated CD8+ T-cells 
from HFE patients were incubated with 3 samples of control and treated matched NEC 
or TEC and the number of CD8+ T-cells adhered to the monolayer were counted. 
Figure 5.5 A illustrates the individual results for 3 samples of matched NEC and TEC 
conditioned with supernatants from matching fibroblasts. For all three lymphocyte 
donors, treatment of NEC with NFB supernatant resulted in an increase in 
CD8+lymphocyte binding (45.5 % mean increase, Figure 5.5A). In contrast, although 
basal adhesion to TEC was higher than to NEC (mean TEC adhesion 260.1±168 vs NEC 
adhesion 178.2±110), treatment with supernatant from TFB resulted in a decrease in 
adhesion in two out of three patients (mean 27% and 38.5% reduction, patient 1&3, 
Figure 5.5a). For one patient we saw a dramatic increase in binding following 
treatment of TEC with TFB supernatant (mean 70.6% increase, patient 2, Figure 5.5a). 
This general adhesion pattern was reflected when we took single paired NEC and TEC 
isolates after conditioning with 6 different NFB and TAFB supernatants (Fig 5.5B). The 
collective results show that there is almost a 50% increase in lymphocyte adhesion to 
NEC when conditioned with NAFB and a significant 250%(p=0.022) increase when 
conditioned with TAFB supernatant. However as before for TEC, lymphocyte adhesion 
falls after conditioning with either NFB or TFB supernatant compared to controls.  
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5.2.3 Soluble IL-6 is present in CRC and produced by human colorectal derived 
Tumour Associated Fibroblasts.  
Next I wanted to determine the identity of any factors within fibroblast supernatants that 
could be responsible for changing adhesion to endothelial cells. I used proteome-profiling 
arrays to assess cytokines production by 3 samples of normal and tumour colorectal 
derived fibroblasts in culture. The most abundant analytes in NFB supernatant, after 
comparison to the mean positive reference, were CCL5, IL-6, MIF and components of the 
IL-1 pathway. Supernatants from TFB also contained abundant IL-6, MIF and CCL5 and 
additionally CCL2 and CXCL1 (Figure 5.6 A and B) From 3 independent proteome profiling 
experiments using 3 different samples, the mean IL-6 abundance in NFB supernatants, 
expressed as a percentage of the reference, was 2.2±2.2% and in TAFB supernatants it was 
significantly higher, measuring 55.6±11.7% (p=0.0015) (Figure 5.6C). This significant 
increase in IL-6 in TAFB supernatant was confirmed by sandwich ELISA using 3 different-
matched NFB and TFB supernatant samples (Figure 5.6 D). These experiments confirmed 
that more IL-6 is present in supernatants from TFB (114.9±15.4pg.ml) than NFB 
(82.6±11.7pg/ml, p=0.0082).    
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Figure 5.6: Cytokine production by fibroblasts isolated from tumour and normal colorectal
tissue.
Cytokines were quantified from the culture supernatant produced by primary fibroblasts
isolated from human colorectal cancer and matched uninvolved colorectal tissue by using a
Proteome Profiler (Human Cytokine Array Panel A, R&D, UK) as per manufacturers guidelines.
Quantification was performed by measuring pixel density with Image J software. Panels A and
B illustrate the cytokine profile of supernatant from Normal fibroblasts (NFB) and tumour
associated fibroblasts (TAFB) respectively from 3 biological repeats. Graph C illustrates the
pixel density of IL-6 in each of the supernatants illustrated as a percentage of the mean pixel
density of positive reference spots for the 3 samples. Graph D is the concentration of IL-6
found in NAFB and TAFB supernatants (standardised by dilution to number of cells in culture)
determined using sandwich ELISA (Duo kit, R&D according to manufacturers instructions).
Statistical analysis was performed using paired Student’s t-test.
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I performed immunohistochemical analysis to visualize IL-6 in whole NC and CRC tissue. 
This revealed that in CRC, positive cytoplasmic staining was associated with stromal 
fibroblasts. This staining pattern was distributed across the tumour and was not seen in 
corresponding NC (Figure 5.7). The intensity of the staining ranged from weak to strong 
across 4 of the tumour specimens however the proportion of the fibroblast population that 
stained positive was less that 20% in all samples. Occasionally positive cytoplasmic staining 
was also identified in the tumour epithelial cells (not shown).  
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Figure 5.7: Immunochemical detection of IL-6 in colorectal tumour stroma.
To assess the presence and location of IL-6 in colorectal stroma, immunohistochemical
analysis of CRC and NC frozen sections was performed. Sections were imaged with a Zeiss
Axiovert microscope and images were captured with Axiovision software. Image A illustrates
positive stromal fibroblast (arrows) in a representative section of Dukes B CRC at x10
magnification. Image B shows no stromal positivity within the matching NC at x10
magnification. Image C is taken at x20 magnification of Dukes C CRC and illustrates IL-6
positive stromal fibroblasts (arrows). Image D is of NC taken at x40 magnification and reveals
no positive stromal staining.
A% B%
C% D%
Colorectal	Cancer																										Normal	Tissue
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5.2.4 IL-6 alters adhesion molecule expression of human colorectal derived NEC 
and TEC. 
Flow cytometrical analysis was performed to find out if the presence of IL-6 would alter cell 
surface expression of adhesion molecules by NEC and TEC. FC analyses showed that the 
mean percentage expression of cell surface of MAdCAM-1 modestly decreased in IL-6 
treated NEC from 6.1±4.5 to 5.3±6.4 (Figure 5.8A) as did the mean MCV of MAdCAM-1  
(25.6±12.2 to 22.5±2.6, Figure 5.8B). The mean percentage of VCAM-1 expression also 
reduced from 11.6±10.1 to 3.4±3.2 (Figure 5.8A&E) after stimulation. However, neither the 
MCV or percentage decrease reached statistical significance. ICAM-1 cell surface expression 
increased in NEC from 31.2±31.7 to 43.3±36.8 and was supported by an increase in MCV 
from 19.4±13 to 32.9±14.0 after stimulation with IL-6, although the results did not reach 
statistical significance. E-Selectin expression also increased (from 43.4±13.3 to 52.3±18.0) 
after stimulation with recombinant human IL-6.   The mean percentage of VCAM-1 
expression reduced after treatment with IL-6 from 11.6±10.1 to 3.4±3.2 (Figure 5.8A&E) 
although the MCV of VCAM-1 in IL-6 treated NEC showed an increased from 26.8±15.5 to 
32.0 ±15.1. The mean percentage cell-surface expression of E-selectin by NEC also increased, 
although not significantly, from 43.4±13.3 to 52.3±18.0 after stimulation with recombinant 
human IL-6.   
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The MCV of E-selectin was relatively unchanged from 22.7±13.7 to 22±12.4 after IL-6 
treatment. The mean percentage of VCAM-1 expression reduced after treatment with IL-6 
from 11.6±10.1 to 3.4±3.2 (Figure 5.8D) although the MCV of VCAM-1 in IL-6 treated NEC 
showed an increased from 26.8±15.5 to 32.0 ±15.1. However, these changes were small and 
not statistically significant.  
 
5.2.5 Soluble IL-6 promotes CD8+ T-cell adhesion to human colorectal derived TEC 
but not NEC. 
When primary human colorectal derived NEC were treated with IL-6 and incubated with 
CD8+ T-cells under static conditions, no difference was observed in the number of 
adherent lymphocytes. Low numbers of CD8+ T-cells were observed to bind to three 
independent NEC samples (approximately 50 lymphocytes per field view). In contrast far 
more (150.4±16.3, Figure 5.9) CD8+T-cells bound to unstimulated TEC, and this increased 
statistically significantly (209.8±18.1, p=0.014, paired student T-test, figure 5.9A) when TEC 
were pretreated with IL-6.  
We then performed experiments similar to those previously described where 3 different 
NEC and TEC were conditioned with 3 different NFB and TAFB supernatants. This time we 
used either supernatant alone or added IL-6 inhibitor to the treatment. Our ELISA data 
(Figure 5.6D) was used to establish the appropriate concentrations of IL-6 inhibitor to use. 
As before, approximately 50 CD8+ T-cells adhered to control NEC per field view and this 
increased significantly to a mean of 136.1±34.5 (p=0.0016) for NEC treated with TAFB. 
Importantly with TAFB and IL-6 inhibitor, the mean adhesion significantly reduced to 
74.9±15.9 cells per field (p=0.002). We saw a similar effect of IL-6 blockade on TEC, except 
basal adhesion was higher (164.7±18.8), this decreased to 144.7±28.3 after TAFB 
	 157	
conditioning and the magnitude of the inhibitory effect of IL-6 blockade was smaller 
(116.2±19.3, p=0.024 Figure 5.9B).  
 
To identify whether these effects were replicated under physiological shear forces, 
flow based adhesion assays were performed with IL-6 stimulated NEC and TEC. 
Recombinant IL-6 treatment increased CD8+ T cell adhesion to NEC marginally  
(from 70.3 ±6.9 adherent cells per mm2/106 in untreated control NEC to 78.4±9.1 after IL-6 
treatment) across 3 independent experiments. However, for TEC the increase was 
significant. Here mean number of adherent cells per mm2/106 in rose from 213.7±15.1 to 
280.3±13.1 in IL-6 treated TEC (p=0.004, Figure 5.10 A, B and C). Whilst total numbers of 
adherent cells increased we saw no difference in the percentage of CD8 T-cells rolling over 
TEC or NEC following IL-6 treatment (Figure 5.10 D).  
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Figure 5.9: IL-6 increases CD8+T-cell adhesion to primary colorectal NEC and TEC under
static conditions.
Monolayers of NEC and TEC were treated with either recombinant human IL-6 (120pg/ml) or
supernatants from 3 in vitro NAFB and TAFB isolates for 24 hours. Where indicated wells
included anti-human IL-6 receptor inhibiting antibody for 1 hour (2ng/ml, R&D, UK). CD8+T-
cells isolated from HFE blood were resuspended in EBM-2 (LONZA, UK) with 1% BSA at a
concentration of 25x104 cell/ml for static adhesion assays. The number of CD8+T-cells
adhered to the endothelium were imaged with Zeiss Axioscope and captured with Axiovision
software at an original magnification x10. Adherent cells were counted using Image J
software. Panels A and B shows CD8+T-cell adhesion to 3 diferent NEC and TEC samples
treated (3 biological repeats) with IL-6 compared to control samples, wells treated with 3
different TAFB supernatants alone, and the same supernatants in the presence of IL-6
receptor blocking antibody. Statistical analysis was performed with paired Student’s t-test.
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Figure	5.10:	IL-6	promotes	CD8+T-cell	adhesion	to	primary	NEC	and	TEC	under	flow	
conditions.	
Primary NEC and TEC were cultured in Ibidi chambers until confluent. EC were incubated with
recombinant IL-6 for (120pg/ml, Peprotech, UK) for 12 hours prior to performing flow based
adhesion assay with isolated CD8+ T-cells from HFE blood. Representative images (A and B)
were taken with a phase contrast microscope at x20 magnification. Black arrows show
adherent T cells. The red arrow indicates a T-cell undergoing transmigration through the
endothelium. Graph C represents mean ± SEM adherent cells per mm2/106perfused. Graph D
represents the % adherent CD8+ T-cells that were observed rolling at low velocity over the
EC surface. Statistical analysis was performed with paired Student’s t-test.
A B
C D
Control IL-6 Control IL-6 
0
100
200
300
400 NEC
TEC
***
Ad
he
re
d&
ce
lls
&p
er
&m
m
² /
10
⁶
Control IL-6 Control IL-6 
0
10
20
30
40
50
NEC
TEC
%
"C
D8
+"
T(
ce
lls
"ro
lli
ng
TEC	alone TEC	+	IL-6
	 160	
5.2.6 Endothelin-1 is up regulated in CRC compared to NC 
We also assessed the abundance of pro-angiogenic proteins in TAFB and NFB supernatants 
using a commercially available proteome profiling array (Figure 5.11). Unsurprisingly, 46 of 
the angiogenesis-related proteins were more abundant in TAFB supernatant (Figure 5.11 
A&B). One of these, Endothelin-1 was of particular interest due to reports that the 
Endothelin-1/Endothelin receptor B axis alters the expression of ICAM-1 in ovarian solid 
tumour vascular endothelium (97). From 3 independent proteome profiling experiments 
using 3 different matched supernatants, the mean percentage of Endothelin-1 in NFB 
supernatants, expressed as a percentage of the reference was 5.8±5.4% and in TAFB 
supernatants it was significantly higher, measuring 23.7±11.9% (p=0.04) (Figure 5.11C). 
Furthermore, the gene EDN-1 that drives expresses of Endothelin-1 protein was up 
regulated in whole CRC based on qPCR from 3 different matched CRC and NC samples 
(Figure 5.11 D). This qPCR analysis confirmed that EDN-1 gene expression was 26.8 times 
higher in CRC than matched NC (p=0.03, Figure 5.11 D).  
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Figure 5.11: Endothelin-1 expression is elevated in supernatants from tumour associated
fibroblasts compared to matched control tissue.
Graphs represent quantification of soluble proteins from the culture supernatant produced by
primary fibroblasts isolated from human colorectal cancer and matched uninvolved colorectal
tissue. Protein abundance was detected using a Proteome Profiler (Human angiogenesis Array
Panel A, R&D, UK) as per manufacturers guidelines. The supernatants were incubated with a
pre-mixed biotinylated detection antibody cocktail mix and a nitrocellulose membrane (pre-
spotted with capture antibodies). Streptavidin-HRP and chemiluminescent reagents were used
to the detect bound cytokine/detection antibody complexes. Quantification of the abundance
of cytokine produced was performed by measuring the mean pixel density from 2 spots with
Image J software. A and B illustrate a representative angiogenesis protein profiles from
primary in vitro colorectal derived NFB and TAFB supernatants respectively. Graph C illustrates
the pixel density of Endothelin-1 produced from independent Angiogenesis array panel
experiments for 3 different NFB and TAFB supernatants presented as abundance relative to
the mean positive control of the mean pixel density for the respective samples. For QPCR, in
vitro endothelial cell homogenates underwent mRNA extraction (Qiagen Rneasy minikit, UK)
and cDNA synthesis (Iscript, Biorad, uk). Real time qPCR was undertaken using an original
concentration of 45ng/μl of mRNA for all samples using Taqman gene probes and primer
(Invitrogen). CT values were calculated using Stratagene Mx3000P and analysis was performed
using ΔΔCT method using GAPDH and Beta Actin as housekeeping genes and obtaining the
TEC value as sample of interest against matched NEC. Statistical analysis was performed using
paired Student’s t-test.
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5.2.7 Endothelin receptor B (ETb) is preferentially expressed by vascular 
endothelium from CRC ex vivo and primary human colorectal TEC in vitro and is 
up-regulated by TAFB supernatant on TEC but not NEC. 
Elevated levels of Endothelin-1 in our tumour supernatants led us to investigate whether 
Endothelial receptor B was expressed on tumour vascular endothelium. Initially 
immunohistochemistry was performed to visualize ETb expression in both NC and CRC 
tissue sections. In NC, endothelial cells showed membrane and cytoplasmic ETb expression 
throughout the mucosal and submucosal layers. In CRC, both membranous and 
cytoplasmic ETb expression was observed on endothelial cells throughout the tumour and 
was also found at the invasive margin and central tumour areas. Semi-quantitative analysis 
of the IHC staining revealed that microvascular endothelial expression of ETb was 
observed across all vessels in CRC, with a maximum mean score of 3/3 whereas expression 
was lower in NC (2.3). However, the intensity of staining was similar between NC and CRC 
(Figure 5.12). 
 ETb expression in NEC and TEC was measured by ELISA. Indirect ELISA showed 
that, in one representative sample, increased ETB expression was identified in in vitro 
TEC compared to NEC. The absorbance value for NEC was quantified as 0.05 
compared to a value of 0.94 found by a matching TEC sample (Figure 5.12 D). This data 
was supported by QPCR data from 3 patient samples, where mean gene expression of 
EDNRB, the gene encoding for the protein ETB, was significantly higher compared to 
the gene expression of NEC (mean gene expression for TEC26.8 ± S.D. 7.65, p=0.03, 
Figure 5.12 E).  
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A B
Endothelin	receptor	B	(ETb) NC	(n=3) CRC	(n=3)
Proportion of	vessels	stained	(range	
of	score) 2.3	(2-3) 3	
Intensity	of staining
(range	of	score) 2.3	(2-3) 2.6	(2-3)
Figure 5.12: Endothelin receptor B expression in NC and CRC tissue and cultured NEC and TEC.
The expression of Endothelin receptor B was assessed in both whole tissue and endothelial cells
derived from human CRC and matched NC. Immunohistochemical staining was performed on
frozen sections of CRC and matched NC using mouse anti human-ETb antibody and DAB substrate.
Sections were imaged with Zeiss Axiovert microscope and images were captured with Axiovision
software. In vitro endothelial cell homogenates underwent mRNA extraction (Qiagen Rneasy
minikit, UK) and cDNA synthesis (Iscript, Biorad, uk). Real time qPCR was undertaken using an
original concentration of 45ng /μl of mRNA for all samples using Taqman gene probes and primer
(Invitrogen). CT values were calculated using Stratagene Mx3000P and analysis was performed
using ΔΔCT method using GAPDH and Beta Actin as housekeeping genes and obtaining the TEC
value as sample of interest against matched NEC. A and B represent sections of NC and Dukes B
CRC stained with human ETb antibody at x10 magnification. The ETb immunohistochemistry
staining was scored on proportion of cells positively stained and the intensity of staining observed.
Table C shows the mean scores and range of scores given for 3 sections of CRC and their matched
NC. In vitro NEC and TEC expression of ETb was assessed using indirect ELISA. D shows the
differences in Endothelin receptor B concentrations represented by absorbance at 450nm. Panel E
shows QPCR data from NEC and TEC indicating the relative gene expression of ETb in NC compared
to CRC. Statistical analysis was performed using the Student’s t-test.
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The baseline expression in NEC reduced slightly but not significantly following treatment 
with 3 different TAFB supernatants (Figure 5.13. In contrast ETb expression in untreated 
TEC increased significantly after conditioning with TAFB supernatants (0.09 to 0.12 ± 0.01 
(p=0.0435), Figure 5.13).  
Figure 5.13: Endothelial receptor B (ETb) expression on colorectal derived NEC and TEC
after conditioning with TAFB supernatant.
NEC and TEC were used in indirect ELISA experiments to compare the expression of
ETb before and after stimulation with culture supernatant from TAFB. In vitro NEC
and TEC were cultured at passage 4 in flat bottom 96 well plates until confluent.
Where indicated, cells were conditioned with standardized concentration of TAFB
supernatant for 24 hours. Expression was determined using indicated primary
antibodies and HRP-conjugated secondary antibody with TMB substrate.
Absorbance was read at 450nm and background values for isotype matched
controls were subtracted from test data. Graphical data is presented as mean and
SEM. Above is a graphical representation of this data. Statistical analysis was
performed using Student’s t-test.
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5.2.8 Inhibiting the ET1/ETb axis in colorectal derived TEC up-regulates cell surface 
ICAM-1 expression and promotes CD8+ T-cell adhesion under static and flow 
conditions.  
ICAM-1 expression by colorectal NEC and TEC before and after incubation with BR-788, a 
synthetic antagonist of Endothelin receptor B (ETb) was assessed using flow cytometry. 
The mean percentage expression of ICAM-1 by control NEC rose slightly but non-
significantly after incubation with ETb antagonist (31.1± 12.4% to 45.2±7.7%, Figure 5.14). A 
similar trend was observed for median channel fluorescence values in NEC. In contrast the 
mean percentage of ICAM-1 expression by control TEC was 26.6±10.9% and this increased 
to 56.6±6.1% (p=0.041) after treatment with ETb antagonist (Figure 5.14). Similarly, MCV of 
control TEC ICAM-1 expression also increased from 19.2±16.1 to 73.2±7.1 after incubation 
with ETb antagonist (p=0.037).  
I assessed the impact of inhibiting the ETb/ET1 axis on adhesion of to CD8+ T 
lymphocytes to tumour endothelium under static conditions. In 3 independent 
experiments, the mean number of adhered CD8+ T lymphocytes to untreated TEC was 
164.7±18.8 cells per field view and after treatment with ETb antagonist this significantly 
increased to 226±26.2 (p=0.008, Figure 5.15). Flow based adhesion showed that 132.3±31.1 
adherent cells per mm2 /106 cells perfused bound to untreated TEC in 3 independent 
experiments. After treatment with ETb antagonist the mean increased significantly to 
331.5±48(p=0.0063), and this could be abrogated with ICAM-1 blockade where adhesion 
reduced to a mean of 188.9±12.3 cells per mm2 /106 (p=0.043). No significant difference in 
the percentage number of rolling CD8+ T cells was observed between the control and the 
treatment groups.  
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Figure 5.14: ICAM-1 expression by NEC and TEC after inhibition of Endothelia l Receptor B
(ETb) using synthetic antagonist BR-788.
Cell surface expression of ICAM-1 was quantif ied using single colour flow cytometry on
primary human colorectal derived NEC and TEC incubated with 200ng/ml of the selective
receptor B antagonis t of Endothelin BR-788 (Enzo life science, U.K.). A illus trates the
percentage ICAM-1 expression by NEC and TEC treatedwith ETb antagonis t compared to NEC
control. B illustra tes median channel value of ICAM-1 expression by NEC and TEC treatedwith
ETb antagonist compared to NEC control. Statistical analysis was performed using ANOVA and
p<0.05was considered significant.
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Figure 5.15: CD8+ T-cell adhesion to NEC and TEC after EDNRB inhibition under static and
flow conditions.
The affect of inhibiting endothelial ETb on primary human colorectal TEC and their adhesive
properties to CD8+ T lymphocytes was assessed by static and flow-based adhes ion assays. For
static experiments , cultures of colorectal TEC were pre-treated with 200ng/ml of the selective
receptor B antagonist of Endothelin BR-788 (Enzo life science, U.K.) for 1 hour and then
incubated with isolated CD8+T lymphocytes isolated from HFE blood, for 30 minutes. The
number of adhered T cells were counted in both treated and non-treated (control) groups.
Graph A illustrates data from 3 independent experiments. Flow assays were performed using
primary colorectal derived NEC and TEC cultured in Ibidi chambers until conf luent. EC were
pre-treated with 200ng/ml of the selective receptor B antagonist of Endothelin BR-788 (Enzo
life science, U.K.) for 1 hour prior to undergoing flow based adhesion assay with isola ted CD8+
T-cells from HFE blood. Images were taken with a phase contrast microscope at x20
magnification. Images were captured using DVD recorder and assessed off-line. Graph B
represents mean and SEM adhesion of cells/mm2/106 cells perfused. Graph C represents the %
of the adherent CD8+ T-cells that were observed rolling at low velocity over the EC surface.
Data are derived from multiple replica te fie lds of view in 3 independent experiments.
Statistical analysis was performed using ANOVA where p<0.05 was considered significant.
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Results	summary:	
• Higher	expression	of	aSMA	by	TAFB	is	found	in	tumours	that	comprise	of	
fewer	TILs.	
• Normal	and	tumour	fibroblast	supernatant	does	not	significantly	change	the	
phenotype	of	NEC.	
• Tumour	fibroblasts	supernatant	may	suppress	ICAM-1,	but	not	MAdCAM-1	
or	VCAM-1	expression	in	TEC.	
• Generally,	adhesion	of	CD8+	T	lymphocytes	was	augmented	in	NEC	but	
reduced	in	TEC	by	normal	and	tumour	fibroblasts.	
• The	chemokine,	Il-6,	is	produced	by	tumour	fibroblasts	and	is	more	
abundant	in	tumour	stroma.	
• Despite	no	observed	modulation	in	adhesion	molecule	expression,	IL-6	
promotes	increased	TEC	adhesion	to	CD8+	T	cell	lymphocytes.	
• The	protein,	Endothelin-1	is	expressed	more	abundantly	by	tumour	
fibroblasts	and	its	receptor,	Endothelin	receptor	B,	is	expressed	by	tumour	
endothelium.		
• Inhibiting	the	ET1/ETb	axis	augments	ICAM-1	expression	by	TEC	and	
increases	TEC	adhesion	to	CD8+T	lymphocytes.	
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5.3 Discussion 
The aim of this chapter was to explore how the cells within tumour stroma might influence 
adhesion of CD8+ T-lymphocytes to tumour endothelium. Previously I have shown that 
although higher numbers of CD8+ T-cells are found in CRC than NC, there are 2 clear 
subgroups of CRC specimens where some tumours contain high numbers of active stromal 
CD8+ T-cells or TIL, and some contain very few TIL.  These tumours with few, inactive 
CD8+ T lymphocytes are often termed “non-immunogenic” in the literature (190, 236, 237) 
and are able to employ immune escape mechanisms. Thus in this chapter, I began by 
considering whether activated αSMA+ fibroblasts, otherwise known as tumour associated 
fibroblasts (TAFB), influence the CD8+ TIL density in a tumour by regulating recruitment 
by tumour endothelium. 
5.3.1 αSMA expression by TAFB corresponds with fewer TIL in CRC.  
By using immunohistochemistry, I could assess the percentage of αSMA expression and 
CD8+ T cell abundance in several different CRC samples. Mean αSMA expression 
varied from 5% to 30% in different samples and this variation was independent of 
standard histopathological staging but showed a significant inverse correlation with 
CD8+ TIL abundance. Data produced by Galon et al (2) illustrated that TIL abundance 
is independent of, and also a more accurate prognostic indicator of patient survival 
than standard histopathological staging of CRC. The correlation between αSMA 
expressing TAFB and CD8+ TIL abundance suggests that there may be causative link 
between TAFB and CD8+T cells within the tumour stroma. It is important to understand 
that the presence of CD8+ T cells does not imply the presence of activated CTLs as 
Granzyme-B production was not assessed. It is possible that cytokines such as IL-1 and IL-6 
produced by tumour fibroblasts directly, or indirectly via myeloid derived suppressor cells 
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(MDSC), T-regs, or TH17 T helper cells, suppress activation of CD8+ T lymphocytes (238). 
Nevertheless, tumour fibroblasts could also contribute to fewer tumour infiltrating CD8+ T 
lymphocytes by triggering accelerated programmed cell death, death via FAS ligands, or 
even reducing recruitment by the tumour endothelium via regulating adhesion molecule 
expression.  My data shows that TAFB supernatant did not affect adhesion molecule 
expression by NEC, but did suppress ICAM-1 in TEC. There was no observed change in 
MAdCAM-1 or VCAM-1 expression. This response has been supported by other studies 
using ECs derived from renal cell carcinoma or HUVEC which show a reduction in ICAM-1 
surface expression when stimulated by TNF- α (239), basic fibroblast growth factor (bFGF) 
(95) or VEGF (215), all growth factors known to be produced by TAFB  (229, 240,  241). 
Considering this data, we were surprised to observe no significant reduction of CD8+ T 
lymphocyte adhesion by TEC conditioned with tumour supernatant. However, significantly 
reduced adhesion was observed between TEC to NEC after TAFB supernatant conditioning, 
suggesting that regulation of CD8+ T lymphocyte adhesion may be tumour endothelial cell 
specific i.e. via binding of receptors specifically expressed or up-regulated by tumour 
endothelium. Data shown in Chapter 3 of this thesis indicate that receptors for adhesion 
molecule suppressing factors (for example, VEGFR-2) are expressed at lower levels in NEC, 
which may explain why TAFB can suppress ICAM-1 expression in TEC but not NEC. 
When examining the effects of tumour fibroblast supernatant on matched TEC on 
an individual patient level both suppression and increased adhesion was observed. This 
data highlights that a larger cohort of patients and sub-group analysis based on the number 
of tumour infiltrating lymphocytes would be helpful to investigate tumour fibroblast and 
TEC effect on CD8+ T lymphocyte adhesion. It is conceivable, in-keeping with the concept 
supporting stratification of CRC into immunogenic and non-immunogenic tumour groups, 
that in patients with few TIL, the TAFB suppress the TEC adhesion and vice versa. 
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Stratification of patients based on the tumour mis-match repair (MMR) status, and thus 
abundance of TILs, has been performed in phase II human trials investigating the effects of 
anti-PD-1 blockade on intra-tumoural T cells. The authors observed improved immune-
related response rate and progression free survival in patients with MMR deficient tumours 
compared to MMR proficient tumours (242). The modality of this immunologic relies on a 
high number of tumour infiltrating lymphocytes and therefore highlights the importance 
of targeting the tumour endothelium to increase recruitment of CD8+ T lymphocytes. 
In light of this, I further investigated the composition of TAFB supernatants.  
 
5.3.2 IL-6 is produced differentially by fibroblasts from tumour and normal colon 
and how this may affect the tumour microenvironment.  
Data does exist to suggest that TAFB contribute to the tumour immune escape by 
producing the chemokine CCL12 to suppress anti-tumour responses (243). Suppressive 
or regulatory cell types such as M2 tumour associated macrophages, neutrophils, 
myeloid derived suppressor cells and T-regs are the predominant cell types found 
where TAFB are abundant (244). A pre-clinical study performed in murine breast 
cancer models shows that by eliminating the TAFB or “carcinoma associated 
fibroblasts” (CAF) from the tumour stroma using a vaccine targeting fibroblast 
activation protein, there was a shift in polarity of immune-environment from Th2 to 
Th1 resulting in significantly more intra-tumoural CD8+ T lymphocytes (245). 
Eliminating the tumour fibroblasts was linked with lower concentrations of intra-
tumoural IL-4 and IL-6 and higher concentrations of IL2 and IL-7. 
My data suggests that TAFB are a more abundant source of Il-6 than NFB. IL-6 has 
been reported to be critical in tumour progression in CRC, produced predominantly by 
cancer associated fibroblasts, promoting tumour angiogenesis and maintaining crosstalk 
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between tumour cells and fibroblasts (246). Despite no significant changes to the 
membranous adhesion molecule phenotype, ICAM-1 expression tended to increase with 
IL-6 treatment. Furthermore, a significant increase was observed in CD8+ T-cell adhesion 
under static and flow conditions to IL-6 stimulated TEC but not NEC. The reduced 
lymphocyte adhesion observed after blocking Il-6 receptors in TAFB supernatant 
conditioned TEC, implies IL-6 up-regulates adhesion molecule expression in TEC 
preferentially. Il-6 has been described to increase membrane ICAM-1, VCAM-1 and E-
selectin on HUVEC facilitating increased CD4+ lymphocyte binding under static 
conditions (247). In addition, in inflammatory conditions such as rheumatoid arthritis, 
soluble factors produced by synovial fibroblasts, such as IL-6, increase lymphocyte 
recruitment by HUVEC (233). 
 
The tumour specific ability of IL-6 to augment CTL adhesion to tumour 
endothelium and leave NEC unaffected provides an attractive potential to target IL-6 as a 
therapeutic target. Tumour specific qualities of IL-6 have been previously reported in 
murine models (248), increasing CD8+ T lymphocyte trafficking by up-regulating the 
expression of IL-6 subunit receptor, gp130, by tumour vessels using thermal therapy. 
However, elevated levels of soluble IL-6 in the serum of patients with CRC is linked to a 
poor prognosis (249) and elevated IL-6 mRNA expression in CRC tissue corresponds with a 
higher risk of CRC recurrence (250). IL-6 has been shown to promote invasion of tumour 
cells in CRC (251) which in turn initiates a positive feedback loop of IL-6 production by 
immune populations. Other tumour-promoting effects of IL-6 may include tumour 
associated macrophage differentiation towards the M2 polarity by inhibiting caspase-8 
cleavage (252), recruitment of suppressive T-regs into the tumour stroma and contributing 
towards metastatic progression. This changes the focus of IL-6 and complicates its use as a 
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therapeutic target. It is interesting to consider whether high levels of IL-6 are produced by 
all TAFB, which would contradict the hypothesis that TAFB suppress CD8+ T lymphocyte 
adhesion as our data suggests otherwise and is supported by current data (248,  253,  254). 
It may be possible that relatively low levels of IL-6 are produced by TAFB from CRC that are 
more active at evading the hosts immune system and this could be addressed by 
stratification of samples by TIL subtypes and correlation with stromal IL-6 concentration. 
 
5.3.3 Endothelin-1 (ET1) preferentially produced by tumour fibroblasts bind with 
endothelin receptor B (ETB), inhibits ICAM-1 expression and reduces lymphocyte 
adhesion by TEC.  
Endothelin-1 (ET1) is a potent peptide ligand of the endothelin system which consists of 4 
ligands (endothelin 1-4), two receptors (endothelin receptor A and B), and endothelin 
converting enzymes. ET-1 is produced by stromal cells, notably endothelial cells where is 
can bind with endothelial membrane bound ETA and B. Downstream signaling causes 
potent vasoconstrictor affects and so therapeutics targeting this mechanism have, to date, 
been aimed towards anti-hypertensives (255, 256). 
Endothelin-1 (ET1) expression in tumour stroma and ETA and ETB expression has 
been demonstrated in skin, small cell lung, breast, colorectal and oral cancers (257,  258, 
259, 260). High levels of ET1 and receptors ETA and ETB, based on semi-quantitative 
analysis of IHC, correlate with a poor prognosis and shorter patient survival (261, 262, 263). 
My data reveals an increase in Endothelin-1 gene expression by whole CRC tissue and 
significantly elevated levels of ET1 in soluble protein form in the supernatant from TAFB 
compared to NFB supernatant. Although increased levels of ET1 are described in stroma 
and whole tumour tissue, there is no published evidence to date that stromal fibroblasts in 
tumours produce ET1.  
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Interestingly, in ovarian cancer models the gene for selective receptor ETB is 
preferentially expressed by tumour endothelium of ovarian tumours that bear low numbers 
of TIL compared to ovarian tumours with high numbers of TIL. By inhibiting tumour 
endothelial expressed ETB receptor, Buckanovich et al., were able to augment EC 
membrane bound ICAM-1 and subsequently increase CD8+ T lymphocyte adhesion on 
HUVEC cell lines and recruitment into murine models (97). Few studies investigate the ET1 
up-regulation in CRC stroma, however, there is evidence by immunohistochemical 
methods and whole patient tissue homogenates that support increased ET1 in CRC stroma 
(263). My data reveals that Endothelin-1 is present in whole CRC tissue and in the 
supernatant from TAFB at significantly higher levels than from NC and NFB supernatant 
respectively. Additionally, my data suggests higher expression of Endothelin receptor B 
(ETB), one of the G-protein coupled receptors for ET1, by TEC compared to NEC. 
Furthermore, simulating the tumour microenvironment by conditioning TEC with TAFB 
supernatant, significantly increased ETB expression by TEC was observed. Inhibition of the 
ET1/ ETB axis has shown increased ICAM-1 expression via reducing nitrous oxide synthesis 
in HUVEC and murine ovarian cancer models, but is not yet described in primary cell lines 
or CRC. To see if this happened in primary colorectal tumour endothelial cells, I used an 
ETB specific antagonist, BQ-788 to block the ET1/ ETB axis. I found that in primary CRC 
TEC, but not NEC, membrane expression of ICAM-1 increases. In keeping with the 
phenotypic change, I was able to increase CD8+ T-lymphocyte adhesion in TEC under 
static and flow conditions.  
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BQ-788 has been used in several cardiovascular human trials safely (264)(265) 
which supports potential use as a therapeutic target in CRC patients. Recently, a proof of 
concept study was published using BQ-788 as an intra-lesional therapy for malignant 
melanoma (266). They reported no adverse effects in patients who received BQ-788. 
Furthermore, although their study was small, using immunohistochemistry after 
treatment, the authors found more blood vessels and lymphocytes, in BQ-788 treated 
tumors. Although studies to date have investigated ET-1 and its receptors in tumours 
including CRC, the focus has been on ETA owing to the downstream events of binding, 
that contribute to tumour growth. Blockade of ET-1 showed some inhibition of cancer cell 
and CAF/TAFB proliferation in CRC (259) via the mitogen activated protein kinases 
(MAPK)	 pathway or via β-catenin (267). In addition, one study shows relative down 
regulation of ETB despite up regulation of ET-1 and ETA within 9 CRC specimen (268) 
and others suggest that ETB and ETA would have an augmented anti-tumour effect 
(269). In the literature to date, there is only one study that analyses the expression of 
ET-1, ETA and ETB in sub divided tumours based in the number of tumour infiltrating 
lymphocytes (97). Although tumour regression was seen in murine ovarian cancer 
models, patient survival data is not available.	 In CRC specifically, my data suggests that 
in some CRCs, blockade of endothelial cell ETB can increase adhesion to CD8+CTLs. 	
This chapter presents novel data supporting the role of stromal fibroblasts in 
regulating the tumour endothelium to evade the host anti-tumour immune response. My 
data suggests that in CRC the numbers of TAFB are inversely related to TIL CD8+ T-
lymphocytes and that the supernatant derived from CRC TAFB can have a suppressive 
effect on the adhesion profile of primary human CRC TEC by producing soluble factors 
such as Endothelin-1. Furthermore, this suppressive affect may be overcome by inhibition 
of endothelial ETB resulting in augmented CD8+ T-cell adhesion using a novel in vitro 
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primary human CRC TEC model under static and shear forces. My data supports the 
importance of further study into commercially available ETB receptor inhibitor BQ-788 to 
therapeutically improve adhesion and recruitment of CD8+ T-lymphocytes in tumours that 
evade an immune response.  
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CHAPTER 6 
________________________________________________________________ 
 
General discussion 
 
 
 
6.1 Summary of key findings  
 To investigate the tumour vasculature in colorectal cancer, it was essential that I 
develop a reliable in-vitro tumour endothelium culture model derived from human 
colorectal cancer tissue. Furthermore, it was essential that the in vitro model was based 
upon human primary cells for several reasons. Firstly, there is good evidence that 
rodent tumour models do not fully recreate the histological patterns of human disease 
or responses to treatment (270,  271). There is also well documented evidence that 
murine immune cell function, and some factors governing recruitment and 
angiogenesis (272, 273) are different to those of human species.  
Furthermore, by using samples derived from human primary tumours I have 
been able to study samples from patients with tumours that evade an immune 
response and those that don’t. Thus, my data may be more representative of typical 
patient cohorts than studies using cell lines. More importantly, the tumour 
microenvironment helps regulates endothelial cell phenotype and such interactions 
may be tumour specific. Therefore, by using matched tumour fibroblasts to condition 
the primary endothelium I have developed a model system that is more representative 
of the situation in vivo and this could not be achieved using cell lines.  
By modifying existing in-house protocols for non-tumour endothelial cell 
isolation, and learning from a published protocol for human tumour endothelial cell 
isolation (136) and one which reported some success with human primary tumour 
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endothelial cell culture (60), I have produced a reproducible protocol for the long-term 
culture of human colorectal tumour endothelial cells. 
I have confirmed the vascular endothelial phenotype of my primary cells. The 
data presented in Chapter 3 confirms this by revealing basal CD31, vWF and VE-
Cadherin positivity and up-regulation of VCAM-1 and ICAM-1 in response to TNFa and 
IL-1b which is consistent with available published data (60). Our gene and protein 
expression analyses confirmed that my cells express characteristic profiles of adhesion 
molecules and inflammatory markers but importantly confirmed that subgroups of 
genes involved in angiogenesis (e.g. VEGFR-1, eNOS) and inflammation (E-Selectin, 
VCAM-1, IL-6) were expressed to a higher level on the tumour-derived endothelium.  
We also report expression of the tumour specific endothelial marker, TEM-8, 
which is preferentially expressed by colorectal TEC compared to NEC, in agreement 
with other studies (44, 4). I also present novel data showing maintained expression of 
TEM-8 throughout long-term culture of cancer endothelial cells. This is in contrast 
with expression of CD13 which has raised interest because of reports of increased 
expression in angiogenic tissue such as tumours (274, 275). Interestingly I found little 
tumour specificity of CD13 expression in TEC derived from CRC using antibody WM15 
but inhibition of CD13 WM15 epitope slowed migration or proliferation of metastatic 
endothelial cells. 
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Figure	6.1:	The	endothelial	phenotype	of	NEC	and	TEC	derived	from	CRC.	
This	schematic	represents	the	phenotype	that	was	identified	as	a	result	of	the	investigation	in	this	thesis.	On	
the	left	of	the	diagram,	the	classic	phenotype	of	EC	isolated	from	NC,	is	displayed.	EC	express	basal	CD31	VWF,	
CD105,	 VE-Cadherin,	 low	 levels	 of	 VEGFR-2,	 MAdCAM-1	 and	 CD13	 (WM15).	 ICAM-1	 and	 VCAM-1	 were	
upregulated	with	 IL-1b	and	TNFa.	The	tumour	specific	phenotypic	characteristics	 include	basal	CD31,	CD105,	
VEGFR-2,	CD13	(WM15),	MAdCAM-1	and	ICAM-1	and	VCAM-1	were	upregulated	with	IL-1b	and	TNFa.	TEM-8	
was	 expressed	by	 TEC	 through	 long	 term	 culture.	 CCL2	 is	 preferentially	 produced	by	 TEC	 compared	 to	NEC.	
Image	is	authors	own.	
 
 
In chapter 4, I presented data describing variation in tumour infiltrating CD8+ 
T-lymphocyte numbers between colorectal cancers specimens. This is strongly 
supported by current literature linking high numbers of CD8+T-cell in tumours to 
improved patient prognosis, data which is key to the reasoning behind current 
therapies that target anti CD8 checkpoint blockade mechanisms. I was able to link 
CD8+ T-cell numbers with percentage CD31 expression which suggests tumours with 
high levels of CD8+ T-cells may also have an increased vessel density. Although 
adhesion molecule expression did not differ between in vitro TEC and NEC we did find 
that in vivo CRC vessels show less intense ICAM-1 expression and fewer vessels in CRC 
express MAdCAM-1. Despite this CD8+ T cell were still more adherent to tumour 
endothelium in CRC and in vitro TEC and inhibition of the key adhesion molecules 
investigated, resulted in reduced CD8+ T cell adhesion to NC and CRC. We found that 
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the chemokine CCL2 was produced in higher concentrations by TEC than NEC which 
may act as a chemoattractant. Certainly, Inhibition of CCL2 and pertussis toxin-
sensitive receptors in addition to ICAM-1, VCAM-1, MAdCAM-1 receptors resulted in 
reduced CD8+ T cell adhesion to NEC and TEC. 
 
 
 
 
 
	
	
	
	
Figure	 6.2:	 TEC	 preferentially	 produce	 chemoattractant	 CCL2	 compared	 to	 NEC	 but	may	 be	 stratified	 per	
tumour	infiltrating	CD8+	T-lymphocytes.	
This	 schematic	 illustrates	 TEC	 producing	 CCL2,	 a	 known	monocyte	 chemoattractant	 protein	 (also	 known	 as	
MCP-1),	which	aids	CD8+	T-lymphocyte	attraction	and	adhesion	to	TEC.	These	may	not	be	CD8+	T-cell	specific	
and	 it	 is	 possible	 that	 suppressive	 T-cell	 populations	 and	 macrophages	 are	 also	 attracted	 to	 the	 tumour	
microenvironment	by	CCL2.		Image	is	authors	own.	
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In chapter 5 the tumour microenvironment was explored for effects on the 
recruitment abilities of TEC. Specifically more aSMA	 tumour associated fibroblasts were 
identified in tumours containing fewer tumour infiltrating CD8+ T-cells. Interestingly, the 
supernatant from neither NFB nor TAFB did not significantly alter the phenotype of NEC 
which suggests the difference in NEC/TEC phenotype is, to some extent independent of 
protein signalling in the tumour microenvironment. However, TAFB supernatant was 
found to suppress ICAM-1 in some cases can also reduce CD8+ T-cell adhesion to TEC 
compared to TEC alone. This led to analyzing the differing constituents of normal and 
tumour fibroblast supernatant. IL-6 and Endothelin-1 were expressed in greater 
concentrations by TAFB. IL-6 actually increased CD8+ T-cell adhesion.  The pro-tumour 
effects via STAT3 of IL-6 are well described (276, 277) however data also support increased 
lymphocyte trafficking in the presence of IL-6 (277, 248).  
Recombinant Endothelin-1 suppressed ICAM-1 expression and CD8+ T-cell adhesion under 
static and flow conditions. Furthermore, inhibition of Endothelin Receptor B, which was 
up-regulated on TEC, and blocking the ET-1/ETb axis, ICAM-1 expression was recovered 
and CD8+ T-cell adhesion under static and flow conditions was augmented. Suggested 
mechanisms of Endothelin-1 contributing to TIL density are outlined in Figure 6.3. There is 
no similar data in the literature, however, in murine and ovarian cancer cell lines, 
Endothelin-1 suppressed tumour endothelial ICAM-1 expression in tumours with low 
numbers of TIL (97).	 
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Figure	6.3:	Suggested	mechanisms	by	which	tumour	associated	fibroblasts	regulate	tumour	endothelial	adhesion	
of	CD8+	T-lymphocytes.	
The	 schematic	 represents	 tumours	with	 low	numbers	of	TAFB	 (on	 the	 left)	 in	which	 there	are	higher	numbers	of	
tumour	infiltrating	CD8+	T-lymphocytes	as	the	adhesion	profile	of	the	tumour	endothelium	has	not	been	regulated	
and	 ICAM-1	 expression	 is	 not	 suppressed.	 Overproduction	 of	 Endothelin-1	 by	 TAFB,	which	 are	 found	within	 CRC	
tumours	that	actively	evade	the	hosts	anti	tumour	immune	response	(represented	by	the	right	hand	side)	binds	to	
Endothelin	Receptor	B	reducing	tumour	endothelial	ICAM-1	expression	via	nitrous	oxide	synthase.	Image	is	authors	
own.	
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6.2 Significance of my findings 
Developing a reliable in vitro TEC model has provided an opportunity to investigate 
recruitment, angiogenic, migratory and proliferative behaviours of tumour 
endothelium. In this thesis, TEM-8 has facilitated validation of the tumour specific 
phenotype of TEC in vitro model. To date, TEM-8 has been used as a target for anti-
tumour vaccines based on tumour specificity in HCC cell lines in murine models and 
shown success. The efficacy of TEM-8 targeted vaccines in colorectal mouse models or 
human cancer trials has not yet been explored. My data illustrates that TEM-8 is 
specific in human colorectal cancer and supports further investigation of TEM-8 
targeted vaccines in human colorectal cancer and the use of TEM-8 as a tumour 
marker to aid cancer detection by positron emission tomography (PET) scanning 
(278). 
Other biomarkers explored in this thesis include CD13 which has raised interest 
because of increased expression in angiogenic tissue. My data show that there was 
little tumour specificity of CD13 (WM15) expression in TEC derived from CRC and 
CD13 expression was also identified in NEC. This may be explained by glycosylation 
differences that exist resulting in at least 5 CD13 sub-populations (279). It is possible 
that the WM15 monoclonal antibody used in our studies did recognize other sub-types 
of the molecule and more tumour specific motifs exist (280). The CD13 ligand, NGR, 
tagged with nanogold particles, to deliver anti-tumour cytokine tumour necrosis factor 
(TNF) is currently being  investigated (281). CD13 has many functions in angiogenesis, 
cell motility, cell adhesion, and promoting tumour invasion, owing to signalling and 
enzymatic mechanism (282).  
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My data suggests that chemical inhibition of CD13 (WM15) using Bestatin 
slowed CRLMEC migration or proliferation of colorectal metastatic endothelial cells 
which is supported by in vitro studies using fibrosarcoma cell lines (283). Mechanisms 
by which CD13 can contribute to increased cell motility, which is key for tumour 
invasion (284) include increased bradykinin activated filopodia formation and protease 
enzymatic activity (285). These data are further supported by trial data in which CD13 
inhibition by Bestatin improved patient survival with squamous cell carcinoma, but 
not adenocarcinoma of the lung (286, 54)  In vitro primary colorectal TEC and 
metastatic EC are useful tools to understand these complex cellular functions in the 
context of colorectal cancer further, in particular how the tumour microenvironment 
regulates intra and extracellular expression of CD13 and how CD13 may contribute to 
lymphocyte adhesion.  
 Chapter 4 identified CCL2/MCP-1 as preferentially produced by colorectal TEC 
displaying chemotactic and T-lymphocyte adhesion properties to TEC. Solid tumours 
such as hepatocellular carcinoma and breast cancer  produce CCL2 (224, 287) and the 
role of CCL2 in tumour progression has been explored. The anti-tumour effects of 
CCL2  include stimulation of monocytes (288), increasing CD8+ T-lymphocyte 
recruitment to tumours (289) and improved tumour antigen presentation (290). 
However, CCL2 also promotes tumour growth by enhancing angiogenesis and 
promoting M2 TAMs (291), and facilitating tumour cell invasion and extravasation 
(292). CCL2 is, in particular, implicated in progression of lung metastases (293, 294). 
Carlumab, an in vitro CCL2 specific monoclonal antibody, has undergone a phase II 
trial in metastatic prostate cancer but with no observed anti-tumour activity (295). 
Furthermore, one study suggests that actual cessation of CCL2 inhibition in breast 
cancer could lead to a spurt in metastases formation via IL-6 and VEGFR-2 driven 
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tumour angiogenesis (297) and another study of CCL2-/- mice suggests that CCL2 
inhibition may be efficacious in regression of established tumours but complete 
inhibition of CCL2/CCR2 may suppress the hosts immune response to metastases 
development (225). 
 Data presented in chapter 5 illustrates preferential IL-6 production by TAFB. 
Despite the overall effects of TAFB conditioning of TEC in suppressing ICAM-1 
expression, IL-6 within the tumour microenvironment enhances CD8+ T-lymphocyte 
adhesion to tumour endothelium. These conflicting findings suggest that the 
microenvironment comprises a balance of anti and pro-inflammatory mediators. Our 
data highlights the pro-inflammatory, and potentially beneficial, anti-cancer functions 
of IL-6 which is also supported in the literature (298, 253, 299, 248). In clinical trials in 
the 1990’s IL-6 was trialed as a therapeutic for renal cell carcinoma with no reported 
toxicity but with no anti-tumour effects (300). Subsequent trials have focused on 
inhibiting IL-6 using monoclonal antibodies in multiple myeloma patients again with 
no conclusive anti-tumour effects (301). Siltuximab, an anti-IL-6 monoclonal antibody, 
has undergone a phase I trial in ovarian cancer patients showing IL-6 inhibition, 
reduced angiogenesis and macrophage infiltration (302). Complete inhibition may 
reduce angiogenesis and macrophage infiltration but it may also compromise the 
host’s anti-tumour immune response.  
αSMA expressing TAFB found in the stroma of CRC are potentially able to 
regulate the immune profile of tumours and employ immune escape by producing 
soluble Endothelin-1. Data in chapter 5 shows TAFB from CRC produce more 
Endothelin-1 and is described in a study using ovarian cancer patients and cell lines 
(97). Additionally, ETB, an Endothelin-1 receptor is preferentially expressed by TEC and 
up-regulated by conditioning TEC with CRC TAFB supernatant. The relevance of this 
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lies in the downstream effects of ET1-ETB axis in which binding of ET1 to ETB causes 
nitric oxide synthase production resulting in nitric oxide (303) and consequently down 
regulates endothelial cell ICAM-1 expression (304, 305). By inhibiting this complex, as 
shown in static and flow assays, adhesion of CD8+ T lymphocytes to tumour 
endothelium was amplified.  Based on my data and supporting evidence in other 
cancer types, inhibition of ET1/ETb binding using a specific monoclonal antibody is an 
attractive potential anti-cancer therapy in CRC.  
 
6.3 Limitation of this work 
The value of primary cell cultures is well described. However, there are practical 
limitations. Reliably reproducible long-term cultures require months of work and a 
relatively low yield of successful cultures from several samples. Maintenance of EC 
cultures requires input 7 days a week and as such is labour intensive. Using cell lines 
could mitigate time lost for protocol development and reduce the work load however 
the resultant data may fall short of accurate in vivo representation. The time taken to 
establish our in vitro model is comparable to murine models and compare favourably 
in terms of financial expenses, which results only from cell culture medium and 
consumables. The resultant cell yields were often sufficient to obtain both pre and 
post-culture phenotyping and analysis of gene expression from the same sample. In the 
original experimental design, however, pre and post-culture phenotyping and gene 
expression data in addition to functional adhesional data by EC from the same sample 
was preferred. Theoretically, this would allow linear comparison of cell adhesion 
molecule profile and functional adhesion properties for each sample. Unfortunately, 
this was not possible with the resultant cell yields.  
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Within endothelial cultures, a typical cobblestone appearance of clusters was 
always identified. However, subjectively, after analyzing the cell morphology over the 
course of the thesis, I noticed pleomorphism in nuclear size and shape. In addition, 
overall cell shape could vary within endothelial cells isolated from the same specimen 
at the same time and maintained in the same conditions. The significance of this 
feature is unknown. Pleomorphism is a morphological characteristic frequently seen in 
primary and metastatic malignant cells and reactive inflammatory cells but not usually 
resting benign cells. The changes may perhaps represent reactive changes or represent 
structural, phenotypic and genotypic changes occurring in the tumour endothelium.  
The most accessible technique for investigating functional adhesion of CD8 T 
cells to either NEC or TEC, was by static adhesion assay. This provided some insight 
into the endothelial-lymphocyte interactions. The disorganised and often static flow of 
blood described in tumours (3) suggests that actually, although purported as a crude 
measurement of adhesional function, may represent intra tumoural blood flow more 
accurately. Conversely, static adhesion studies are unlikely to accurately reflect the 
blood flow in normal colon. This highlights the importance of identifying the most 
representative flow rates that can replicate the physiological flows to use when 
comparing normal and tumour endothelium. There are no data currently surrounding 
this. Our adhesion assays used blood from patients with haemachromatosis and not 
matched patient blood or even unmatched blood from other patients with colorectal 
cancer. HFE blood is unlikely to be enriched in CD8+ T-lymphocytes. 
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6.4 Further work 
Addressing existing limitations of the studies 
To address the issue of significant inter-specimen heterogeneity, inevitable with 
primary samples, I aim to continue TEC phenotyping to provide larger cohort 
numbers. By utilizing dual immunofluorescence, positive staining with adhesion 
markers, angiogenic factors or tumour specific markers can be compared directly to 
CD31 staining. Collating all the endothelial cell phenotype data with abundance of 
CD8+ CTL in the tumour stroma, conventional histological staging and crucially 5-year 
survival data would be interesting in light of data that significantly links tumours with 
high numbers of tumour infiltrating CD8+CTLs  (2, 102). 
 Investigation the monocyte recruitment abilities of CD13 (WM15) could reveal 
anti-tumour effects as could further exploration of the anti-migratory and anti-
proliferative effects of CD13 (WM15) Other CD13 epitopes for enhanced tumour 
specificity could be further investigated for targeting vaccines or directing PET scan 
imaging.  
	
Future assays developed from TEC model 
I would aim to utilize the TEC in vitro model to explore the recruitment of specific 
subsets of immune cells to identify if ET1/ETB axis blockade would facilitate increased 
adhesion of CD4+ memory cells and pro-tumour TAMs, TH17 cells, T-Regs with the 
aim to identify a CD8+ T lymphocyte specific mechanism that could be preferentially 
exploited.  
 Given the data produced by supernatant conditioning of the TEC in vitro model 
by fibroblast supernatant, co-culturing TEC with matched cultured primary fibroblasts 
and tumour cells using fenestrated inserts, or development of an in vitro CRC 3D 
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tumour model is possible. Co-culturing of primary cells from the tumour stroma and 
matched primary cancer cells could provide additional insight into how the tumour 
microenvironment governs the its immune profile. 
Furthermore, to answer the question “does increasing the recruitment of CD8+ T 
lymphocytes into the stroma across tumour endothelium increase the density of CD8+ 
T-cells and therefore improve patient outcomes?” which would require investigation of 
the fate of CD8+Tcells after transmigration through TEC in the presence of TAFB 
compared to NFB using the TEC model. 
 
Future work towards therapeutic aim 
The two key areas highlighted by this thesis for potential therapeutic aim include; the 
use of TEM-8 as a tumour specific anti-tumour vaccine in colorectal cancer; and the 
use of ET1/ETB axis blockade with the aim to increase numbers of tumour infiltrating 
CD8+ T-cells. Human primary 3D tumour models may provide useful to investigate the 
delivery of TEM-8 labelled anti-tumour vaccines as opposed to using murine models.  
To further investigate the therapeutic potential of ET1/ETB inhibition requires 
investigation of whether up-regulating ICAM-1 expression indiscriminately by the 
endothelium of colorectal tumours causes an increased risk of inflammatory disorders 
such as colitis. These questions could be addressed by using murine models and early 
phase 1 and II trials. Before trialing ET1/ETB blockade, consideration should be made as 
to whether more benefit would be achieved by selecting patients based upon the 
number of TILs, whereby patients whose tumours are found to have “low” numbers of 
TILs are specifically recruited. Should ETB inhibition prove successful, there would also 
be implications of how the biopsy diagnosis was made and if based on conventional 
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TNM staging histology would require additional CD8+ IHC and additional 
histopathology review.  
 
 
 
 
6.5 Conclusion 
This thesis has demonstrated successful development of a validated in vitro TEC 
model for CRC and has revealed novel data of a tumour specific phenotype by 
expressing TEM-8. CD13 (WM15) was found to not be specific to CRC TEC, although 
more tumour specific subtypes are reported to exist (282). CCL2 produced by CRC TEC 
and IL-6 preferentially expressed by CRC tumour fibroblasts are both a CD8+ T-
lymphocyte towards TEC, however, both of these cytokines have pro and anti-tumour 
effects that complicate complete inhibition in clinical anti-cancer studies (225, 299). 
Endothelin-1 is also preferentially produced by CRC TAFB and the receptor ETB is 
upregulated on tumour endothelium. Inhibition of ET1/ETB binding augmented TEC 
ICAM-1 expression and facilitated increased recruitment of CD8+ T-lymphocytes into 
the tumour stroma. ET1/ETB inhibition has shown promise in in vitro ovarian cancer 
studies (97) and commands further investigation with the aim of developing an anti-
cancer therapy in CRC. 
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